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Abstract 
Pharmaceutical product claim and help-seeking advertisements have prompted the types 
and purposes of medical dermatology service(s) that patients have used in the United 
States. Indeed, researchers have demonstrated that 94% of working nurse practitioners 
affirmed receiving from their patients a request for a cancer drug advertised. However, 
adult dermatology patients members of Saint Nicholas Catholic Church or/and patients at 
MedStar Clinic in Houston, Texas, have not been of interest for any study so far. The 
purpose of this quantitative study was to assess the relationship between product claim, 
help-seeking, types, and purposes of medical dermatology services used amongst males 
and females aged at least18 years. Prospect theory (PT) was the theoretical framework 
used to analyze the purpose of this study. A cross-sectional survey approach permitted to 
collect primary data from 120 participants who were members of Saint Nicholas Catholic 
Church or/and patients at MedStar Clinic. The results, based on a forced entry multiple 
regression analysis at 95% confidence interval, indicated that product claim and help-
seeking significantly explained (p ≤ .05) the variances of certain types and purposes of 
medical dermatology services used. Thus, product claim and help-seeking predicted the 
types and purposes of medical services used by the study population. Pharmaceutical 
announcers may benefit from the results of this study by using the study results to create 
new direct-to-consumers advertisements for the dermatology health promotion. The study 
population may benefit healthy skin, hairs, and nails by using medical dermatology 
services after exposure to the new pharmaceutical direct-to-consumer advertisements. 
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Chapter 1: Introduction to the Study 
Introduction 
This section addresses the concepts of Direct-To-Consumer Advertisements 
(DTCAs) and the utilization (use) of medical services as the variables of the study. 
Analysis of the Concept of DTCA 
The pharmaceutical DTCAs are device, drug, and disease information that 
pharmaceutical companies and distributors convey directly to consumers, without any 
health professional mediation. The DTCAs are marketing or promotion efforts in the 
United States of America. According to the United States Food and Drug Administration 
(FDA) (2012c), doctors and pharmacists were the information link between drug 
manufacturers and consumers until 1980. Indeed, they received drug information from 
the manufacturers, and if convenient, passed the information over to the consumers. 
However, in the mid-1980s, a sudden change occurred: Some manufacturers started 
passing the drug related information via advertising directly to consumers without any 
health professional intervention (FDA, 2012c). That was the beginning of the DTCAs of 
prescription drug. The phenomenon continued from year to year (FDA, 2012c).  Then, in 
1997, the development of DTCAs became significant after the FDA (2012a), the 
regulatory authority, revised its policy concerning drug firms (Frosch, Grande, Tarn, & 
Kravitz, 2010). In addition, the FDA published the federal food, drug, and cosmetic act in 
1999, where sections 502 and 503 set the setting to advertise prescription medicines 
(FDA, 2012a). The act established that prescription drug advertisement has to be accurate 
and avoid misleading the public (FDA, 2012a). 
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According to Arney, Street Jr., and Naik (2013), Al-Dmour, Al-Zu’bi, and 
Fahmawi (2013), and Van de Pol and De Bakker (2010), the DTCAs reached target 
consumers via television, radios, newspapers, magazines, the Internet, and outdoors 
media to promote prescription drug and devices and to inform patients about conditions. 
The supporting marketing tool of the DTCAs spread was advertising or direct-to-
consumer advertising of prescription drug, diseases, and devices (Arney et al., 2013; 
Limbu, Huhmann, & Peterson, 2012).  
In addition, pharmaceutical research and manufacturers of America (PhRMA) is 
the consortium of pharmaceutical companies, leading new drug and biotechnology 
research in the United States of America. The group initiated the DTCAs in the 1980s, 
passing drug and disease information directly to consumers. That was a breakthrough 
given that before the 1980s, pharmaceutical companies were passing drug information to 
the physicians and pharmacists who were responsible for determining the necessity of 
passing that information to the patients and costumers or not (Dieringer, Kukkamma, 
Somes, & Shorr, 2011; Faerber & Kreling, 2012; FDA, 2012c;  Van de Pol & De Bakker, 
2010). Indeed, PhRMA (2011) claimed that the DTCAs created a medical environment 
where patients and care providers did have an informed conversation regarding drug, 
diseases, new treatment options, or a particular health concern.  Furthermore, PhRMA 
thought that the DTCAs of prescription drug and diseases informed people concerning 
conditions, provided training to patients on the various treatments available, prompted 
patients to discuss health issues with the providers, and prompted patients to stick to the 
3 
 
 
 
drug therapy plan. However, The DTCAs’ roles encounter divergent appreciations in the 
public opinion.  
A diversified opinion on DTCAs roles. The general opinion about the DTCAs’ 
role is very divergent. Those who are in favor of the DTCAs think that DTCAs have an 
educational value for the target audience. The DTCAs inform patients about prescription 
drug, diseases, and possible treatments in a practical way (Arney et al., 2013; Van de Pol 
& De Bakker, 2010). The DTCAs empower patients to have a sound medical discussion 
with the provider, bring drug prices down through competition stimulation, help patients 
better follow their treatment, and enable a better physician-patient relationship in the 
process of care delivery (Arney et al., 2013; Van de Pol & De Bakker, 2010).  
Conversely, the opponents think that the DTCAs are partial in terms of the 
product’s risk and benefits disclosure (more detailed benefits appear in the 
advertisement). In addition, the DTCAs costs are part of and increase drug price and lead 
to unnecessary prescriptions and test requests as well as the wrong autodiagnosis by 
costumers (Arney et al., 2013; Van de Pol & De Bakker, 2010). Moreover, the DTCAs 
communicate more curative than preventive medicines and can provoke an unnecessary 
prescription of a more expensive new drug compare to an existing cheap one (Arney et 
al., 2013; Van de Pol & De Bakker, 2010). The preceding advantages and disadvantages 
of the DTCAs continue to nourish the debates whether to ban the practice of the DTCAs 
in the United States of America (Lee-Wingate & Xie, 2010; Wellington, 2010). The 
practice of the DTCAs is legal in only two countries around the world: the United States 
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and New Zealand (Dave & Saffer, 2012; Faerber & Kreling, 2012; Taylor, Bell, & 
Kravitz, 2011).  
The DTCAs generated spending from the marketers in the United States of 
America. In fact, from 2003 through 2006, marketers increased the DTCAs spending. In 
2003, pharmaceutical companies invested 3.8 billion dollars in the DTCAs in the United 
States of America. The same marketers, increasing the 2003 spending (around 111% 
increase), paid 4.2 billion U.S. dollars to support the DTCAs activities in 2005 and 5.6 
billion in 2006 (133% increase from 2005; Dave & Saffer, 2012; Lee-Wingate & Xie, 
2010; Limbu et al., 2012). In 2009, the DTCAs through all media were $4.6 billion 
(Limbu et al., 2012) versus $4,371,000 in 2010 (Kornfield, Donohue, Berndt, & 
Alexander, 2013). Some scholars and practitioners correlated the health care cost increase 
to the DTCAs spending increase regarding the three types of the DTCAs. 
Brief presentation of types of DTCAs and regulation. The three types of 
DTCAs that the United States’ FDA recognizes are the focus of this analysis. The FDA 
has distinguished three types of DTCAs and has partially regulated the practice of 
DTCAs in the United States since 1962 (FDA, 2012a, 2012b; Lee-Wingate & Xie, 2010; 
Mulligan, 2011). According to the FDA (2012b) and Lee-Wingate and Xie (2010), the 
three forms of DTCAs are product claim, help-seeking, and reminder. Product claim 
refers to the advertisement that contains a drug name and the use, the treated condition, 
and the associated risks and benefits of the drug use. Help-seeking focuses only on the 
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disease without any drug recommendation for treatment. Reminder communicates the 
drug name and does not discuss the drug use (FDA, 2012b; Lee-Wingate and Xie, 2010).  
In terms of regulation, the FDA is the legal regulatory agency of the DTCAs 
(product claim) in the United States. The authority to regulate the DTCAs since 1962 has 
been the food, drug, and cosmetic act (FDCA) of 1938 (FD A, 2012e) and its 
amendment, namely the food and drug administration amendments act (FDAAA) of 2007 
(Abrams, 2011; S. Res. 110-85, 2007). Product claim is the only type of the DTCAs 
under FDA regulation (FDA, 2012b; La Barbera, 2012; Rollins, King, Zinkhan, & Perri, 
2010). Help-seeking is under Federal Trade Commission regulation. When a help-seeking 
advertisement mentions a drug name, it becomes a product claim and consequently falls 
under FDA regulations. Reminder advertisement is not under any regulation and is for 
experienced patients (FDA, 2012b; La Barbera, 2012).  
Product claim and help-seeking advertisements are the two independent variables 
of this study. The regulation of the DTCAs in the United States limits the risk of the 
consumer being misled by the advertisement. In addition, putting the regulations in place 
is not enough. The FDA has to use measures to gain compliance from advertisers or 
pharmaceutical companies. At this point, the utilization of medical services as the 
dependent variable of this study deserves an attention. 
Analysis of the Concept of Utilization of Medical Services 
The utilization of medical services is one of the variables of the access to health 
services. Health services refer to what a human being undertakes to affect human health 
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in terms of keeping a healthy life or condition, shifting from poor to excellent health, or 
curing a disease completely (Barton, 2010; Shi & Singh, 2008). The examples of medical 
care services are to go to the emergency room, to stay in a hospital, or to use an injury 
care in a medical facility (French, Fang, & Balsa, 2011).  
The utilization of health services belongs to the types of access to medical care 
(Aday & Anderson, 1974; Shi & Singh, 2008). Amongst the different types of access, the 
utilization of medical care services is the realization of the access to care. The realization 
can encompass four variants: type, site, purpose, and frequency of utilization (Aday & 
Anderson, 1974; Shi & Singh, 2008). The type of health care services is the particular 
care service and the care provider that can be a hospital, surgeon, nurse, or a physical 
therapist (Aday & Anderson, 1974; Shi & Singh, 2008). Then, the site is the venue or 
physical place where patient uses or receives medical care services. Moreover, the 
purpose represents the reason why the care seeker uses medical care: to prevent, to treat, 
to monitor, to stay well, to protect, or to alleviate (Aday & Anderson, 1974; Barton, 
2010; Shi & Singh, 2008). Finally, the frequency of the utilization refers to the number of 
times the care seeker uses the medical care services during certain time, the quantity of 
medical services used in a time frame, and the returning aspect of the patient to use more 
medical care services in accordance with influencing factors (Aday & Anderson, 1974). 
The medical services utilization occurs when a patient receives medical treatment or 
services. The service received varies depending on the place, the outcome, the regularity 
of the reception, and the influencing factors.  
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Factors influencing the utilization of medical services. Many factors impact the 
utilization of medical services. The personal characteristics that influence health services 
utilization are age, gender, race, education, religion, ethnic groups, and the number of 
family members (Aday & Anderson, 1974; Barton, 2010; Shi & Singh, 2008). The social 
factors that determine the use or not of medical care services are the revenue, the price, 
the employment status, the mean of payment, and the patient’s job type (Aday & 
Anderson, 1974; Barton, 2010; Shi & Singh, 2008).  
Conclusion of the Section and Contents of Chapter 1 
The FDA differentiates three types of the DTCAs: product claim, help-seeking, 
and reminder. Product claim is the only one under FDA’s regulations. Public opinions are 
conflicting about the value of the DTCAs. The DTCAs facilitate a sound conversation 
between care provider and seeker. Additionally, the DTCAs contribute to the increase in 
the costs of the care. The utilization of medical services is the realization of the access to 
health care. This realization has four dimensions: types, site, purpose, and frequency of 
the utilization. The gender, age, race, education, revenue, price, and job are some factors 
that prompt the utilization of medical services.  
The analysis of the DTCAs and the utilization of medical care services has led to 
the question of a statistically significant relationship between the two concepts. The 
answer of this question will follow in the next section in order to identify the gap in the 
literature that represents the source of this study. Chapter 1, in addition to the 
background, contains the problem statement, purpose of the study, research question(s) 
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and hypotheses, theoretical framework, the nature of the study, the operational 
definitions, assumptions, scope and delimitations, limitations, significance, and a 
summary of the chapter. 
Background of the Study 
Past researchers have claimed there is a relationship between the pharmaceutical 
DTCAs and the utilization of medical services amongst the American population in 
general. In the background of the study, I summarize the key literature on the topic, 
underline the gap, and justify the need of undertaking this study. 
PhRMA Influence 
PhRMA has impacted the progress of the DTCAs in the United States of America. 
On March 2, 2009, PhRMA published the revised version of personal rules governing the 
practice of the DTCAs of prescription drug. PhRMA’s members committed, through the 
publication of the principles, to convey plausible and true information to both providers 
and patients. According to PhRMA’s members, the information from the DTCAs 
supported the delivery and utilization of care by the two parties. The principles aimed to 
educate patients more about drug, diseases, and treatment options (PhRMA, 2011). The 
principles also enabled PhRMA’s members to follow the DTCAs laws and regulations 
from the FDA. In fact, the FDA law requires each DTCA to be true, fair in terms of 
drug’s risks and benefits presentation, and not to mislead the public. In addition, the 
DTCAs should provide information exactly as the information is in the labeling approved 
by the FDA (FDA, 2012a; Phrma, 2011). According to PhRMA and Limbu and Torres 
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(2009), the DTCAs information did not seek to persuade the consumer to purchase any 
drug or products/services after exposure. However, evidence exists and proves that the 
DTCAs prompt the utilization of medical services by patients after exposure.  
Evidence in Favor of the Correlation Between DTCAs and the Utilization of Medical 
Services 
There is evidence supporting that exposure to the DTCAs leads to the utilization 
of medical services. In that regard, 69.6% of advanced practice nurses (APNs) have 
experienced patients specifying the drug they wanted as the result of their exposure to 
DTCA (Mackert, Eastin, & Ball, 2010).  Furthermore, 57.8% of the APNs claimed 
witnessing patients shifting from an usual prescription drug under use to a new one 
because of the effect of the DTCAs (Mackert et al., 2010). Also, 63.8% of the APNs 
believed that the DTCAs enabled the patients to play more an active role during the 
utilization of medical care services while 57.7% recognized that the DTCAs prompted 
patient to ask for wrong and avoidable treatments (Mackert et al., 2010). In the same 
context, 63.5% of the APNs affirmed having seeing patients exposed to the DTCAs 
asking reasonable and logical questions during a medical conversation regarding diseases 
or treatments (Mackert et al., 2010). Finally, around 26% of the APNs agreed having seen 
patients sticking to the treatment plan under the influence of the DTCAs (Mackert et al., 
2010). 
    Limbu and Torres (2009) provided other evidence on the impact of the DTCAs 
on the utilization of medical care services by Americans in general. Thirty-one percent of 
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Americans recognized in 1999 having visited their doctors and having a discussion with 
the doctors regarding a prescription drug that they had seen in an advertisement. 
Moreover, in 1999, around 25% of a group of Americans surveyed claimed having 
visited their doctors to ask more about a condition or illness after an exposure to a help-
seeking advertisement (Limbu &Torres, 2009). In the meantime, 44% of another 1999 
survey respondents affirmed talking with their doctors about the prescription drug they 
saw in a product claim advertisement (Limbu &Torres, 2009).  In 2003, a survey 
discovered that 2 out of 5 Americans agreed having a high propensity to meet with their 
doctors to ask more about a prescription drug after being in contact with a product claim 
advertisement (Limbu & Torres, 2009). Another 2003 survey claimed 35% of 
respondents agreed that a product claim advertisement prompted them to seek and to gain 
more information from their physicians regarding the prescription medicine they saw in 
the pharmaceutical advertisement (Limbu & Torres, 2009). 
Gap From the Literature and the Need of This Study 
The data above showed a sufficient relationship between the DTCAs and the 
utilization of medical services by Americans in general. However, none of the data 
addressed the question of the relationship between the DTCAs and the utilization of 
medical care services amongst the specific group of adult dermatology patients attending 
church services at Saint Nicholas Catholic Church or/and receiving primary care services 
at MedStar Primary Care clinic in Houston, Texas. MedStar and Saint Nicholas are both 
multicultural and multiethnic group communities as described with more details in the 
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study sites section of the Chapter 3. Therefore, there is a need to address this gap found in 
the literature.  
Dermatology disease is frequently listed as the motivation of a visit to a doctor. 
Additionally, many of the 10 leading dermatology conditions by prevalence are curable. 
Those 10 diseases are herpes simplex and zoster (188.61 million), effects of sun exposure 
(123.15 million), contact dermatitis (77.29 million), hair and nail disorders (70.46 
million), juman papillomavirus (58.49 million), actinic keratosis(58.08 million), acne 
(50.18 million), cutaneous fungal infections (29.37 million), benign neoplasms (29.37 
million), and atopic dermatitis (15.17 million) (American Academy of Dermatology 
[AAD], 2011).  Indeed, herpes simplex’s sores usually disappear without patient 
receiving any treatment (AAD, 2014a). Contact dermatitis’s rashes clear simply by the 
patient avoiding what has caused them or by following the rash treatment recommended 
by a dermatologist (AAD, 2014a). Nonmelanoma skin cancer, one of the conditions 
caused by the sun exposure (basal and squamous cell carcinomas), is the most common 
and curable type of cancers (American Cancer Society, 2013a, 2013b; 
Baghianimoghadam, Noorbala, & Mahmoodabad, 2011; Skin Cancer Foundation, 
2013a). Consequently, undertaking this study is a healthy and lifesaving enterprise 
through prevention and treatment promotion of dermatology diseases. Patients will use 
more medical dermatology services under the influence of the DTCAs. Moreover, 
patients will avoid dermatology diseases or have their disease cured. The DTCAs serve as 
an informative and educational tool for dermatology patients seeking medical care 
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services. DTCA are also informative and educational for the population at risk of 
dermatology diseases as it appears in the problem statement of the study. 
Problem Statement 
The above analysis of the recent literature showed that there is a relationship 
between the DTCAs and the utilization of medical services amongst Americans in 
general. However, that relationship is not analyzed specifically amongst adult 
dermatology patients in the United States. Therefore, the empirical research problem 
under investigation is the likely relationship between the DTCAs and the utilization of 
medical services amongst adult dermatology patients. The study’s independent variables 
of interest are product claim and help-seeking advertisements. They have a probable 
relationship with the dependent variables, which are the types and purposes of medical 
services utilization by the target population. 
A cross-sectional survey method was the methodological support for this study as 
described in more detail in Chapter 3 (Creswell, 2009; Frankfort-Nachmia & Nachmias, 
2008; Rudestam & Newton, 2007). The study population was all English speaking men 
and women with permanent resident or citizen status. The participants had lived 
continuously for at least 6 months in Houston, Texas. They were also at least 18 years 
old, had seen, heard, or read (exposure) a pharmaceutical DTCA in the past 12 months at 
the time of the questionnaire completion, and had used medical dermatology service as 
the consequence of that exposure. Moreover, the participants attended church services at 
Saint Nicholas Catholic and/or were receiving primary care services at MedStar Primary 
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Care Clinic, both in Houston, Texas. The method consisted of asking a nonprobability 
sample of 120 dermatology patients to express their attitudes and views about the 
phenomenon under investigation. The selection of the sample was according to my 
personal judgment. I used the eligibility questions contained in the questionnaire to 
support the judgment and to select only qualified respondents. The respondents expressed 
their attitudes and views by responding to a series of questions on a scale of 5 points 
using their personal past experiences and backgrounds in the context of medical 
dermatology services utilization due to the exposure to the pharmaceutical DTCAs.  The 
descriptive (frequency and means score) and advance (multiple regression)  data analysis 
techniques using SPSS 21.0 version helped to organize data, to test the research 
hypotheses, and to respond to the research questions and purpose of the study.   
Purpose of the Study 
The purpose of this quantitative correlation research was to describe the 
relationship between the pharmaceutical DTCAs and the utilization of medical services 
amongst adult dermatology patients in the United States of America. In other words, I 
sought to describe the relationship between dermatology product claim, help-seeking 
advertisements, and types and purposes of the utilization of medical dermatology 
service(s) amongst adult patients aged 18 years and over. The set of the independent 
variables was the DTCAs. The DTCAs of selection were product claim and help-seeking. 
The measurement items of product claim and help-seeking were the characteristics from 
FDA. In that regard, product claim advertisement specified the name of the drug, stated 
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the treated disease, and disclosed the product risks and benefits (FDA, 2012b, 2012d; La 
Barbera, 2012). Help-seeking advertisement discussed only the condition or disease of 
interest without any drug recommendation for treatment (FDA, 2012b, 2012d; La 
Barbera, 2012).   
Conversely, the set of the dependent variables were the types and purposes of the 
utilization. The type of utilization was the specific medical service(s) that the medical 
care seeker has received at a certain point in time and at an identified place (Aday & 
Anderson, 1974; Shi & Singh, 2008). The purpose of the utilization referred to the 
reason(s) why the medical care seeker has received the medical services (Aday & 
Anderson, 1974; Barton, 2010; Shi & Singh, 2008). The measurement items for the types 
of medical services used were the medical services found in the literature reviewed on the 
utilization of medical services. In terms of the purposes of utilization of the medical 
services, the items for the observation also came from the literature reviewed in Chapter 
2. The operational definitions section of this chapter offers a clear landscape of the 
different measurement items of each set of variable.  
The research approach was a cross-sectional survey for the primary data 
collection via the administration of questionnaires to the selected sample from the target 
population. The research results enabled me to add new knowledge to the existing 
knowledge in the field of interest of this study. PT was the theoretical framework or basis 
of this study from the literature. PT was the analysis of the individuals’ behavior while 
making a decision in a risky situation or condition. An example of a risky condition was 
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to decide to seek for treatment or not when dealing with a dermatology disease. The 
research approach facilitated the answers of the research questions of this study.  
Research Questions and Hypotheses 
Main Research Question and Hypothesis 
In this quantitative research, I sought to answer the following main research 
question: Is there a statistically significant relationship between product claim, help-
seeking advertisements, and types and purposes of medical service utilization amongst 
adult dermatology patients in the United States of America? 
The related hypothesis to this main research question was the following: 
Hypothesis 1 (H0): Product claim and help-seeking advertisements do not 
significantly prompt the utilization of the types and purposes of medical services amongst 
adult dermatology patients in the United States.  
Hypothesis 1 (H1): Product claim and help-seeking advertisements significantly 
prompt the utilization of the types and purposes of the medical services amongst adult 
dermatology patients in the United States. 
Secondary Research Questions and Hypotheses  
The secondary research questions proceeding from the central question were as 
follows:  
Is product claim advertisement a predictor of the types of medical services used 
amongst adult dermatology patients in the United States? 
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Hypothesis 2.1 (H0): Product claim advertisement does not significantly prompt 
the utilization of the types of medical services amongst adult dermatology patients in the 
United Stated.  
Hypothesis 2.1 (H1): Product claim advertisement significantly prompts the 
utilization of the types of the medical services amongst adult dermatology patients in the 
United States.  
Is product claim advertisement a predictor of the purposes of medical services 
utilization amongst adult dermatology patients in the United States? 
Hypothesis 2.2 (H0): Product claim advertisement does not significantly prompt 
the purposes of medical services utilization amongst adult dermatology patients in the 
United States.  
Hypothesis 2.2 (H1): Product claim advertisement significantly prompts the 
purposes of the medical services utilization amongst adult dermatology patients in the 
United States.  
Is help-seeking advertisement a predictor of the types of medical services utilized 
amongst adult dermatology patients in the United States? 
Hypothesis 2.3 (H0): Help-seeking advertisement does not significantly prompt 
the types of medical services utilized amongst adult dermatology patients in the United 
States.  
Hypothesis 2.3 (H1): Help-seeking advertisement significantly prompts the types 
of the medical services utilized amongst adult dermatology patients in the United States.  
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Is help-seeking advertisement a predictor of the purposes of medical services 
utilization amongst skin cancer adult patients in the United States? 
Hypothesis 2.4 (H0): Help-seeking advertisement does not significantly prompt 
the purposes of medical services utilization amongst adult dermatology patients in the 
United States.  
Hypothesis 2.4 (H1): Help-seeking advertisement significantly prompts the 
purposes of the medical services utilization amongst adult dermatology patients in the 
United States.  
Theoretical Framework for the Study 
Theory Identity and Origin: Prospect Theory (PT) 
  PT is the theoretical framework of this study. PT emerged in 1979 in the context 
of decision making in a risky situation. PT focused on individuals’ behavior while 
making a decision in a risky situation (Kahneman & Tversky, 1979).  Expected utility 
theory (EUT), before the PT emergence, was the reference theory in terms of the analysis 
of the individual behavior and economic situations when making a decision or choice in a 
risky condition (Alghalith, 2010; Kahneman & Tversky, 1979; O'Connell, 2011).  EUT’s 
foundation was that individuals know most of the time what would be the consequence of 
their choice in the context of uncertainty. In other words, individuals made rational 
choices frequently. Human beings evaluate the different consequences of the choice 
facing uncertainty and opt for only the best options (Kahneman & Tversky, 1979; 
Kothiyal, Spinu, & Wakker, 2011; O'Connell, 2011). Kahneman and Tversky (1979), the 
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founders of PT, contradicted this well established theory of rational choice and economic 
behavior with the results of their experiments study. They claimed that in a situation of 
uncertainty, people were not looking for the options that offered the maximum 
satisfaction (Kahneman & Tversky, 1979; O'Connell, 2011). People analyzed the results 
of their decision as what to gain or to lose compared to the starting condition considered 
as the reference point (Kahneman & Tversky, 1979; O'Connell, 2011).  
PT Theoretical Foundations/Assumptions 
The value and weighting functions are the two assumptions of the PT as analyzed 
in Chapter 2. According to the value assumption, individuals create values through the 
change that they bring to their assets when deciding under uncertainty (Alghalith, 2010; 
Kahneman & Tversky, 1979; Kuo & Chen, 2012). The value creation comes from the 
combination of the change and its size. The evaluation of the change is in reference to the 
situation of the asset before the change (status quo). When the outcome of the decision 
under uncertainty is perceived as a loss, the individual will accept to take the risk to make 
the change happen or to create the value. The individual behaved differently when the 
outcome is a gain by refusing to take any risk (Alghalith, 2010; Kahneman & Tversky, 
1979; Kuo & Chen, 2012; Pfiffelmann, 2011). 
The weighting assumption states that each value assigned to each outcome should 
be multiplied by the same criterion used to select each prospect. However, the criterion 
should not be a probability or a measurement instrument (Kahneman, & Tversky, 1979).    
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PT Connection to This Study 
PT analyzes the individuals’ behavior when making a decision during uncertainty. 
The outcomes of the decision are introduced to the individuals as what to gain or to lose 
in reference to an initial point (reference point). The research hypotheses related the 
pharmaceutical DTCAs to the types and purposes of the utilization of medical services 
amongst adult dermatology patients in the United States. The decision to use the medical 
dermatology services or not after an exposure to a DTCA was an uncertainty condition. 
The outcomes of the decision to use or not represented a gain or a loss. The gain in case 
of the utilization was the dermatology patient recovering from the disease. The loss was 
to die because of the dermatology condition in case of nonutilization. The reference 
point, in the context of dermatology disease, was the stage of the disease before the use of 
the medical services or not due to the exposure to a DTCA. Consequently, PT was in 
alignment with this study and helped to place this study in its social context. Chapter 2 
provides more details on PT. Before then, I am going to examine the nature of this study. 
Nature of the Study 
The units or elements of analysis here are the study method, variables, and 
methodology. This research was a quantitative correlational design due to the quantitative 
nature of the research question and the statement of five hypotheses. The study method 
was the cross-sectional survey. The reasons of the selection of the cross-sectional survey 
were (a) the quantitative research question, (b) the need of generating numbers to 
describe attitudes and views, (c) the random sample, (d) the rapid data collection, (e) the 
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statistical analysis and generalization of the results when possible, and (f) the test of the 
theory based on hypotheses testing (Creswell, 2009; Frankfort-Nachmias & Nachmias, 
2008). In addition, others researches on the prediction of the utilization of medical 
services used the cross-sectional survey method (French, Fang, & Balsa, 2011).   
 The study variables were DTCAs and utilization of medical services. 
DTCAs represented the predictor or independent variable through product claim and 
help-seeking advertisements. The dependent variable was the utilization of medical 
services observed through the types and purposes of the utilization. The empirical 
research problem (Creswell, 2009) under investigation was the analysis of the impact of 
the pharmaceutical DTCAs on the utilization of medical services amongst adult 
dermatology patients. 
The study followed a specific methodology. The study population was all men 
and women adult dermatology patients living in Houston, Texas. They had all seen, read, 
or heard (exposure) a DTCA in the past 12 months from the date of the completion of the 
questionnaire and had used medical dermatology services as the consequence of that 
exposure. The members of the population were Saint Nicholas Catholic Church 
community members and/or MedStar Primary Care Clinic’s patients. G*Power 3.1.2. 
software permitted me to determine the nonrandom sample size of 82 individuals 
(rounded up to 120 in the final sample) drawn from the study population. The input 
parameters for the sample size computerization were two-tailed hypotheses testing, a 
Cohen’s d medium conventional effect size = .30, α = .05, and power = .80%. The 
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selection of the respondent followed the nonrandom purposive sample scheme rule 
(Collins, Onwuegbuzie, & Jiao, 2006; Frankfort-Nachmias & Nachmias, 2008). Thus, my 
personal judgment and the screening questions from the questionnaire guided the 
selection of the representative statistical unit for the completion of the questionnaire. 
Each participant/respondent who accepted voluntarily to participate in the study provided 
informed consent using the form duly approved by the Walden University’s Institutional 
Review Board (IRB.) office. The primary data collection was from 120 structured 
questionnaires completed by the respondents. I developed a structured questionnaire for 
the purpose of this study. The questionnaire went through a pilot study for validation 
before being used for the final study. The questionnaire has the Likert interval scale of 5 
points as the rating instrument. The completion was the face-to-face. All completions 
took place at the two study sites: Saint Nicholas Catholic Church and MedStar Primary 
Care Clinic both in Houston, Texas. The population size was unknown. A code book 
development followed after the completion and approval of the 120 questionnaires. Then, 
SPSS 21.0 was the software for the data analysis. Data analysis tools were the descriptive 
statistics (frequency and mean scores) used to organize the data. In addition, multiple 
regressions analysis was used to test the hypotheses of the study. More detail on the 
nature of this study appears in Chapter 3. 
Definitions (Operational) 
In this section, I define the key terms or concepts of the topic under investigation: 
DTCAs, utilization of medical services, medical service, and dermatology disease. Then, 
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I define the variables that measure DTCAs and the utilization of medical services that are 
respectively the independent and dependent variables of the study. The DTCAs set of 
measurement variables are product claim and help-seeking advertisements. The 
utilization of medical services set of measurement variables are types and purposes of 
utilization. Finally, I provide definitions of each item that permits empirical observation 
(the operational definitions) of the variables product claim, help-seeking advertisements, 
types, and purposes of the medical services utilization. Those items come from the 
literature reviewed in Chapter 2.  
Concepts Definitions 
Dermatology disease/condition: Disease(s) that attacks skin, hair, and nails 
(AAD, 2014b). 
DTCAs: Announcements or information  about dermatology drug, disease, 
treatment options, and devices passed directly to the dermatology patients by 
pharmaceutical companies and distributors through the television, radio, newspapers, 
telephone, brochures, magazines, or online without any medical professional mediation 
(Hall, Jones, & Hoek, 2010; Lee-Wingate & Xie, 2010).  
Help-seeking advertisement: Announcement that talks only about the dermatology 
disease or condition without any reference to a drug that can treat the condition (FDA, 
2012d, 2012f; La Barbera, 2012).  
Medical services/physician services: Dermatology healthcare services or supplies 
delivered or whose delivery is coordinated by a physician or medical doctor who has a 
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medical license to practice medicine or osteopathy (Healthcare Government 
[Healthcare.gov], 2013; U.S. Government Printing Office [GPO], 2013). 
Product claim advertisement: Announcement that states the dermatology drug 
name, the treated condition, and the risks and benefits related to the use of the advertised 
drug (FDA, 2012b, 2012f; La Barbera, 2012). 
Purpose of medical services utilization: Reason why the dermatology care seeker 
uses medical care services. The reason can be disease prevention, treatment of disease, 
monitoring, seeking well-being, protection, or alleviating a condition (Aday & Anderson, 
1974; Barton, 2010; Shi & Singh, 2008). 
Dermatology disease/condition: Disease(s) that attacks skin, hair, and nails 
(AAD, 2014b). 
Type of medical services utilization: A particular medical service or care provider 
that can be a nurse, hospital, surgeon, or a physical therapist used by a dermatology care 
seeker (Aday & Anderson, 1974; Shi & Singh, 2008). 
Utilization of medical services: Reception of dermatology services provided by or 
under the supervision of a state’s licensed dermatologist at a physical place, for an 
identified medical reason, and based on a frequency of utilization (Aday & Anderson, 
1974; Shi & Singh, 2008). 
Operational Definitions 
The following is the operationalization of the study variables or presentation of 
the measurement items. This study has a total of four set of variables. Product claim and 
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help-seeking advertisements are the two sets of independent variables. The types and 
purposes of the medical dermatology services utilization after an exposure to a 
dermatology pharmaceutical DTCA are the two sets of dependent variables. The 
measurement variables of each set of independent and dependent variables are as follows. 
Dermatology help-seeking/disease advertisement (characteristics). 
Description of the type of dermatology disease without any recommendation of a specific 
dermatology drug for treatment: The advertisement presents to the public the disease and 
its symptoms without telling what drug can treat the condition (FDA, 2012f). 
Encouraging people with the symptoms of the described type of dermatology 
disease to talk to their doctor: Recommendation to the public to consult the 
dermatologist if the person notices on the skin, hair, or nails any indication/sign of the 
advertised disease (FDA, 2012f). 
Inclusion of the company's name of the advertised dermatology drug: Designation 
of the drug’s manufacturer (FDA, 2012f). 
Provision of a telephone number/website to call or to visit for more information 
about the advertised dermatology disease (described condition): Communication to the 
public of the available telephone number or website to use to collect extra information 
regarding the particular advertised dermatology disease if necessary (FDA, 2012f). 
Dermatology product claim or prescription drug advertisement 
(characteristics).  Equal statement of the advantages and possible negative effects of the 
dermatology drug use: Presentation to the patients, in a balanced way, of what the 
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benefits and potential negative consequences are of using the advertised drug (FDA, 
2012d, 2012f). 
Equal statement of the benefits and risks associated with the dermatology drug 
use: Equitable presentation of the advantages and dangers related to the use of the 
advertised drug (FDA, 2012f). 
Inclusion in the dermatology print product claim advertisement of the statement 
"You are encouraged to report negative side effects of prescription drug to the FDA Visit 
MedWatch5 or call 1-800-FDA-1088.": Clear statement of how the patient can 
communicate to the FDA office any not desired secondary consequences of the drug 
advertised (FDA, 2012f). 
Statement by the dermatology broadcast product claim of different sources where 
to find the FDA approved prescribing information of the advertised drug (adequate 
provision): Statement of where the patient can get additional product information 
approved by the FDA. 
Statement by the dermatology audio broadcast product claim of the most 
important risks of the dermatology drug (major statement): Presentation of the most 
serious dangers that the dermatology drug user may encounter.   
Statement by the dermatology print product claim of all the drug risks approved 
by FDA as prescribing information (brief summary): Presentation of the dangerous 
aspects of the drug approved by the FDA and contained in the drug information or label. 
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Statement of the most significant dermatology drug’s risks: Presentation of the 
very important dangers that the patient may face taking the advertised drug (FDA, 
2012f). 
Statement of the name of the dermatology drug: Statement of the vulgar 
designation of the drug approved by the U.S. government (brand) and the U.S. 
government nonapproved drug designation used (generic) to advertise the drug (FDA, 
2012f). 
Statement of a minimum of one type of dermatology disease (the condition[s]) 
treated by the advertised dermatology disease drug (approved drug use by the FDA): 
Presentation of the form of dermatology disease treated by the advertised drug (FDA, 
2012f). 
Purposes of medical services utilization after exposure to dermatology help-
seeking/disease advertisement. Dermatology disease symptom management: Preventive 
measures taken, self-examination of the skin to detect any change that may indicate a 
dermatology disease type, identification of the surrounding possible causes for more 
prevention and control, and screening test when necessary (Kontos & Viswanath, 2011). 
 Early detection of the dermatology disease: Diagnosis of the condition at its 
very first stage (Kontos & Viswanath, 2011; The University of Texas MD Anderson 
Cancer Center [MDACC.], 2013a). 
Dermatology disease symptom management: Preventive measures taken, self-
examination of the skin to detect any change that may indicate a dermatology disease 
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type, identification of the surrounding possible causes for more prevention and control, 
and screening test when necessary (Kontos & Viswanath, 2011). 
Tumor/disease clearance: Complete cure of the disease (Samarasinghe et al., 
2011). 
Tumor/disease lesion excision: Use of instruments to remove the abnormal part of 
the cell or tissue and its surrounding normal cell in order to cure the dermatology 
condition (Medical Doctors Guidelines [MDGuidelines], 2013; Samarasinghe et al., 
2011). 
Purposes of medical dermatology services utilization after exposure to a 
dermatology product claim/drug advertisement. Mohs defect repair using a rhombic 
transposition: Rebuilding of the part of the body damaged by the dermatology disease 
using Mohs surgery and the rhombic transposition method (Samarasinghe et al., 2011). 
Treatment/cure of the dermatology disease looking for well-being: Complete 
destruction or removal of the dermatology disease so that the patient will become healthy 
(MDACC, 2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b). 
Tumor/disease clearance: Complete elimination of the dermatology tumor 
(Samarasinghe et al., 2011). 
Tumor/disease lesion excision: Removal of the abnormal part of the cell and its 
surrounding normal tissue (MDGuidelines, 2013; Samarasinghe et al., 2011). 
Types of medical dermatology services utilized after exposure to dermatology 
help-seeking/disease advertisement. Clinical trial/experimental: Participation in a 
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research study that seeks to know how well a dermatology disease treatment approach or 
technique works on individuals (American Cancer Society, 2013b; MDACC, 2013a; 
NCI, 2013e; The Skin Cancer Foundation, 2013b).  
Consulting dermatologist regarding any symptom related to dermatology disease 
for early detection: Discussion with the dermatologist about the possible symptoms of the 
dermatology disease that the patient has (Kontos & Viswanath, 2011). 
Cryotherapy/Cryosurgery: Use of liquid nitrogen to freeze and eliminate skin 
tissues affected by the disease (MDACC, 2013a; Samarasinghe et al., 2011; The Skin 
Cancer Foundation, 2013b). 
Curettage and cautery/Curettage and electrodessiccation/Electrodessiccation and 
curettage: Use of an instrument called a curette to scrap off the skin tumor followed by 
the destruction of any remaining tumor with the heat generated by the electrocautery 
needle (AAD, 2013; American Cancer Society, 2013b; Samarasinghe et al., 2011; The 
Skin Cancer Foundation, 2013b). 
Dermatology disease screening test: Checkup to diagnose a dermatology disease 
before any symptom appears (Kontos & Viswanath, 2011; National Cancer Institute 
[NCI], 2013e). 
Gene therapy/biological therapy: Destruction of the dermatology disease by 
including genes into the patient’s cells affected by the cancer (NCI, 2013a; The Skin 
Cancer Foundation, 2013d). 
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Clinical trial/experimental. Participation to a research study that seeks to know 
how well a dermatology disease treatment approach or technique works on individuals 
(American Cancer Society, 2013b; MDACC, 2013a; NCI, 2013e; The Skin Cancer 
Foundation, 2013b). 
Cryotherapy/Cryosurgery. Use of the liquid nitrogen to freeze and eliminate skin 
tissues affected by the disease (Samarasinghe et al., 2011; The Skin Cancer Foundation, 
2013b; MDACC, 2013a). 
Curettage and cautery/Curettage and electrodessiccation/Electrodessiccation and 
curettage. Use of instruments called curette to scrap off the skin tumor followed by the 
destruction of any remaining tumor with the heat generated by the electrocautery needle 
(AAD, 2013; American Cancer Society, 2013b; Samarasinghe et al., 2011; The Skin 
Cancer Foundation, 2013b). 
Laser surgery: Removal of the external layers of the cell (epidermis) and the 
tissues of the skin affected by the tumor using a laser strong beam light, erbium YAG 
laser, or carbon dioxide (MDACC, 2013a; NCI, 2013a ,2013d; The Skin Cancer 
Foundation, 2013b). 
Lymph node surgery: Operation of the lymph nodes for biopsy to look for 
cancerous tumors or for the removal of the lymph nodes in case of the presence of a skin 
cancer tumor (American Cancer Society, 2013b). 
Mohs micrographic surgery: Excision of a malignant tumor with the help of 
staged, intraoperative frozen sections processed in the Mohs technique. Sections excised 
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are histologically clear of malignancy (American Cancer Society, 2013b; MDACC, 
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b) 
Radiotherapy/Radiation: Destruction or treatment of the tumor in the tissue of the 
patient using X-ray beams (NCI, 2013d; Samarasinghe et al., 2011; The Skin Cancer 
Foundation, 2013b). 
Skin grafting and reconstructive surgery: Removal of the skin cancer tumor 
followed by the collection of a skin free of tumor from the patient’s body to graft the skin 
on the wound. The grafting helps the wounded part to recover completely (American 
Cancer Society, 2013b). 
Standard surgical excision/resection: Use of anesthesia to paralyze the area of the 
skin with tumor for a short time. Then, removal of the tumor surrounded with a certain 
normal skin followed by the tumor examination under microscope to make sure the entire 
tumor has been removed. Stitches are used to repair the surgical area to end the procedure 
(AAD, 2013; American Cancer Society, 2013b; NCI, 2013d; Samarasinghe et al., 2011; 
The Skin Cancer Foundation, 2013b). 
To search for additional health information outside disease advertisement 
(company’s website): Other sources of information are consulted to complete the 
information received from the advertisement and to be able to make an informed health 
decision (Kontos & Viswanath, 2011). 
Types of medical dermatology services utilized after exposure to a 
dermatology product claim/prescription drug advertisement. Adherence to the 
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dermatology disease treatment regimen: Normal participation to the treatment plan 
prescribed by the dermatologist (Frosch, Grande, Tarn, & Kravitz, 2010; Wellington, 
2010). 
Chemotherapy: Treatment of the patient using the dermatology advertised 
prescription drug following the patient’s request (American Cancer Society, 2013b; NCI, 
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b) 
Dermatology prescription drug refill: Obtainment of another quantity of the same 
drug from the pharmacist after running out of the drug (Frosch et al., 2010; Wellington, 
2010). 
Physician/dermatologist office visit: Meeting with a dermatologist/doctor in 
his/her office for medical dermatology reasons (Gray & Abel, 2012). 
Request and obtainment of a medical prescription of the dermatology drug 
advertised: Meeting with the dermatologist to request and obtain from him/her the 
prescription of the advertised dermatology drug (Gray & Abel, 2012). 
Chemotherapy: Treatment of the patient using the dermatology advertised 
prescription drug following the patient’s request (American Cancer Society, 2013b; NCI, 
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b) 
Adherence to the dermatology disease treatment regimen: Normal participation to 
the treatment plan prescribed by the dermatologist (Frosch et al., 2010; Wellington, 
2010). 
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Dermatology prescription drug refill: Obtainment of another quantity of the same 
drug from the pharmacist after running out of the drug (Frosch et al., 2010; Wellington, 
2010). 
Skin, hair, and nails health maintenance: Treating the patient to improve his/her 
appearance instead of taking care of a specific dermatology disease (AAD, 2014b). 
To talk to dermatologist/doctor about dermatology advertised medication: 
Meeting with the dermatologist/doctor to discuss the dermatology medicine presented in 
the advertisement (Gray & Abel, 2012). 
Physician/dermatologist office visit: Meeting with a dermatologist/doctor in 
his/her office for medical dermatology reasons (Gray & Abel, 2012). 
Skin, hair, and nails health maintenance: Treat the patient to improve his/her 
appearance not to take care of a specific dermatology disease (AAD, 2014b). 
Assumptions 
The achievement of this study required the consideration of three assumptions. 
The first assumption was the goodwill of the respondents. It was assumed that the 
respondents filled out the questionnaire with true information that represented their 
experience with product claim and help-seeking advertisements in the context of the 
medical dermatology service utilization. If the answers from the respondents were not 
accurate, then the research results would not be accurate and would not represent the 
reality from the field. In that case, any decision made using the results of this study would 
be wrong.  
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The second assumption was that the Likert scale of attitude was appropriate to 
measure the attitude and views of adult dermatology patients regarding the impact of 
product claim and help-seeking advertisements on the types and purposes of medical 
dermatology services used. The Likert scale of attitude was not the only scale in social 
sciences research. For instance, there was the Guttman scale that has existed since 1940 
as the result of Guttman’s research (Frankfort-Nachmias & Nachmias, 2008). The 
Guttman scale is also used for an empirical test of a group of items. However, I assumed 
that the Likert scale of attitude would be more appropriate for this study due to the scale’s 
validity and effectiveness in past research measuring peoples’ attitudes and views. 
The third assumption was the validity of the measurement instrument or 
questionnaire. I developed this study’s questionnaire. I used this questionnaire for the 
first time in this study after the pilot phase. Consequently, I assumed that the 
questionnaire was able to measure the concept under investigation in this study.  A bias 
from the instrument would affect negatively the research results.   
Scope and Delimitations 
This research has scope as well as delimitations. The scope of the study was the 
description of the relationship between product claim, help-seeking, and the types and 
purposes of medical dermatology care services utilization amongst adult dermatology 
patients aged 18 years and over and members of Saint Nicholas Catholic Church and/or 
patients at MedStar Primary Care Clinic both in Houston, Texas.  U.S. dermatology 
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patients aged 40 years and above represented 68% of the market in terms of aged (Harris 
Williams & Cooperation [Harris Williams & Co.], 2013).    
The results of the study identified the FDA’s product claim and help-seeking 
characteristics that influenced more than others a type and purpose of the medical 
dermatology services used by the target population. Furthermore, for each identified 
characteristic, I identified the respective type and purpose of utilization that the identified 
characteristic predicted more.  The selection of the above scope had multiple motivations. 
Indeed, past researchers have claimed that the dermatology DTCAs of prescription drug 
and diseases are a reality in the United States. Patients who have seen, read, or heard a 
dermatology DTCA have learned about diseases treated by the advertised drug, the 
diseases treatment options and symptom control, prevention, adherence to the treatment 
regimen, and early detection (Kontos & Viswanath, 2011).  Product claim and help-
seeking advertisements derived from this study’s results may empower dermatology 
patients and the population at risk in general, particularly in Houston, Texas, to know 
more about symptoms, treatment options, and purposes. 
The study has delimitations. The age bracket of the target population was 18 years 
and over. The population was the skin, hair, and nail adult patients (dermatology) who 
have used medical services within 1year as the consequence of having seen, heard, or 
read (exposure) dermatology DTCAs of prescription drug or disease. The adult 
dermatology patient was an American citizen or a legal permanent resident alien living 
for at least 6 months in Houston, Texas. While living in Houston, Texas, the patient 
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received primary care services at MedStar Primary Care Clinic or attended church 
services at Saint Nicholas Catholic Church. Both organizations were the study sites. In 
addition, reminder advertisement, which was the third type of the DTCAs according to 
the FDA, was not part of this study. Finally, the site and time interval of the utilization of 
dermatology health services from the framework of access (Adey & Anderson, 1974) 
were not subject to this investigation. Future researchers may consider focusing on those 
variables and populations excluded from this study.  
Limitations 
This study contained weaknesses or limitations. The limitation of the cross-
sectional method resided in the difficulty to control the factors that could affect the 
internal and external validity of the research. A cross-sectional survey method led to the 
use of sophisticated instruments of questionnaire and computer software SPSS 21.0 for 
data collection and analysis. A cross-sectional survey permitted data collection only one 
time and not continuously as described in Chapter 4 (Creswell, 2009; Frankfort-
Nachmias & Nachmias, 2008). The first threat to validity was the environment and the 
time of completion of the questionnaire. The settings of completion were not completely 
free of any source of noise or distraction. The parishioners were holding meetings during 
the questionnaire completion around the parish hall, which was the completion setting at 
Saint Nicholas Catholic Church. The participants heard some noises from time to time 
from the meeting attendees. The participants completing the questionnaire at the MedStar 
Primary Care Clinic’s meeting rooms heard some noise from the television located in the 
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lobby area or from the clinic personal and other patients’ conversations. The doors were 
constantly kept closed at the two sites during completion to limit the effect of the noise 
on the participant.  The questionnaire completion time may have not been appropriate for 
the respondent to avoid any bias in the answers (Creswell, 2009; Frankfort-Nachmias & 
Nachmias, 2008). The time of completion was after church service or meeting with a 
doctor. The participants at that time were possibly thinking about going home. However, 
they all agreed on the completion time during recruitment and did not express any rush 
until the end of the completion.   
The second threat was the construct validity: the use of a new questionnaire. I 
designed the questionnaire. It was not sure if the new questionnaire would be capable 
exactly of measuring the concepts under investigation. The pilot study results validated 
the questionnaire and verified the capability of the questionnaire to measure the concepts 
of the DTCAs and the utilization of medical dermatology services. Experts’ opinions of 
dermatologists in Houston, Texas, and the DTCAs professionals at the FDA’s Office of 
Prescription Drug Promotion (OPDP) validated the questionnaire before the pilot study. 
The final study results were consistent with the pilot study.   
The last limitation was the sampling bias that could occur during this study due to 
the lack of a sample frame and could affect the external validity of the study results.  In 
that regard, all the final respondents met the study’s inclusion criteria. The inclusion 
criteria used in the questionnaire permitted me to filter the respondents during the 
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recruitment of each respondent in order to avoid a sampling bias. This study used a 
convenient sample not a random sample.  
Significance 
The study closed the gap and added knowledge to the area of the dermatology 
DTCAs and medical utilization. I sought to know if dermatology product claim and help-
seeing advertisements prompted the utilization of the types and purposes of medical 
services amongst adult dermatology patients in the United States with the application in 
Houston, Texas.  Therefore, the study results added new knowledge to the DTCAs 
influencing the utilization of medical dermatology services in America. The research 
showed, in the specific era of dermatology, the FDA’s characteristics of product claim 
and help-seeking advertisements that predicted more a type and purpose of medical 
services used by the study population. I identified a specific type and purpose of 
utilization predicted more by the considered characteristic. Finally, future researchers will 
use these results as the source of secondary data for their research.  
The study has practice and policy implications. As stated earlier, this study results 
provide the DTCAs characteristics that predicted more than other characteristics a 
specific type and purpose of utilization of medical dermatology services amongst the 
target population. Those characteristics could be the communication axes for new 
DTCAs of pharmaceutical companies exclusively targeting the population under 
investigation. Indeed, the DTCAs inform and educate patients about drug, diseases, and 
treatment options. DTCAs prompt patients to adhere to the drug treatment plan (Phrma, 
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2011).Therefore, the statistically significant relationship between the DTCAs and the 
utilization of medical dermatology service(s) could lead to the new dermatology product 
claim and help-seeking advertisements directed directly to the adult dermatology patients 
in Houston, Texas. The target population could benefit from the following values of the 
advertisements: education, information, and informed conversation with dermatologists 
(PhRMA, 2011).  As far as policy is concerned, the FDA as well as Phrma could use the 
results of this study to develop new DTCAs regulations, policies, principles, and laws or 
to revise the existing one. 
The study also has social change impacts. The social change implication is the 
health promotion amongst adult dermatology patients in Houston, Texas. In that regard, 
help-seeking advertisements from these results will educate and create awareness 
amongst patients about dermatology disease, early detection due to screening test, and 
skin, hair, and/or nails health maintenance treatment. Conversely, product claim 
advertisement created based on these results could promote dermatology prescription 
drug requests, educate and inform patients about prescription drug, and prompt doctor 
visits amongst the target population. Skin cancer is the driving force of the dermatology 
service demand in the United States (Harris Williams & Co., 2013). Health promotion in 
the context of skin cancer has various motivations. Early detection and early treatment 
can lead to the cure of the skin cancer. From 1992 through 2006, the nonmelanoma skin 
cancer treatment increased almost up to 77% (American Cancer Society, 2013a; NCI, 
2013a; Skin Cancer Foundation, 2013b).  
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Summary 
Previous researchers have addressed the relationship between the pharmaceutical 
DTCAs and the utilization of medical services. In 1999, 44% of Americans discussed the 
prescription drug they saw in a product claim advertisement with their doctors. However, 
there was no evidence of the impact of the dermatology DTCAs on the utilization of 
medical dermatology services amongst adult patients who live in Houston, Texas and 
who receive primary care services at MedStar Primary Care Clinic or attend the church 
services at Saint Nicholas Catholic Church. This study filled the gap.  
The quantitative correlation design using a cross-sectional survey method was the 
research design. The intent of the research was to describe the relationship between the 
dermatology pharmaceutical DTCAs and the utilization of medical dermatology care 
services amongst skin, hair, and nails adult patients. The independent variables were the 
dermatology product claim and help-seeking. The dependent variables were the types and 
purposes of the utilization of medical dermatology services. The study has five 
hypotheses. PT was the theoretical framework of this study.  
Furthermore, I defined the variables of the study in this chapter: product claim 
and help-seeking advertisements (independent variables) and types and purposes of 
medical services utilization (dependent variables). I also identified and defined the items 
used for the empirical observation of the variables. The study has three assumptions: the 
respondents’ goodwill to provide with true answers, the validity of the Likert scale of 
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attitude to measure adult dermatology patients’ attitudes and views, and the validity of 
the questionnaire to be used for the data collection.  
The research scope was the description of the relationship between product claim, 
help-seeking, and the types and purposes of medical services used exclusively amongst 
adult dermatology patients in Houston, Texas. The limitations of the study were the 
cross-sectional survey method, the use of a new questionnaire as measurement 
instrument, and the possible bias from the sampling procedure. The key social change 
value of this study was the health promotion amongst the target population: awareness 
and education.   
Chapter 2 that follows addresses the literature on the variables of the study in 
order to learn about what has been said so far regarding the problem under investigation. 
Then, the literature reviewed permits the identification of the gap that justifies the 
essence of this research study. Furthermore, Chapter 2 covers PT as the theoretical 
framework of the study, the literature search strategy, and the study’s model of the impact 
of product claim and help-seeking advertisements on the types and purposes of the 
utilization of medical dermatology services. Finally, in Chapter 2, I present the study 
model that I elaborated, tested empirically and statistically through hypotheses testing.       
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Chapter 2: Literature Review 
Introduction  
This chapter contains a background, literature review method, approach to the 
resources identification used in this literature review, and the theoretical framework (PT) 
of the study. In this chapter, I also analyze the independent and dependent variables of 
the study and present the explicative model found in the literature of the impact of DTCA 
of prescription drug on the utilization of medical services after being exposed to a DTCA. 
Finally, Chapter 2 contains the study’s model of the relationship between the 
dermatology DTCAs and the utilization of medical dermatology services amongst adult 
patients after an exposure to a DTCA.  
Background, Problem and Gap 
In this section, I describe the evolution of the pharmaceutical DTCAs. The 
phenomenon of the DTCAs in the United States goes back up to 1980 as described in 
Chapter 1 (Dieringer et al., 2011; FDA, 2012c). The FDA (2012a) revised in 1997 the 
policy about the DTCAs and authorized the drug manufacturers to broadcast the branded 
products’ advertising (Bradford & Kleit, 2011; Dieringer et al., 2011; Frosch et al., 
2010). This progress of the DTCAs increased in 1999. The FDA required, at that time, 
that the marketers provided true information and the right direction to costumers in 
marketers advertising (Dieringer et al., 2011; FDA, 2012a).  
The pharmaceutical DTCAs represent the information about prescription drug or 
diseases mostly that pharmaceutical companies are passing directly to the consumers via 
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advertising and not through the pharmacists and physicians (Hall et al., 2010; Lee-
Wingate & Xie, 2010). The expansion of the DTCAs of prescription drug has led to the 
recurrent question of the impact on the consumer in terms of the utilization of medical 
services after an exposure (Limbu & Torres, 2009). In that regard, researchers have 
claimed more than 53 million consumers have talked to their physicians about a 
particular prescription drug following their exposure to the drug advertising in the United 
of America (Limbu & Torres, 2009). Additionally, approximately 21.2 million consumers 
talked to their doctors about an illness because of a drug advertisement (Limbu & Torres, 
2009). In the same logic, children consumed more prescription drug between 2007 and 
2008. Indeed, amongst five children surveyed, at least one used a minimum of one drug 
prescribed by a physician (Gu, Dillon, & Burt, 2010; La Barbera, 2012).  These multiple 
figures point to the relationship between the DTCAs of prescription drug and disease and 
the utilization of medical services in general in the United States (Kim & Park, 2010; 
Macias, Lewis, & Baek, 2010). However, little is known about the relationship between 
the DTCAs of prescription drug and disease and the utilization of medical services 
amongst adult dermatology patients who live in Houston, Texas, and are receiving the 
primary care services at MedStar Primary Care Clinic, or attending the church services at 
Saint Nicholas Catholic Church. Consequently, this study seeks to address that gap. The 
literature review that follows aims to analyze, in relation with the identified gap, the 
current publications on the relationship between the DTCAs and the utilization of 
medical services to justify the relevance of this etude. 
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Literature Review Method and Chapter’s Content 
Creswell’s (2009) literature review method (pp. 25-26) guides the present chapter. 
According to Creswell, a quantitative literature review has two steps that are: 
1. The researcher creates a thorough outline of the themes of interest and the 
  gathers the related literature. 
2. The researcher analyzes of the topics in the chapter consecrated to the 
  literature review. 
When analyzing the literature review’s possible approaches, Creswell stated, “Another 
approach is to develop a detailed outline of the topics and potential references that will 
later be developed into an entire chapter, usually the second, titled “Literature review”, 
which runs from 20 to 60 pages or so” (p.26).        
Resource Identification Method 
 The identification of the resources started with the creation of the identifiers or 
search terms. The identifiers were prospect theory, Direct-To-Consumer Advertisements, 
prescription drug advertising, product-claim advertisement, help-seeking advertisement, 
utilization of medical services, medical services, types of medical services, purposes of 
the utilization of medical services, dermatology services, dermatology diseases and 
treatments, and Direct-To-Consumer Advertisements and dermatology diseases 
treatments. The keywords permitted me to search for peer-reviewed articles to identify 
the original and current publications about the theoretical framework, and the 
independent and dependents variables of the study. The searches were through multiple 
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databases at Walden’s virtual library: “Academic Search Complete/Premier”, “ProQuest 
Central”, and “Google Scholar”. Primary searches took place on the website of the 
United States FDA (2011b) to identify the characteristics of the pharmaceutical DTCAs 
of prescription drug and diseases used as independents variables of the study. The 
American Cancer Society (2013a) and American Academy of Dermatology’s websites, 
and Shi and Singh (2008) provided the dependent variables and operational definitions.  
The search for peer-reviewed articles at the Walden library combined three search 
modes called “Boolean/Phrase”, “find all my search terms”, and “find any of my search 
terms”. The selection of the “Scholarly (Peer-Reviewed) Journals” option during the 
search assured the retrieval of only the articles from the peer-reviewed journals. “Ulrich’s 
Periodicals Directory” at Walden library permitted me to assure the peer-reviewed nature 
of the journal. The “publication date from” option enabled the specification of the desired 
5 years to which the retrieved articles should belong. This literature review used only the 
relevant articles considering the different topics of interest. These search efforts covered 
the period of Summer 2011 through Summer 2014. From January through June 2013, the 
review of the retrieved articles permitted to delete and replace the articles older than 5 
years with more recent ones.  
Theoretical Framework of the Study: PT  
Origin  
The origin of PT goes back to the year 1979. In fact, PT was a decision making 
theory model that permitted an individual to describe how to make a choice when facing 
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a risky situation or uncertainty (Kahneman & Tversky, 1979; Kothiyal et al., 2011; Mello 
& Cajueiro, 2010; O'Connell, 2011).  This theory was the main idea of Kahneman and 
Tversky’s works achieved in 1979. It was in reaction to the expected utility theory’s 
(EUT) failure (Alghalith, 2010; Kahneman & Tversky, 1979). EUT was the most used 
model by researchers and economists during those years to describe individuals’ 
behaviors and economic phenomena in the risky conditions (Alghalith, 2010; Kahneman 
& Tversky, 1979; O'Connell, 2011). EUT’s assumption stated that the probability 
associated with the outcome of a possible choice was always known. The reason was that 
the subject always compare different outcomes and selected only those that offered a 
maximum benefit, satisfaction, or welfare (Kahneman & Tversky, 1979; Kothiyal et al., 
2011; O'Connell, 2011). Conversely, Kahneman & Tversky conducted experiments 
study. The study results were a breakthrough because they contradicted the well-
established EUT (Kahneman & Tversky, 1979; Kothiyal et al., 2011; O'Connell, 2011). 
Kahneman & Tversky’s experiments’ results corroborated the idea that people made their 
choices in a risky condition after analyzing the different outcomes as what to gain or to 
loose based on a referent point of the asset or the condition (Kahneman & Tversky, 1979; 
O'Connell, 2011). In other words, agents evaluated the outcomes of their decision as 
gains and losses compared to the status quo of the situation or asset (Kothiyal et al, 2011; 
O'Connell, 2011). 
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Characteristics  
PT was a descriptive model initially for a noncomplex prospect. The prospect had 
money as outcomes with known probability associated with the results. However, PT was 
applied to the multiple choices games with financial results or not (Kahneman & 
Tversky, 1979). The following analysis is in the context of noncomplex 
prospects/opportunities.  
PT has two main assumptions: the value and weighting functions (Alghalith, 
2010; Kahneman & Tversky, 1979; Kuo & Chen, 2012). The first assumption or value 
stated that the modifications that happened to the subject’s asset/good were the creation 
of value for the decision making under uncertainty. Thus, this value should be attributed 
both to the change and size of the value. The analysis of the value was about the status 
quo of the subject’s good (Kahneman & Tversky, 1979). The value function was near or 
concave to the gains and far or convex from the losses as outcomes of the decision made 
under uncertainty (Alghalith, 2010; Kahneman & Tversky, 1979; Kuo & Chen, 2012; 
Pfiffelmann, 2011). In other words, the subject took or accepted risk when he/she 
perceived the outcome of the decision regarding a prospect as losses. Conversely, when 
the agent perceived the outcome as gains, he/she would not take any risk (Alghalith, 
2010; Kahneman & Tversky, 1979; Kuo & Chen, 2012; Pfiffelmann, 2011). Finally, the 
curve of the value function inclined more toward gains than the losses (steeper) 
(Kahneman & Tversky, 1979; Pfiffelmann, 2011). 
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 The second assumption of PT was the weighting. PT weighting referred to the 
multiplication of the value attributed to each outcome by the criterion applied to the 
selection of each selected opportunity. According to PT, the criterion was neither 
probabilities nor measurement instrument for the subject’s belief during the choice. 
However, when the agent considered the low probability, the agent always over weighted 
the small probability during the choice (Kahneman & Tversky, 1979). There were the 
steps applicable to the decision making under uncertainty. 
In addition to the assumptions, PT had two key steps applied to a questionable 
choice to facilitate the decision making by the subject: the “editing” and the “evaluation” 
(Kahneman & Tversky, 1979, p. 274). A subject started making a choice under risk by 
trying to comprehend or differentiate the prospects in presence (“editing”). Firstly, the 
“editing” efforts of the subject consisted of building a perception of the offers or 
prospects regarding what could be the gains or the losses (outcomes) of the decision 
(Kahneman & Tversky, 1979; Kothiyal et al, 2011; O'Connell, 2011). The perception of 
the decision’s outcomes as gains (quantity or amount to receive) and losses (what to 
release) depended on the subject’s current state or condition: he or she had not gained or 
lost anything yet. This was the “neutral reference point” in the PT (Kahneman & 
Tversky, 1979; Kothiyal et al., 2011; O'Connell, 2011). Secondly, the perception in the 
“editing” step led to the reduction phase of the prospect. This reduction consisted of 
adding together the probabilities associated with the same opportunity. The addition 
yields the new probability (the double of the two added) added to the opportunity 
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(Kahneman & Tversky, 1979). Finally, the “editing” continued with the separation of the 
part of the prospect that had a risk from the one that did not have any (Kahneman & 
Tversky, 1979). 
 The profiles of the opportunities obtained from the “editing” process enabled the 
subject to compare the prospects/opportunities and to opt for the one or those with first 
value: “evaluation”. The “evaluation” focused on the overall edited prospect’s global 
value (Kahneman & Tversky, 1979).                
 Two scales permitted to conduct the “evaluation”. The first scale measured the 
impact of the prospect’s associated probability on the global value of the considered 
prospect. The second scale measured the subjective value of the opportunity based on a 
number assigned subjectively to the prospect’s outcomes (Kahneman & Tversky, 1979). 
PT has limitations.               
Limitations 
Regarding the limitations, PT did not integrate the preference variable amongst 
the assumptions. Sometimes the agent made a choice when making a decision under 
uncertainty because he or she preferred a particular prospect. In other words, the 
preference was enough for the agent to select an opportunity without any other 
consideration (Kothiyal et al, 2011; Pfiffelmann, 2011). This drawback generated an 
evolution of the PT that became cumulative prospect theory (CPT) in 1992. In 1992, 
Daniel Kahneman and Amos Tversky added this feature to their original PT model and 
created a new model called CPT (Pfiffelmann, 2011). Besides, PT was created to describe 
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behavior when dealing with simple prospects and only in the risky conditions (Kothiyal 
et al., 2011; Kahneman & Tversky, 1979). PT is applied in the concrete social problems 
nowadays.   
Contemporary Applications of P T 
PT application has occurred in many fields to describe social phenomena. 
Morrissette (2010) used PT to facilitate a clearer understanding of Russian President 
Boris Yeltsin’s political and international behavior in 1994 under uncertainty. In 1994, 
President Yeltsin decided and launched an invasion of the Republic of Chechnya. 
Morrissette used PT to analyze Yeltsin’s behavior due to the theory ability to describe 
decision taken subjectively under uncertainty. Moreover, PT analyzed the decision 
outcomes as gains or losses (Morrissette, 2010). The research question was why did 
President Yeltsin launch the military invasion of the Republic of Chechnya in 1994? The 
review of the literature was the research method applied to answer the research question. 
The study reached the conclusion that President Yeltsin attack or use of force was a risk 
as supported by the PT. The attack was risky because of an improper preparation, the 
timing was not necessary at that time, and the invasion could not rebuild the Yeltsin’s 
domestic tarnished popularity (Morrissette, 2010). Future research will find here an 
example of the implementation of the PT to describe contemporary issues. However, the 
study lacks empirical results of the application of the PT to the Yeltsin case. 
Kuo and Chen (2012) applied PT to the investment phenomenon. Indeed, when 
the price of a good or asset changes positively, investors have the high propensity to sell 
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them while purchasing those with deteriorated values. Kuo & Chen used the Taiwan 
investors’ disposition patterns survey date to answer the research question. The research 
question was about the appropriate time for the investors to sell assets with deteriorated 
price, and the length of time to keep the assets that have gained value. As the results, the 
researchers found that at least 50% respondents have disposition patterns instead of 
disposition effect to sell assets that have gained value and to buy goods whose price has 
fallen (Kuo & Chen, 2012). This example will inspire future researchers. The research 
results shed light on the fact that investors had disposition patterns that were different 
from disposition effects in a risky situation of buying deteriorated assets (Kuo & Chen, 
2012). However, the reason of that difference was still unclear at the end of the study.  
O'Connell (2011) used the lens of PT to analyze and describe the strategies that 
presidential candidates used to manage their campaign during primary elections. The 
candidates of interest were the following United States presidential candidates: Edward 
Kennedy, Jimmy Carter, Ronald Reagan, and Georges H W Bush in the 1980s 
(O'Connell, 2011). The researcher discovered that PT’s risk averse and acceptance impact 
the management of political campaign by candidates. The study method was the in-depth 
interview (O'Connell, 2011). The research question was why each candidate wanted to 
become president?  The author answered this question by analyzing each candidate’s 
strategic options during the campaign regarding riskiness. Therefore, Kennedy in 1979, 
Reagan in 1980, and Carter in 1980 were in a situation of loss while choosing options for 
their campaign. Carter in 1979/1980, Bush in 1980, and Kennedy in march-april 1980 
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perceived the outcomes of their campaign options as gains domain (O'Connell, 2011). 
This research has a credit of a successful application of PT to the electoral campaign 
management of the candidates. However, the studies failed to tell if the phenomena 
considered as losses or gains were due to the nature of the political party and the 
personality of the candidate, or were independent of the two variables. This said PT 
corresponds with this study. 
Matching With This Study 
There are many reasons why PT was a match to the present study. The study’s 
target population was adult dermatology patients of both sexes, who lived in Houston, 
Texas, received primary care services at the MedStar Primary Care Clinic or/and attended 
to the church service at the Saint Nicholas Catholic Church. Then, he or she was living 
continuously for at least six months in Houston, Texas. They were adults aged 18 years 
and over who had seen, heard, or read a dermatology product claim or help-seeking 
advertisement (exposure) in the past 12 months and had utilized medical dermatology 
service(s) as the consequence of that exposure.  
PT, as analyzed earlier, was the analysis of the human behavior when making a 
decision in a risky situation. The agent perceived the outcomes of the decision as gains or 
losses in relation to a reference point or status quo of the condition. The subject was risk 
acceptant when he/she saw the outcomes as benefits. He/she was a risk adverse when the 
consequences of the decision were losses (Kahneman & Tversky, 1979; Kothiyal et al, 
2011; O'Connell, 2011).   
52 
 
 
 
The condition or reference point for the dermatology patient is his/her health 
status: the presence of the dermatology disease. The prospect or risky situation is to 
recover/stay alive due to medical dermatology services use after an exposure to the 
DTCAs or to lose the life/decease in the case of nonutilization. The decision to make by 
the dermatology patient is to use medical services or not after an exposure to a 
dermatology product claim or help-seeking advertisement. The dermatology patient who 
decides not to use medical dermatology services after an exposure to a product claim or 
help-seeking advertisement because he/she perceives the outcome of this decision as a 
loss or death is a risk adverse. Conversely, the dermatology patient who decides to utilize 
medical services after an exposure to a product claim or help-seeking advertisement 
because he/she perceives the outcome of the decision as a gain is a risk acceptant. Thus, 
to decide to use medical dermatology services or not is a risky situation. The patient 
obtains the restoration of his/her health by seeking medical dermatology services or lost 
his/her life by not seeking medical services (Kahneman & Tversky, 1979). The preceding 
analysis showed the alignment between PT and this study. Product claim and help-
seeking advertisements as are the independent variables. 
Analysis of the Independent Variables: Product Claim and Help-Seeking 
Advertisements 
Product Claim Advertisement’s Regulatory Agency  
The United States FDA is the regulatory agency of product claim advertisement. 
The FDA is the regulator of the product claim advertisement since 1962 (Dave & Saffer, 
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2012; FD A, 2012a, 2012c; Mulligan, 2011). Product claim is the only pharmaceutical 
DTCA under the FDA’s regulations (FDA, 2012b; La Barbera, 2012; Rollins et al., 
2010). Conversely, help-seeking and reminder are not under  FDA’s regulations  giving 
that they are not mentioning any drug or device name as required by the law (FDA, 
2012b; La Barbera, 2012; Rollins et al., 2010).  
In the same context of regulations, Abrams (2011), Dave & Saffer (2012), Eby 
(2012), FDA (2012a, 2012c) and senate resolution(S R) 110-85 (2007) addressed the 
legal setting. In that regard, The FDA regulates product claim advertisement due to the 
law named federal food, drug, and cosmetic act (F DCA) of 1938 (FDA, 2012e), and its 
amendment of 2007. Indeed, federal trade commission (FTC) played this role until 1962. 
Then, Kefauver-Harris brought modifications to the federal food, drug, and cosmetic act 
in 1962 (Dave & Saffer, 2012; FDA, 2012e; Mulligan, 2011). According to the 1962 
modifications, each marketer had to prove and support with evidence the fact that the 
advertised drug did not represent any danger to the public. Then, the advertised drug was 
capable of keeping the manufacturing promises. Moreover, the marketer had to provide in 
print advertisements the risks and benefits of using the advertised drug. Finally, the 
modifications placed product claim or prescription drug advertising under the FDA’s 
regulatory power. In one word, Kefauver-Harris’ modifications of 1962 recognized and 
accepted that prescription drug advertising was essential to pharmaceutical companies 
(Dave & Saffer, 2012; Mulligan, 2011). However, the FDA amended this law in 2007. 
The 2007 amendment gave birth to a new law: food and drug administration amendments 
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act (FDAAA) of 2007 (Abrams, 2011; S. Res. 110-85, 2007). The FDCA’s section 
502(n) on prescription drug advertisements was amended by adding to the content the 
FDAAA’s section 901(d)(3)(A) entitled provision  on DTCAs (Abrams, 2011; S. Res. 
110-85, 2007). Therefore, the FDA’s oversight of the DTCA of prescription drug 
activities followed the FDAAA’s section 901(d)(3)(A) (Abrams, 2011; S. Res. 110-85, 
2007).          
The office of prescription drug promotion (OPDP) within the center for drug 
evaluation and research (CDER) at the FDA implements the supervision strategies of the 
drug advertisement activities (Eby, 2012; FDA, 2011c). The OPDP ensures that each 
advertisement complies with the law in place or applies sanctions in case of the violation 
(FDA, 2011c). Then, the OPDP provides drug advertisers with training opportunities to 
get familiar with the law and regulations. Finally, OPDP exhorts drug advertisers to 
improve the quality of the communication of the drug selling information to stakeholders 
regularly (FDA, 2011c). The office regulates broadcast and printed advertisements such 
as mailing, booklets, brochures, posters, and presentations (Eby, 2012). 
I clarified in this subsection the regulatory authority (FDA) and the legal setting 
of the product claim advertisement as the independent variable of this study (Dave & 
Saffer, 2012; FD A, 2011a, 2011c; Mulligan, 2011). However, I did not address the issue 
of relationship or not between product claim and the types, and purposes of utilization of 
medical dermatology services amongst adult patients in the United States. 
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Product Claim Advertisement’s Legal Content 
Product claim advertisement’s content is stated by a particular United States 
public law. The above referred FDCA law requires in its section 502(n) that the statement 
should contain (a) the popular name of the drug, (b) the list of the drug’s ingredients and 
their quantity (formula) in conformity with this act, and (c) a quick note on its 
contraindications, effectiveness, and side effects (FDA, 2012a). Conversely, other authors 
argued that the product claim should have a brief summary (print advertisement), a major 
statement, the drug side effects, and contraindications (broadcast advertisement) of the 
advertised drug (Dave & Saffer, 2012; FDA, 2012b; Flood, 2010; La Barbera, 2012; 
Mendonca et al., 2011). In addition to FDCA’s section 502(n), the FDAAA’s provision 
901(d) (3) (A) stipulates that the major statement has to be “clear”, “conspicuous” and 
“neutral” (Abrams, 2011; S. Res. 110-85, 2007, p. 940). 
 Meanwhile, the FDA (2012b), La Barbera (2012), Phrma (2011) shed light on a 
different component of printed product claim:  a statement motivating the readers to 
report to the FDA via MedWatch5 or 1-800-FDA-1088 any drug’s negative side effect. 
The statement was the provision 906(a) of FDAAA (S. Res. 110-85, 2007).  However, 
the FDA and Frosch et al. (2010) argued that the broadcast product claim has to 
communicate to the viewers the source of risk related information about the drug 
advertised. The sources could be a care provider, a free of charge phone line, a magazine, 
or a website. Finally, all product claim announcement most be correct and should not lose 
the consumer (FDA, 2011a; 2011c; Phrma, 2011). 
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I have identified in this subsection the basic legal components of product claim as 
the independent variable of the study: brand name, formula, and quick note (FDA, 
2011a).  
However, I am still silent on the possible relationship between product claim and the 
types and purposes of utilization of medical dermatology services by an adult patient. 
There are different types of DTCAs. 
DTCAs Typology 
 There are different types of DTCAs. The FDA distinguishes three kinds of the 
DTCAs: (a) product claim, (b) reminder, and (c) help-seeking (FDA, 2012b, 2012d; La 
Barbera, 2012; Mendonca, McCaffrey III, Banahan III, Bentle & Yang, 2011). The 
product claim announcement has three key features that are (a) drug’s name, (b) the 
disease/condition that the drug can treat, and (c) the benefits and risks associated with the 
drug use (FDA, 2012d, f; La Barbera, 2012; Mendonca et al., 2011). Al contrary, other 
authors claim that reminder advertisement contains only the drug name, while help-
seeking advertisement details the disease/condition without any reference to a drug for 
the treatment (FDA, 2012d, 2012f; La Barbera, 2012; Mendonca et al., 2011).  
The two types of DTCAs are the focuses of this study: product claim and help-
seeking that are the sets of independent variables. Product claim and help-seeking were 
the two familiar and frequent types in the DTCAs landscape (La Barbera, 2012; 
Mendonca et al., 2011). Product claim had an awareness rate of about 80% amongst 
Americans (Mendonca et al., 2011). The resources for the analysis of those two types 
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were available, and the contents had many features for analysis (FDA, 2012b; La 
Barbera, 2012). Conversely, reminder announcement was rare in the practice, and limited 
concerning the content (just product name) (FDA, 2012d; La Barbera, 2012). Indeed, 
reminder announcement was subject to critiques or calls for banishment because of the 
content limitation and lack of accuracy (FDA, 2012d; La Barbera, 2012). Moreover, 
reminder announcement did not provide information regarding the advertised drug. 
Consequently, reminder announcement could not help the patient to make an informed 
medical choice (FDA, 2012b; La Barbera, 2012).   
The outcome of this analysis is the three types of DTCAs and their characteristics: 
product claim, help-seeking, and reminder. The two independent variables that are 
product claim and help-seeking are clear and identified. But, the question of the possible 
relationship between product claim and help-seeking, and the types and purposes of the 
utilization of medical dermatology services by the adult patient is still without an answer. 
At this point, I am going to analyze the current state of cons and pros debate about the 
product claim and help-seeking advertisements. 
Product Claim and Help-Seeking Advertisements Cons Debate 
Product claim advertisement.  The authors have condemned product claim 
advertisement for many reasons. Dave and Saffer (2012), Frosch et al. (2010), La Barbera 
(2012), and Lee and Begley (2010) reproached product claim announcement to 
unnecessarily generate an overutilization of medical services. According to the authors, 
advertisers seem to have underestimated or ignored the product claim’s capability of 
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prompting the consumers’ medical options after exposure (Dave & Saffer, 2012; Frosch 
et al., 2010; La Barbera, 2012; Lee & Begley, 2010). Then, Chaar and Lee (2012) and La 
Barbera claimed that product claim violates the patient right to make personal medical 
decisions: patients sometimes decide about their health based on the influence of the 
product claim and not on a personal initiative. The violation could lead to a harmful 
choice for the consumer.  
Moreover, La Barbera (2012), Kontos and Viswanath (2011), and Willington 
(2010) thought that product claim information was capable of empowering the patient to 
interpret and to understand the drug’s chemical components and effect side statements. 
Indeed, the exposed patient was not knowledgeable enough to manipulate the message of 
advertising for proper health decision making (La Barbera, 2012; Kontos & Viswanath, 
2011; Willington, 2010). Therefore, the patient still needed the physician’s help for the 
utilization of the drug despite the education provided by the product claim announcement 
(Kontos & Viswanath, 2011; La Barbera, 2012).  
In the same logic of cons debate, Mendonca et al. (2011) conducted experimental 
research about new information search after being exposed to the product claim 
announcement. They found that product claim had a small capacity of persuading the 
exposed patient to seek for additional information about the availability of new medicine 
outside of the announcement. Then, the two group posttest experimental design of 
Mendonca et al. (2011) concluded that product claim as well as help-seeking 
59 
 
 
 
announcement did not decide asthma patients to gather new information regarding the 
possible new drug.  
Conversely, Brody and Light (2011) and Willington (2010), in the context of cons 
debate analysis, took the discussion to the arena of the patient protection. According to 
those two authors, certain approved and advertised drug were risky, unsafe, and 
inefficacious for the patient health. They were capable of developing a new condition or 
disease to the patient going through a drug therapy for another illness (Brody & Light, 
2011). This limitation was evident through the annual consequences of drug therapy in 
the United States regarding adverse reactions (46 million), hospitalizations (2.2 millions), 
and deaths (111,000). The patient is still not safe from such harms (Brody & Light, 
2011).  
La Barbera (2012), Kornfield et al. (2013), and Willington (2010) opposed to the 
preceding critiques the modification of the physician prescription habit by the product 
claim. Indeed, the authors claimed that product claim provoked a change in the familiar 
doctor practice of prescribing the drug to patients (La Barbera, 2012; Kornfield et al., 
2013; Willington, 2010). Physician, usually, selected the drug to prescribe to the patient. 
Now, the patient requested and obtained from his/her physician an advertised drug. The 
patient, by doing so, changed the usual course of medical prescribing (La Barbera, 2012; 
Kornfield et al., 2013; Willington, 2010). The physician could create overprescribing by 
honoring the patient’s request for the advertised drug (Kontos & Viswanath, 2011).  
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Contrarily to La Barbera (2012) and Willington (2010), Hall et al. (2010) and Lee 
& Begley (2010) criticized product claim to be a threat to the patient-physician 
relationship stability mostly amongst minority groups. In fact, a disagreement between 
both parties when the exposed patient would be requesting from the physician the 
prescription of a particular advertised drug could break the relationship (Hall et al., 2010; 
Lee & Begley, 2010). Patient reacted to the physician’s refusal to prescribe the advertised 
drug by selecting a new doctor (Lee & Begley, 2010) 
However, Frosch et al. (2010) considered product claim announcement as a health 
inequity driver amongst cardiovascular disease patients. According to the authors, 
product claim rarely contained African American’s values, beliefs, and cultural elements 
when centered on the preventive drug for cardiovascular disease. Moreover, marketers 
published less cardiovascular product claim announcement in the magazines accessible to 
African Americans. 
Lee and Begley (2010) found health disparity due to product claim amongst 
Hispanics, African Americans, and Whites after exposure.  When exposed to product 
claim announcement, the three ethnic groups reacted differently (Lee and Begley, 2010). 
Hispanics requested for health care services more than Whites and African Americans. 
African Americans met their doctors to discuss a drug seen in product claim 
announcement more than other ethnic groups. Whites requested and obtained an 
advertised prescription drug from their doctors while the minorities Hispanics and 
African Americans saw their request denied by their physicians (Lee & Begley, 2010).        
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The preceding authors have the common merit of stating the weaknesses of the 
practice of product claim announcement. However, none of those authors has clarified the 
characteristics of product claim that decided more the adult dermatology patients to 
utilize medical services.  
Help-seeking announcement. They were many critiques again help-seeking 
announcement. Help-seeking announcement lacked the name of the medicine for the 
benefit of the manufacturer’s name (Rollins et al., 2010; FDA, 2012b). Frosch et al. 
(2010) and Hall et al. (2010) argued that help-seeking announcement encouraged drug 
therapy or medicalization instead of lifestyle change (Frosch et al., 2010; Hall et al., 
2010; O’hara, 2010). Consequently, help-seeking announcement ended up creating a 
massive dependence of the people on the medication or drug therapy (Frosch et al., 2010; 
Hall et al., 2010; O’hara, 2010). 
The above contrasting reflexion again both product claim and help-seeking helped 
to shed light on the demerits of the two types of DTCAs. However, I did not answer the 
research question of this study presented in Chapter 1. Product claim and help-seeking 
announcements did have supports from the literature.  
Product Claim and Help-Seeking Advertisements Pros Debate 
Product claim advertisement. Many writers supported the product claim 
announcement. The product claim advertisement represented an essential source of 
information about the drug, treatable conditions, and new treatment options for the 
consumers (Chaar & Lee, 2012; Frosch et al., 2010; Hall et al., 2010; La Barbera, 2012; 
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O’hara, 2010). According to Frosch et al. (2010); Hall et al. (2010), La Barbera (2012), 
and O’hara (2010) product claim announcement helped to build the mental strength of the 
consumer through education. The consumer easily adhered to a medical prescription due 
to the mental power (Frosch et al., 2010; Hall et al., 2010; La Barbera, 2012; Limbu & 
Torres, 2009; O’hara, 2010; Phrma, 2011). 
However, the FDA (2012b) and La Barbera (2012) found that product claim 
length gave enough time to the announcement to disclose to the patient how the drug 
worked, what the drug cured, the dangers of taking the drug, and the potential side 
effects. Then, with the product claim, the patient has the choice to meet with his/her 
doctor to discuss the appropriateness of the advertised drug to the patient condition. The 
discussion permitted to eradicate any possible risk of harm to the patient due to the use of 
an advertised drug (FDA, 2012b; La Barbera, 2012).  
Willington (2010) thought differently. In fact, product claim restored the natural 
health rights of the human being. According to Willington, a human being should have 
access to medical care and the related information. The related information is about how 
and where to get the right medicine and the possible consequences of using that 
medicine. Furthermore, the product claim health information enabled the patient to 
exercise his/her right to decide about the right care and best way of taking care of the 
personal health (Willington, 2010). In the same logic, Willington recognized that product 
claim had the virtue of increasing the number of people aware of a drug as well as those 
following their treatment plan rigorously. Finally, Willington claimed that product claim 
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lowers the treatment cost through the appropriate and proper form of drug therapy. The 
hospitalization cost in some cases was null with the drug therapy (Willington, 2010). 
There are multiple strengths for the product claim such as informing patients, 
facilitating patients’ access to health care, and educating patients about drug use and 
conditions treated. However, the authors did not state why adult dermatology patients 
utilize medical services after an exposure to a product claim and help-seeking 
advertisements. 
Help-seeking advertisement. The authors have identified various help-seeking 
strengths. Help-seeking had the reputation of educating patient about diseases and 
possible treatments as well as helping the patient to comply with the medication use 
(Chaar & Lee, 2012), Dave and  Saffer, 2012; Frosch et al., 2010; Kontos and Viswanath, 
2011; Mendonca et al., 2011; O’hara, 2010; Rollins et al., 2010). In the same view with 
Frosch et al. (2010) and Mendonca et al. (2011), Rollins et al. (2010) asserted that help-
seeking announcement did decide patients to seek for additional information about their 
condition. Furthermore, help-seeking empowered consumer to initiate a discussion with 
their care provider about not yet diagnosed disease, symptoms, and treatment options of 
an existing illness (Dave & Saffer, 2012; Frosch et al., 2010; Mendonca et al., 2011; 
Rollins et al., 2010).  
However, Hall et al. (2010) found the help-seeking strength in the earlier 
diagnosis of a condition sometimes ignored by the patient before an exposure to the 
announcement. Help-seeking recommended to the viewers to contact their care provider 
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for diagnosis in case of any symptom mentioned in the announcement (Hall et al., 2010; 
FDA, 2012d). Frosch et al. (2010) and Hall et al. (2010), contrarily to Mendonca et al. 
(2011) and Rollins et al. (2010), identified the help-seeking merit in the patient education, 
mainly those with a low level of health literacy. Thus, the exposure to a help-seeking 
announcement provided health information to people less educated that enabled them to 
utilize medical care as well as those with a high level of health education (Frosch et al., 
2010; Hall et al., 2010). Help-seeking had the positive impact of reducing the health care 
utilization disparity between those two groups.     
The authors analyzed product claim and help-seeking announcement mostly 
concerning the characteristics and capability of motivating exposed patients to seek for 
more information about the condition and new drug. However, they did not analyze the 
possible relationship between DTCAs and the utilization of medical services amongst the 
adult dermatology patients.  
Product Claim and Help-Seeking Advertisements’ Regulatory Debate 
Product claim advertisement regulatory trend. The regulation of product claim 
by United States federal government has been a long and continuing process. In that 
regard, Mulligan (2011) focused the attention on the trend analysis of the regulation. 
According to Mulligan, the regulatory trend of product claim by FAD went back up to 
1969. Indeed, the birth and progress of the product claim regulations had four key 
periods: 1969, 1997 through 1999, 2004, and 2007 (Mulligan, 2011). 
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The 1969 regulations were four constraints applicable to product claim 
announcements (Mulligan, 2011). The first was the truthfulness of the information 
conveyed to the population. The communicated information should tell the true about the 
product and give the right advice and direction to the target public (Mulligan, 2011). The 
second was the constraint of the balanced presentation of what the product represented as 
risks and benefits for the consumer (Mulligan, 2011). In other words, the positive and 
negative consequences of using the advertised product should have the same weight in 
the announcement (Mulligan, 2011).  The third principle was about the other utilization 
of the product. The regulations required each advertiser to state clearly in the 
announcement the essential information for a comfortable and safe use of the drug by the 
consumer (Mulligan, 2011). The fourth requirement was about all risk statement that the 
consumer incurred during or after the utilization of the product. These risks should appear 
clearly in the announcement (Mulligan, 2011). 
The second period of 1997 through 1999 was the FDA’s response to the growth of 
the broadcast DTCAs in general and product claim in particular (Frosch et al., 2010; 
Mulligan, 2011). In fact, stating all or “every risk” (FDA, 2012b) related to the use of the 
product of interest in a broadcast announcement, in compliance with the 1969 
regulations’ principle number four, was very challenging. This because the advertisers 
have to face the time constraint related to the media (Frosch et al., 2010; Mulligan, 2011). 
Consequently, the FDA issued new regulations to modify the 1969’s number 4 principle. 
In that regard, the FDA gave two choices to the advertisers. The first choice was the 
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objective and proper introduction in the announcement of the “major statement”. The 
“major statement” referred to the very relevant risk associated with the use of the product 
(FDA, 2012b). Furthermore, the advertisers in lieu of the “major statement” could list all 
the risks of the product use, or could tell the consumer the additional sources where to 
obtain other risks of using the advertised product (Dave & Saffer, 2012; FDA, 2012b; 
Flood, 2010; Frosch et al., 2010; Mulligan, 2011). 
The third period was 2004 (Frosch et al., 2010; Mulligan, 2011). FAD’s product 
claim print announcement was the target. Print advertisers did not satisfy the FDA’s 
requirement for the clear communication of the risks information to the public. 
According to the FDA, advertisers were using a language not familiar or not accessible to 
the readers. Therefore, to reverse this tendency, the 2004’s amendments imposed to the 
print advertisers the obligation of communicating product’s risks to the readers using a 
popular language known by the public (Frosch et al., 2010; Mulligan, 2011).  Moreover, 
the announcement should communicate clearly the following to the public: (a) at least 
three moderate adverse side effects, (b) warnings, (c) contraindications, and (d) the 
necessary precaution related to the product (FDA, 2012b; Mulligan, 2011).  
The fourth period was 2007/2008. It was an Act or Public Law named Food and 
Drug Administration Amendments Act (FDAAA) of 2007 (FDA, 2012b; Mulligan, 
2011). The legislators introduced some changes in the law. The changes aimed to 
reinforce the FDA’s control power on the product claim announcement of prescription 
drug. The changes were (a) the FDA can ask to review an announcement prior to the 
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release to the media by the advertiser (pre-market review); (b) the creation of an ad hoc 
program to motivate TV advertisers to participate freely in the FDA’s review prior to the 
release (advisory review program), and (c) the requirement of a fee for those willing to 
participate to pre-review program (FDA, 2012b; Mulligan, 2011). 
The above product claim regulatory efforts were about both broadcast and print 
announcements. The 1997 regulation increased the product claim broadcast 
announcements. The law makers did not predict how to keep under the Federal 
Government’s scrutiny the high and increasing number of the broadcast product claim. 
Moreover, the regulatory efforts did not state why product claim influence consumers, 
mostly adult dermatology patients, to seek medical care after exposure. Finally, there is a 
connection between the preceding product claim regulatory efforts and the 
pharmaceutical industry’s efforts for self-regulation.  
Pharmaceutical industry’s regulation initiative for product claim and help-
seeking. The pharmaceutical companies gathered within PhRMA have undertaken many 
regulatory initiatives regarding the DTCAs. Indeed, contrarily to other contributors who 
focused on the trend of the regulation of the DTCAs, PhRMA’s members and Marcias et 
al. (2010) analyzed the pharmaceutical industry’s efforts for self-regulation. PhRMA is 
the group of companies that lead pharmaceutical research and biotechnology aimed to 
develop new drug and devices in the United States of America (Marcias et al., 2010; 
Phrma, 2011). PhRMA undertook in 2008 the revision of the existing guidelines put in 
place by the industry to govern the practice of the DTCAs. The objective of developing 
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those principles was to comply with the FDA requirements regarding DTCA of 
prescription medicine. Moreover, the aim was to provide the consumers with 
communication that was a value added to the public health field (Limbu & Torres, 2009; 
Phrma, 2011). In other words, the principles did not seek to influence the consumers’ 
purchase behavior (Limbu & Torres, 2009). The revised policies became mandatory 
within the industry as from March 2, 2009. 
The self-regulation effort was a set of 18 principles. The first guiding principle 
presented what PhRMA organization believed to be the DTCAs contributions to the 
public health field. Those contributions are (a) to make more people to know a disease 
by, (b) to make patients be knowledgeable about possible options of treatment for a 
condition, (c) to promote meeting between patient and doctor about patient health 
problem, (d) to improve the under diagnosed and under treated conditions amongst 
patients, (e) and to promote the adherence to drug therapy schedule amongst patients 
(Phrma, 2011). The second principle stated the regulatory characteristics of all drug 
information conveyed directly to the consumer. Those are (a) accuracy and rightness, (b) 
evidence-based claim, (c) balanced presentation of drug risks and benefits, and (d) use of 
information from the label approved by the FDA (Phrma, 2011). The principle number 
eighteen was an exhortation to the DTCAs advertisers to tell uninsured and underinsured 
in the announcements how and where they can obtain help if needed (Phrma, 2011). 
I described in the regulatory discussion the different mutations that occurred over time 
within the United States’ legal context of the DTCAs. Then, I presented how those 
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mutations have impacted the independent variables of the study that were product claim 
and help-seeking announcements. Moreover, I shed light on the self-regulatory efforts 
that members of the US pharmaceutical industry undertook to facilitate the members’ 
compliance with the FDA’s laws and regulations of the DTCAs. However, I did not 
answer the research question of the possible relationship or not between product claim, 
help-seeking, and types and purposes of the utilization of medical dermatology services 
by adult patients. Moreover, it is not clear so far how the FDA agents enforced those 
regulations to avoid violations or to punish violators.  
Product claim regulations: Enforcement.  
 Enforcement goals and objectives. The FDA’s authorities have assigned 
clear and distinctive goals and objectives to the enforcement measures put in place to 
force marketers to comply with the product claim announcement law. Thus, conversely to 
the above PhRMA organization analysis, Abrams (2010, 2011) and Nguyen, Seoane-
Vazquez, Rodriguez-Monguio, and Montagne (2013) analyzed the product claim 
regulations under the enforcement corner. Enforcement options were possible actions that 
the FDA could take against the DTCAs advertisers to ensure compliance with the 
FDAAA. The FDA’s authorities measured the enforcement options to prevent and to 
punish any violation of the FDAAA law and related regulation (Abrams, 2010, 2011; 
Nguyen et al., 2013). The FDA pursued the goal of the protection and promotion of 
public health through enforcement. Public health was safe if the medicines for public use 
had proven safety and effectiveness (Abrams, 2010; Nguyen et al., 2013). According to 
70 
 
 
 
Abrams (2010) enforcement had multiple objectives that were (a) to assure accurate drug 
promotion that did not mislead patients, (b) to assure that the statement in the 
announcement of risk and benefit of drug use was fairly balanced, (c) and to contribute to 
the dissemination of helpful information to American citizens. 
Product claim common violations and enforcement options. There were 
 certain numbers of violation usually committed by marketers in the context of product 
claim announcement. The FDA defined some enforcement strategies to contain and to 
limit those violations. In that logic, Abrams (2010, 2011) enumerated the violations that 
frequently occur in the DTCAs practice: (a) the risk information were not provided or 
were presented in small proportion, (b) lack of the drug efficacy and safety in the 
announcement, (c) the announcement did not contain a comparative analysis of claims, 
and (d) the advertiser communicated on the drug uses unauthorized by the FDA. 
The FDA’s authorities had the following enforcement options when a violation 
occurred: (a) untitled letter, (b) warning letters, (c) injections or consent decrees, (d) 
seizures, (e) collaborative work with Department of Justice and States Attorney General, 
(f) disqualification of the researchers’ clinical trials or studies, (g) recall requests, (h) 
market withdrawals, (i) license revocation and suspension, (j) debarment of firm and 
individual, and (k) civil penalties in money (Abrams, 2010, 2011; FDA, 2011; Nguyen et 
al., 2013).  
Civil financial penalties after a product claim law violation. There were 
 civil financial penalties dictated by the law for marketers who violated the product claim 
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 law. Indeed, contrarily to Abrams (2010, 2011), FDA (2011), Nguyen 
et al. (2013), Senate Resolution 110-85 (2007) analyzed the civil penalties regarding 
money applicable when product claim was not right and misled the consumers in any 
manner. In that regard, Senate Resolution 110-85 (2007)’s section 901(d)(4) stated that, 
within a 3-year period, the first dissemination of a DTCA of a prescription drug that was 
false and misleading was liable to a civil monetary penalty of $250,000 maximum. This 
amount increased not more than $500,000 in the case of new violations by the same 
violator for a 3-year period. The Secretary of Health and Human Services started this 
process by notifying in written the violator (S. Res. 110-85, 2007). Then, the violator 
must go through a hearing process before the Secretary could assess the applicable civil 
monetary penalty. The violator should not face any other penalty from FDAAA (S. Res. 
110-85, 2007). 
This section clarified the legal measures and financial penalties that the regulatory 
agency usually used to prevent or to punish cases of false and misleading product claim 
announcements. However, the section was silent about the study’s research question and 
the DTCAs spending debate. 
Product Claim and Help-seeking Advertisements Spending Debate  
 The marketers using product claim and help-seeking generated diverse types of 
spending within the health care system. In one hand, product claim of a new drug was a 
cost driver for medical care. Indeed, new drug were still expensive. Manufacturers 
invested enormous amount of money increasingly (Chaar & Lee, 2012; Hall et al., 2010) 
72 
 
 
 
to promote and to sell new drug. The number of patients requesting for a new drug for a 
treatment increased over time due to the effect of product claim announcement (Hall et 
al., 2010; Willington, 2010). In fact, product claim made patients believe that new drug 
were more efficient and safe than existing one (Howard, 2011; Willington, 2010).   
In another hand, Dave and Saffer (2012) analyzed the product claim’s cost 
regarding the demands and prices of a prescription drug. According to Dave and Saffer, 
product claim’s spending growth was due to multiple factors. Marketers were doing more 
product claim announcement. The utilization of medical service was frequent. The drug 
prices increased regularly. The FDA adjusted the guidelines regarding the broadcast of 
the DTCAs through television after 1997. Finally, the components of the drug advertised 
changed over time (Dave & Saffer, 2012). Concretely, all DTCAs represented a value of 
$150 million for the year 1993 versus $4.24 billion for 2005 (Dave & Saffer, 2012). 
Moreover, the sales of the advertised drug in general within the therapeutic classes of the 
drug increased due to the effect of the product claim announcement. Thus, Dave and 
Saffer (2012) claimed that product claim did create migration of costumers from another 
drug to the advertised drug. The movement led to the advertised drug’s market share 
increase. Finally, the authors found that the rise of the DTCAs generated 11.8% increase 
of the cost per unit of a prescription drug (Dave & Saffer, 2012). 
Conversely to Dave and Saffer (2012), Kornfield et al. (2013) conducted a DTCA 
spending trend analysis from 2001 through 2010.  The DTCAs of interest were both to 
consumers and physicians. The data came from IMS Health Integrated Promotional 
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Service (all DTCAs, all promotion to care providers, and all sales) and the SDI (E-
promotion, meetings, and conferences data). Focusing only on the direct-to-consumer 
advertisings to consumers, Kornfield et al. stated that marketers spent UD$46,759,000 
over 10 years to promote drug and other pharmaceutical products directly to consumers 
through television, print, internet, radio, and outdoor media. 2006 was the year of the 
highest spending or the peak period with an amount of $5,891,000 which represented 12, 
59% of the overall amount spent in 10 years. In addition, a constant increase of those 
direct-to-consumer advertisings to consumers’ spending marked the periods of 
2003($4,124,000), and 2004 ($5,151,000), and 2005 ($5,231,000) (Kornfield et al., 
2013). But, after 2006, the spending entered a fluctuating period until 2010. 2001 
represented the year of the lowest spending ($3,500,000) in 10 year period (Kornfield et 
al., 2013).  
Dieringer et al. (2011) differed from Hall et al. (2010), Kornfield et al. (2013), 
and Dave and Saffer (2012) by analyzing the reasons why and when DTC Advertising 
spending started increasing faster. According to the authors, the FDA issued project 
guidelines on broadcast advertisings after 1997 (Bradford & Kleit, 2011; Dieringer et al., 
2011). The guidelines specified the ways marketers should present information regarding 
drug and other vital products to the target audience through television and radio. Those 
guidelines stimulated more DTCAs and marked the starting point of the fast spending 
increase of pharmaceutical advertisings in general (Dieringer et al., 2011).    
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I described in this analysis a proven relationship between the DTCAs and the 
increase in the cost of care as well as the rise in the drug consumption and price. 
However, as the preceding analysis, I did not answer the research question of this study. 
Bearing this is mind; I am going to focus now on the state of the debate surrounding the 
types and purposes of medical services utilized as the consequence of an exposure to a 
product claim or help-seeking announcements. 
Analysis of the Dependent Variables: Types and Purposes of Utilization of Medical 
Services  
The dependent variables of this study were the types and purposes of medical 
services utilization.  
Types of Medical Services Utilization After Exposure to a Product Claim 
Advertisement 
The exposure to a product claim advertisement can lead to the use of medical 
services. In that regard, Chaar and Lee (2012), Frosch et al. (2010), Kornfield et al. 
(2013), and Macias et al. (2010) claimed the patients exposed to a product claim 
announcement may request prescriptions of the advertised drug from their health care 
provider. Moreover, Frosch et al. (2010) and Wellington (2010) found an exposure to a 
product claim created better adherence to the treatment plan and medicalization.  
Moreover, the exposure to a product claim prompted a reception of a timely 
follow-up care. Then, product claim exposure helped the patient to remember to refill 
his/her prescription (Frosch et al., 2010; Wellington, 2010). Chaar and Lee (2012), Flood 
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(2010), Limbu and Torres (2010), and Macias et al. (2010), compared to Frosch et al. 
(2010) and Wellington (2010), identified to consult/ask/talk with their doctors about a 
particular prescription drug advertised as other medical services used after an exposure to 
a product claim. The different authors shed light on the operational variables used to 
measure the dependent variable of types of medical services utilized. The limitation of 
the analysis was the lack of an answer the research question under investigation.  
Types of Medical Services Utilization After Exposure to Help-Seeking 
Advertisement 
 A variety of medical services used after exposure to help-seeking announcement 
existed in the literature. Help-seeking exposure persuaded a patient to believe in a 
medical solution to his/her condition. Moreover, help-seeking exposure helped the patient 
to remember his/her disease (Frosch et al., 2010).  In the same logic, Dave and Saffer 
(2012), Hall, Jones, and Iverson (2011a, b), Flood (2010), Kornfield et al. (2013), Limbu 
and Torres (2010) and Wellington (2010) identified new services. The identified services 
were (a) to visit/consult the doctor about symptoms, (b) to talk with the doctor regarding 
a condition or illness, (c) to discuss new medical conditions with their physicians, and (d) 
to visit more the doctor and talk about the condition treated by the drug advertised.   
On the contrary, Bradford and Kleit (2011) and Dave and Saffer (2012) found that 
help-seeking advertisement prompted patients to obtain a new diagnosis from their 
physicians of a medical condition so far ignored and helped to treat the conditions 
undertreated before completely. Hall et al. (2011a), compared to Bradford and Kleit 
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(2011) and Dave and Saffer, conducted a survey study of mock advertisements of two 
diseases (Fibromyalgia and Osteopenia) amongst 241 women of 48 through 85 years old. 
The study identified the following medical services that the women were intending to 
search as the consequence of their exposure to the announcement: (a) to ask their doctor 
for a referral (49%), (b) to ask their physicians about the tests regarding the condition 
advertised, (c) to look for information according to the advertisement orientation, (d) and 
to search for information from outside of the announcement (Hall et al., 201b).  
These authors identified other operational variables for the measurement of the 
dependent variable: types of medical services. However, they did not provide a response 
to the research question of this study.          
Purposes of Medical Services Utilization After Exposure to a Product Claim 
Advertisement 
French et al. (2011) stated that patients sought recovery from illness when 
utilizing medical services after exposure to a product claim.   
Purposes of Medical Services Utilization After Exposure to Help-Seeking 
Advertisement 
According to French et al. (2011) and Wellington (2010) patients exposed to help-
seeking announcement utilized medical services for wellness and wellbeing purposes.  
Analysis of the Dependent Variables: the Dermatology Services Context 
The dermatology diseases are conditions that attack the human skin, hair, and 
nails. Consequently, the medical dermatology services are the services rendered by a 
77 
 
 
 
dermatologist to diagnose, treat, or prevent conditions that affect the skin, hair, and nails 
(AAD, 2014b). The effective treatment of the skin conditions requires the use of updated 
therapy (Stevens, 2013). Then, the dermatologist should be comfortable applying the 
current therapy and should keep the treatment of the chronic skin conditions constant or 
continuing (Stevens, 2013). The signs of healthy hair are the length, brilliancy, 
smoothness, high quantity, and no loss of hair. Hair treatment using cosmetics aims to 
make the hair look beautiful, solid, to grow more, or to maintain the hair. There is a 
variety of cosmetics used to treat hairs such as shampoos, detergents, conditioners, 
foaming agents, thickeners and opacifiers, gels, and waxes (Madmani, 2013).  
According to AAD (2014c), there are different types of nails conditions such as 
color change, vertical lines located under nails, white spots, and nails infection due to 
bacteria. The nails problems are sometimes the sign of different health issues like liver, 
kidney, heart, anemia, and lung diseases. The nails disease(s) treatment(s) varies as well 
as conditions (AAD, 2014c). There is a variety of dermatology treatments or medical 
services used for different purposes due to the DTCAs exposure as analyzed in the 
following subsections.  
Types of Medical Services Utilized After Exposure to Dermatology Product Claim 
Advertisement  
Product claim exposure prompted the utilization of a variety of medical services 
amongst dermatology patients. Thus, Gray and Abel (2012) found that 94% of nurse 
practitioners working in the cancer field affirmed having received from the patients a 
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request of the cancer drug advertised. Patients who were in contact with a cancer 
announcement talked/asked their doctor about the medication featured in the 
advertisement, or visit a dermatologist office. Besides, the patients requested and 
obtained from their physician the prescription of the featured medicine.  
However, AAD (2013), American Cancer Society (2013b), NCI, (2013a), 
Samarasinghe et al. (2011), and The Skin Cancer Foundation (2013d) compare to Gray 
and Abel (2012), identified other drug therapies use after exposure: chemotherapy, 
immunotherapies/bio-chemotherapy, chemical peeling, medicated creams and 
solution/topical medication, photodynamic therapy, and Imiquimod. 
In conclusion, multiple medical dermatology services are available to 
dermatology patients who have seen, heard, or read a dermatology product claim 
announcement: prescription request, a visit to a dermatologist office, chemical peeling, 
and chemotherapy for instance. The services are different from those used due to the 
help-seeking advertisement exposure. 
Types of Medical Services Utilized After Exposure to Dermatology Help-Seeking 
Advertisement  
Help-seeking advertisement exposure prompted the utilization of various medical 
services. According to Kontos and Viswanath (2011), a patient exposure to a help-
seeking cancer advertisement led to consulting a dermatologist regarding any symptom 
that could be a sign of the skin cancer. In addition, Kontos and Viswanath added that 
help-seeking advertisement helped the skin cancer patients to utilize preventive services 
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(chemoprevention medicine), screening/testing services for early detection of the disease 
(whole-body imaging and genetic testing), and the search for additional health 
information outside of the DTCAs (drug’s company website/online). In the same view, 
Narang et al. (2013) found that 59% of American adults searched additional health 
information via the internet after exposure to a dermatology help-seeking announcement.  
 Contrarily to Kontos and Viswanath (2011), Samarasinghe et al. (2011) analyzed 
different nondrug therapies in the context of the treatment options for skin cancer named 
basal cell carcinoma. In that regard, the authors identified the following surgical and 
nonsurgical treatment options available for basal cell carcinoma: (a) surgical 
excision/resection, (b) Mohs micrographic surgery, (c) radiotherapy/radiation, (d) 
curettage and cautery, and (e) cryotherapy. The Skin Cancer Foundation (2013a) and 
MDACC (2013) listed the same treatment options plus laser surgery and 
electrodesiccation for the treatment of basal cell carcinoma.  Furthermore, American 
Cancer Society (2013b), National Cancer Institute [NCI], 2013b, MDACC (2013), and 
The Skin Cancer Foundation (2013d) identified the following treatments options 
available for skin cancer and another dermatology patients: lymph node surgery, skin 
grafting and reconstructive surgery, electrodesiccation, gene therapy/ biological therapy, 
clinical trial/experimental. 
The value of this section is the obvious relationship between help-seeking 
announcement and the medical services utilization in the context of skin cancer and 
dermatology care globally. However, the question regarding the same relationship 
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amongst study’s target population suffering from dermatology diseases is still without 
any answer.  
Purposes of Medical Services Utilization After Exposure to Dermatology Product 
Claim Announcement  
According to Samarasinghe et al. (2011), the exposure to dermatology product 
claim led to receiving medical treatment for the tumor clearance and tumor lesion 
excision. However, Kontos and Viswanath (2011) found patients utilized medical 
dermatology services after an exposure to a dermatology product claim announcement to 
detect a skin cancer or other dermatology conditions early. 
Purposes of Medical Services Utilization After Exposure to Dermatology Help-
Seeking Advertisement  
 Adult dermatology patients who have seen, heard, or read a dermatology 
help-seeking announcement received medical dermatology services to treat the condition 
or to manage the diseases symptom (MD Anderson Cancer Center, 2013; Samarasinghe 
et al., 2011; The Skin Cancer Foundation, 2013a). Moreover, they received medical 
dermatology services to detect the disease early (Kontos & Viswanath, 2011). I have 
presented in the preceding analysis the correlation between the DTCAs and utilization of 
medical dermatology services by adult patients, in general, however not amongst this 
study’s target population. The following model found in the literature and adopted for 
this study describes and explained the correlation between the drug DTCA and the 
utilization of medical services as the result of the exposure. 
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Model of Impact of DTCAs on the Consumer’s Participation in the Medical 
Decision Making After Exposure  
The following model from the literature was the result, and key summary of the 
literature reviewed regarding this research study question.  Indeed, patients did play and 
continue to play nowadays an important role in the clinical decisions making with the 
providers due to the pharmaceutical DTCA of prescription drug exposure. Frosch et al. 
(2010) developed the below explicative model (Figure 1.) of the impacts of prescription 
drug advertising on the consumer’s participation in the healthcare decision making. The 
model was the results of Frosch et al. (2010) research on the policy and practice of drug 
advertising in the United States of America.  
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Figure 1. Conceptual model of the effects of prescription drug advertising.  Reproduced 
with copyright official written permission (Appendix Q) from “A Decade of Controversy: 
Balancing Policy with Evidence in the Regulation of Prescription Drug Advertising”, by 
D.L.  Frosch, D. Grande, D.M. Tarn, and   R.L.  Kravitz, 2010,   American Journal of 
Public Health, 100, p. 25. Copyright 2010 by American Public Health Association. 
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Model Presentation 
The model’s underlying principle was that both medical care seekers and 
providers make medical decision in a participative way. The physician did listen and 
could consider the patient’s opinion/request concerning the possible options for 
addressing the clinical situation. Medical care seekers started by being in contact with the 
DTCA of a prescription drug. Then, moderating or mediating factors such as patients’ 
age, sex, education, or medical history influenced the two effects of the exposure to the 
patients. The two effects were to request a prescription from the care providers, or to 
believe that the condition or behavior could have a medical solution (medicalization).  
The information of poor (low) or excellent (high) quality received from the 
announcement determined the prescription request effect on the patients. The patients 
participated in the clinical care by requiring from the care provider a prescription of the 
drug advertised in the DTCA. If the information that drove the patients’ participation was 
of poor quality, the outcome of prescription request effect could be a risky medicine to 
the patient by the care provider (inappropriate prescribing). The doctor, in this case, could 
prevent this dangerous outcome by denying the patient’s prescription request. However, 
the physician should be knowledgeable and have a good will to identify and to correct the 
patient request deemed medically nonconvenient. When information of excellent quality 
determined the prescription request effect, the effect’s outcomes could be sticking to the 
advised course of treatment (prescribed regimen) and the obtainment of more medical 
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prescriptions from the physician to improve undertreatment. This model has weaknesses 
and strengths that are necessary for a review. 
Model Critique 
 The conceptual model has strengths and weaknesses. The model has the merit of 
explaining the mechanism of participatory clinical care as the effects of prescription drug 
advertising exposure. Indeed, the elements of the participatory clinical care system were 
the drug announcement exposure as the starting point. Then, some mediators or 
moderators factors were patients’ sex, age, education, and medical history. Other 
elements were the information of poor or excellent quality of conveyed by the 
announcement, the effects of the patient’s exposure to the drug advertising that are 
prescription request and medicalization. Finally, the outcomes in the prescription request 
effect could be (a) adherence to the treatment plan, (b) an improvement of the quality of 
treatment received so far, (c) or an inappropriateness of the prescribed drug. Those 
outcomes depended on the driving types of the quality of the information. All those 
components interacted to produce a participatory care between care provider and the 
patient who was in contact with As far as this study is concerned, the model has the merit 
of demonstrating and confirming the influence of the DTCA (product claim) on the 
utilization of medical services amongst the patients in general after exposure. 
 Conversely, the model’s weakness is the lack of a test and the test results not 
presented in the article for the readers’ information and use. In other words, the authors 
seem to have not stated in the article if they have tested or not the model empirically and 
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statistically before the publication of this article. A test and test results would give more 
reliability and validity to the model for future use. Also, medicalization effect has gotten 
less attention in the analysis or the development of the model than the prescription 
request effect. The model analyzed only one type of the DTCAs: product claim, ignoring 
the two others that were help-seeking and reminder announcements. Finally, the model 
was silent regarding the drug announcement effect on the utilization of medical services 
amongst adult dermatology patients.  
The study model that follows (Figure 2.) is an attempt to explain the relationship 
between the dermatology DTCAs and the utilization of medical services amongst adult 
dermatology patients in the United States. I did create and propose this model after the 
literature reviewed. I did empirically and statistically test and validate the model in 
Chapter 4.  
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Figure 2. Conceptual model of the relationship between dermatology DTCAs and utilization of medical services by adult 
dermatology adult patients after exposure to DTCAs, by H. Zouetchou, 2015, “Direct-to-consumer advertisements and medical 
services utilization amongst adult dermatology patients in the United States”, dissertation submitted as partial requirements for 
the degree of Doctor of Philosophy, Health Services, p. 87, unpublished. Copyright 2015 by Walden University. 
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Model Background 
The background consists of detailing how this model came to the existence. The 
review of the literature in Chapter 2 provided evidence of the relationship between 
DTCAs and the use of medical services amongst Americans in general. The existing 
evidence from the literature, as well as the model in figure 1, inspired this study’s model 
(Figure 2). The study’s model aimed to explain the sequences of the exposure to the 
dermatology DTCAs and the utilization of medical dermatology services by the patients 
as the consequence of the exposure. The model’s foundation is that an exposure to the 
dermatology DTCAs leads to the utilization of the medical dermatology services in the 
United States of America. I, empirically tested the model in figure 2 amongst adult 
dermatology patients who lived in Houston, Texas, and were receiving primary care 
services at MedStar Primary Care Clinic, or/and attending to the church service at Saint 
Nicholas Catholic Church. The empirical testing of the study model through the 
questionnaire completion enabled to verify that the relationship between the DTCAs and 
the utilization of medical services was valid amongst the study’s target population. Then, 
the statistical test of the model in figure 2 permitted to examine also the P T, which was 
the theoretical framework of this research study. The figure 2 statistical test was through 
the research hypotheses statistical testing in the course of the data analysis in Chapter 4. 
In fact, the independent (DTCAs exposure) and dependent (types and purposes of the 
utilization) variables of the study are the principal components of the model in figure 2. 
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Model Presentation 
The presentation of the model in figure 2 consists of explaining how an adult 
dermatology patients utilized medical services as the consequence of the exposure to the 
dermatology product claim, or/and help-seeking announcements. Indeed, an adult 
dermatology patient (health status) viewed, heard, or read the dermatology DTCAs 
(exposure) that could be product claim, or help-seeking. Product claim and help-seeking 
provided the adult dermatology patient with information that had educational values. 
Product claim provided information about the advertised drug and the condition treated. 
Help-seeking conveyed information on the dermatology condition or disease and the 
available treatment options. The information could be complete or incomplete (sufficient 
or not to seek and to use medical dermatology services). The adult dermatology patient, 
after exposure, uses the full information to seek and to utilize the medical dermatology 
service(s). The use of the full information for the medical dermatology services 
utilization depends on the mediation or moderation of the patient’s individual factors or 
backgrounds such as sex, age, level of education, medical history, and ethnic group. The 
medical services utilized vary according to the types of the DTCAs exposure. In that 
regard, the dermatology patient in contact with the product claim announcement uses for 
example one or more of the following services: (a) to request prescriptions for the 
advertised drug from their health care provider, (b) better adherence to the treatment plan 
and medicalization/to take medication on a regular basis, (d) to remember to fill his/her 
prescription, and (e) to consult/ask/talk with their doctors about a particular prescription 
drug advertised.  Meanwhile the patient in contact with help-seeking advertisement uses 
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one or more of these services: (a) to persuade a patient to believe that his/her disease can 
have a medical solution , (b) to remember his/her condition, (c) to visit/consult the doctor 
about symptoms, (d) to talk with the physician regarding a condition or illness, (e) to 
discuss new medical conditions with their physicians, (f) to visit the doctor and to talk 
about the personal disease, (g) to obtain new diagnosis from their doctors of a medical 
condition so far ignored, (h) to treat completely conditions undertreated before, (i) to 
search additional medical information outside of the announcement, (j) to ask the doctor 
for a referral, (k) to ask the physicians about the tests regarding the condition advertised, 
and (l) to look for information according to the announcement orientation. When the 
information is incomplete, the patient will search for additional information outside of the 
dermatology product claim or help-seeking announcements. Then, he/she uses the 
complete information to utilize the medical services under the mediation or moderation of 
the individual factors and for a particular or many reasons.  
Dermatology patients exposed to a DTCA utilize medical services for one or 
multiple purposes. The utilization of medical services after an exposure to a product 
claim announcement could be for the purpose (s) of (a) to seek recovery from an 
illness/tumor clearance, (b) for tumor lesion excision, and (c) to check if the person has 
contacted or not dermatology disease/screening test. Contrarily, patient’s exposure to a 
help-seeking announcement leads to the utilization of medical services for the purpose (s) 
of wellness and wellbeing. 
Finally, product claim and help-seeking are the sets of the independent variables 
of the study. The types and purposes of utilization of medical dermatology services are 
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the sets of the dependent variables. Both independent and dependent variables generated 
the hypotheses of this research study. 
Model Critique 
The model has strengths. In fact, the study’s model explains the possible process 
of the exposure to product claim, help-seeking, and the consequent utilization of the 
medical dermatology services by the adult patients. In addition, the study’s model 
presents the elements of the process, when and how they interact during the process of 
exposure-utilization-purpose. Those elements are the health status, product claim, help-
seeking, information, mediators, moderators, types, and purposes of medical dermatology 
services utilization. 
However, the model has weaknesses. Indeed, the study’s model does not tell 
which of the dermatology product claim or help-seeking advertisements could prompt 
more than others the utilization of the medical services for a purpose by the target 
population after exposure. Moreover, the model is silent on which characteristic(s) of the 
product claim, and help-seeking advertisements could prompt more the utilization of 
which particular medical service and/or purpose. These weaknesses have the solutions in 
Chapter 4. 
Summary and Conclusion 
There are evidence from the analysis in this Chapter 2 that product claim and 
health-seeking advertisements prompt the utilization of the medical services for a purpose 
or reason amongst Americans in general and specifically the adult dermatology patients. 
In that regard, an exposure to a product claim advertisement prompted the request for a 
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prescription of the drug advertised to treat a condition. Moreover, an exposure to a 
product claim advertisement decided the patients to follow regularly the treatment plans 
and to believe that medicine was the solution to the conditions. The dermatology patients 
talked about or requested from the physician a drug that treated skin cancer/condition due 
to the contact with the advertisement of that drug. The reason for this request was to cure 
the tumor/disease through drug therapy. Conversely, help-seeking advertisement 
exposure led (a) to a doctor visit about a symptom, (b) to talk to the doctor about the 
condition advertised, or (c) to obtain a new diagnosis from the dermatologist. The 
patients who utilized the medical services sought wellness and wellbeing. The 
dermatology/skin cancer help-seeking advertisements prompted the use of (a) 
chemotherapy, (b) preventive services, (c) surgery therapy, (d) screening/testing, and (e) 
to consult a dermatologist about new symptoms. Multiple reasons justified the utilization 
of those services: (a) tumor clearance, (b) tumor lesion excision, (c) to avoid dermatology 
disease, and (d) to check the presence or not of the dermatology disease in the skin.  
The relationship between product claim, help-seeking advertisements, and the 
utilization of medical services for medical reason sought to increase drug therapy and 
disease awareness amongst patients in general and adult dermatology patients in 
particular. Indeed, some dermatology diseases were the most curable in the United States. 
The exposure to the product claim and help-seeking advertisements prompted the 
utilization of the multiple medical dermatology services for medical reason(s). In doing 
so, patients could survive from the dermatology disease and could continue to live a 
healthy and productive life. However, the question of the prediction between product 
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claim, help-seeking advertisements, and the utilization of medical dermatology services 
amongst adult patients who lived in Houston, Texas, and were MedStar Primary Care 
Clinic’s patients, or/and members of Saint Nicholas Catholic Church was still without 
any answer. Therefore, undertaking this study to answer that question was still necessary 
and required a precise research method definition. 
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Chapter 3: Research Method 
Introduction 
The purpose of this study was to describe the relationship between dermatology 
product claim, help-seeking advertisements, and the types and purposes of the utilization 
of the medical dermatology services amongst the adult dermatology patients in the United 
States. The adult dermatology patients sampled were those who lived in Houston, Texas, 
and were receiving primary care services at MedStar Primary Care Clinic, or/and 
attending church services at Saint Nicholas Catholic Church. 
Past researchers have claimed the relationship between the DTCAs and the 
utilization of medical services in the United States, in general, but not amongst the 
specific adult dermatology patient population in Houston, Texas (Limbu & Torres, 2009; 
Mackert et al., 2010). Chapter 1 was the introduction of the study with the analysis of the 
concepts of the pharmaceutical DTCAs and the utilization of medical services. In Chapter 
1, I addressed the background and the gap in the existing literature on the topic, the 
problem statement, the purpose of the study, the research questions and hypotheses. Also, 
I addressed the theoretical framework (PT), the nature of the study, the operational 
definitions of the study variables, the assumptions, the scope and delimitations, the 
limitations, and significance of the study. Then, Chapter 2 followed, and I focused on the 
review of the publications on the relationship between the independent and dependent 
variables and the theoretical framework of the study. In the review, I aimed to clarify and 
to understand the state of the problem introduced in Chapter 1. Moreover, I presented the 
model from the literature that described the relationship between the independent and 
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dependent variables of the study. Finally, I presented in Chapter 2 this study’s model of 
the relationship between the dermatology DTCAs and the utilization of the medical 
dermatology services amongst this study population. In Chapter 3, I expand on the 
Chapters 1 and 2 by analyzing a new component of the study: the methodology used to 
investigate the research problem stated in Chapter 1 and clarified in Chapter 2. The key 
contents of this chapter are the research design and rationale of the selection, the 
methodology focusing on the population, the sampling and sampling procedure, the data 
collection procedure and instrument, and the pilot study. Besides, in Chapter 3, I analyze 
the threats to the research validity, the ethical procedure, and do the summary and 
transition to Chapter 4. 
Research Design and Rationale 
The Study’s Variables 
The study’s independent and dependent variables are the focus of this section. In 
this correlation research study, I sought to describe the relationship between dermatology 
product claim, help seeking advertisements, and types and purposes of medical 
dermatology services utilization amongst the adult patients living in Houston, Texas. The 
adult patients were Saint Nicholas Catholic Church members and/or patients at MedStar 
Primary Care Clinic. In that regard, the set of independent variables were the 
dermatology product claim and help- seeking advertisements that may prompt the 
utilization of the medical dermatology services amongst the target population. The items 
for the observation of the product claim and help-seeking were the characteristics of each 
as defined in general by the FDA (FDA, 2012f). The sets of dependent variables were the 
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types and purposes of medical dermatology services used after exposure to the 
dermatology product claim or/and help seeking advertisements. The observation of the 
types and purposes of the medical dermatology services utilization were the variables 
from the current literature reviewed on the topic in Chapter 2. The section of this chapter 
entitled operationalization of the variables provides readers with the definition of each 
observation item. 
Research Design and Connection With the Research Question 
The design and rationale. This research study followed the quantitative design. 
Social science researchers have the option amongst three complementary types of design, 
which are qualitative, mixed method, and quantitative (Creswell, 2009; Frankfort-
Nachmias & Nachmias, 2008). The qualitative design uses an exploratory method aimed 
to understand the senses that human beings in a group or individually assign to the 
problems in society. Data are words (Creswell, 2009; Frankfort-Nachmias & Nachmias, 
2008). The qualitative design is inductive or generates general ideas from those 
individuals. The data collection occurs in a setting. This study is about the relationship 
between variables and not about the meaning given to the DTCAs and the utilization of 
medical services in the context of dermatology care. 
The mixed method research design is another research design. The mixed method 
makes the use of both quantitative and qualitative strategies to answer the research 
question. The combination of the strengths of the two designs leads to a higher strength 
for the mixed method. This study has existing literature and a testable theory. Therefore, 
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the combination of both quantitative and qualitative designs was not necessary to answer 
the research study question. 
The quantitative design is the third design available for the social science 
research. The quantitative design seeks to test theories based on the description of the 
relationship amongst the variables of interest. The observation of the variables is through 
the use of instruments that facilitate the generation of numbers for statistical test 
purposes. The quantitative design is a deductive approach with the key issues being the 
statistical inference and the replication of the research results (Creswell, 2009). This 
study falls within the quantitative design given that the purpose is to test the PT by 
describing the relationship amongst dermatology product claim and help-seeking 
advertisements (independent variables) and the types and purposes of medical 
dermatology services utilization (dependent variables). Multiple research methods are 
available for the implementation of the quantitative design. 
The selected quantitative research method and rationale. A cross-sectional survey 
was the quantitative method of selection for this study. The selection of the cross-
sectional survey approach was due to the quantitative nature of the research question 
(Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). The cross-sectional survey 
was not the only quantitative approach. Therefore, other applicable quantitative methods 
were subject to a comparative analysis to justify the final selection of the cross-section 
survey for this study. In that regard, the classic experimental method was an applicable 
quantitative method. The classic experimental method uses two identical groups to 
conduct the inquiry: the experimental and control groups. 
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The classic experimental allows the assessment of treatment or independent 
variable. The researcher randomly assigned the cases to the groups (Frankfort-Nachmias 
& Nachmias, 2008). A pretest takes place with the experimental group before the 
administration of the treatment. Then, a posttest follows after the same group has gone 
through the treatment. The control group does not go through the treatment (Frankfort-
Nachmias & Nachmias, 2008). The experimenter compares the results of the tests 
between the two groups. The aim is to see if there are any significant difference between 
the two groups that are attributable to the effect of the treatment (Frankfort-Nachmias & 
Nachmias, 2008).The strength of this method consists of allowing the establishment of 
the cause-en-effect relationship between variables, the manipulation of variables, the 
comparison amongst control and experimental groups, and the random assignment of the 
cases to each of the groups. The risk of internal invalidity is very limited (Frankfort-
Nachmias & Nachmias, 2008). The limitation is that the generalization of the research 
results to the nontested population is impossible (Frankfort-Nachmias & Nachmias, 
2008). The classic experimental always rhymes with biological and physical sciences 
rather than the social sciences. The structure is rigid and classic experiments cannot 
easily fit to study a social phenomenon (Frankfort-Nachmias & Nachmias, 2008). This 
research study did not use this method because the aim was not to assess treatment. 
The panel was another applicable quantitative method for this study. The panel is 
a quasi-experimental method. The panel method is necessary when the researcher wants 
to observe changes in the dependent variables over a long period (Frankfort-Nachmias & 
Nachmias, 2008). The researcher assesses the same panel on a regular frequency and time 
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intervals. In that condition, the researcher has the most accurate assessment of the 
situation under investigation before and after the assessment (Frankfort-Nachmias & 
Nachmias, 2008). The panel facilitates the identification of the variable that has an effect 
on other variables, and the collection of data from the same person is over time 
(Frankfort-Nachmias & Nachmias, 2008). The limitation of the panel research is the 
difficulty constituting a representative sample of respondents at the beginning of the 
research. Then, it is difficult to have the respondents’ approval to participate the research 
regularly and for a long time (Frankfort-Nachmias & Nachmias, 2008). The panel is not 
appropriate for this research giving that the research question can be answered using data 
collected once and not many times. 
One-short case study was part of the quantitative methods that could be the 
methodological support. The preexperimental one-short case study method refers to the 
observation of only one event or a group at a specific moment in time (Frankfort-
Nachmias & Nachmias, 2008). The one-short case study, as another preexperimental 
method, does not randomly assign cases to the experimental groups. The one-short case 
study does not permit the comparison of both control and experimental groups. 
Moreover, the sample is not randomly drawn from the general population. No statistical 
technique helps to control the threats to internal validity of the research (Frankfort-
Nachmias & Nachmias, 2008). One-short case study helps in pretesting hypotheses and 
conducting exploratory research as the base of future research (Frankfort-Nachmias & 
Nachmias, 2008). However, the lack of a random sample does not give equal chance to 
all members of the population to appear in the sample. Besides, the lack of random 
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assignment of the participants to the groups cannot lead to a representative sample. The 
aim of this research is not to test treatment: One-short case study is not appropriate. 
The cross-sectional survey was another quantitative method. Cross-sectional 
survey research method consists of asking a sample selected randomly or not from the 
general population to express the attitude and views about the phenomenon under 
investigation. The sample does so by responding to a series of questions related to the 
past experiences and backgrounds. The researcher, when appropriate, will infer the 
results from the representative sample of the general population (Frankfort-Nachmias & 
Nachmias, 2008; Creswell, 2009). Cross-sectional method allows the researcher to 
establish a cause-and-effect relationship amongst variables, or to describe the type of 
relationship amongst the variables (Frankfort-Nachmias & Nachmias, 2008). The survey 
offers a rapid data collection, the economy of time, and the identification of the 
characteristics of the general population only in the sample (Creswell, 2009). The 
limitation of the cross-sectional method resides in the difficulty to control the factors that 
affect the research internal validity and the use of sophisticated instruments like a 
questionnaire and computer software (Frankfort-Nachmias & Nachmias, 2008). The 
strength of the approach is the rapid data collection and analysis, the statistical inference, 
the random sample when possible and the use of statistical analysis to reduce the risk of 
internal invalidity (Frankfort-Nachmias & Nachmias, 2008; Creswell, 2009). The cross-
sectional survey adheres to this study whose purpose is to describe the relationship 
amongst the quantitative variables. 
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The above review of the applicable quantitative methods led to the conclusion that 
cross-sectional research design was appropriate to address this research question. In fact, 
the cross-sectional research design allows rapid data collection and analysis, the 
statistical analysis and inference when appropriate, the random sample and the test of 
theory via hypotheses that establish the relationship amongst independent and dependent 
variables (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). This study’s 
question is about a statistically significant relationship between the independent and 
dependent variables. This study's question is in alignment with the cross-sectional design 
purpose. 
Furthermore, this study tested PT via four hypotheses to describe the relationship 
between product claim, help-seeking advertisements, and types and purposes of medical 
services utilization in the context of dermatology care (Creswell, 2009; Frankfort-
Nachmias & Nachmias, 2008). Also, the cross-sectional survey uses instruments to 
measure the variables and generate quantitative data or numbers for statistical analysis to 
answer the research question (Creswell, 2009). The measurement instrument for this 
study was a structured questionnaire. The questionnaire enabled the collection of 
quantitative data and the use of statistical tools to analyze data and to answer the research 
question. 
Cross-Sectional Survey Design’s Constraints 
The cross-sectional survey has multiple constraints. The limited time is one of the 
constraints: data collection occurs at a specific moment in time. In other words, the 
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researcher collects data once not over time and at a specific period (Creswell, 2009).  The 
researcher collected primary data from respondents during one month and 10 days. 
Another constraint is the resources necessary to conduct the cross-sectional 
survey fully: material and finance. In fact, primary data collection requires instrument or 
questionnaire. The researcher can develop one or use an existing one, if possible, with the 
written permission of the copyright (Creswell, 2009). The development or the written 
permission has a cost. Furthermore, online primary data collection requires a creation or 
use of a website to host the survey and for respondents to take the survey. The secondary 
data or the use of the existing primary data has a fee. Also, the researcher and other data 
collection team person do travel for the data collection. The respondents may have 
financial compensations for the participation in the study as well as the research team. 
The accommodation and feeding costs for the research team do exist. Then, data analysis 
and interpretation both need a computer and statistical software like SPSS (Frankfort-
Nachmias & Nachmias, 2008). Some of those constraints affected this study: use 
questionnaire, computer, and SPSS software. 
Consistency of the Cross-section Survey Selection With the Designs in Health 
Sciences 
Health sciences are part of social science. Three designs are dominant in social 
sciences for the inquiry as developed earlier. The three designs are quantitative, 
qualitative, and mix methods (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). 
The first tests theories to describe the relationship between variables. The second is the 
exploration of the understanding of the meanings assigned to problems by individuals or 
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groups. The third combines the quantitative and qualitative designs’ strength to respond 
to the research question (Creswell, 2009). Cross-sectional survey belongs to the 
quantitative design and has the reputation of being the most common method in social 
sciences (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). The cross-sectional 
survey follows a specific methodology for data collection, analysis, interpretation, and 
reporting. 
Methodology 
Population and Disease of Interest 
The Walden University’s Institutional Review Board (IRB) approval number for 
this study was # 12-09-14-0177813. The study’s target population was American 
residents male and female aged 18 years and over who had skin, hair, and/or nail disease. 
He/she was living in Houston, Texas currently receiving primary care treatments at the 
MedStar Primary Care Clinic or attending to the church services at Saint Nicholas 
Catholic Church. The individual did speak, read, and understand the English language. 
The individual resided in Houston, Texas for at least six months continuously. Then, the 
person should have seen, viewed, or read a pharmaceutical dermatology advertisement 
directed directly to the consumer about a dermatology drug or disease in the past 12 
months. The individual should have utilized a medical dermatology service/treatment for 
a medical reason as the consequence of having seen, viewed, or read (exposure) a 
pharmaceutical advertisement directed to the dermatology patients. The 12 month period 
started from the questionnaire completion day. The population size was unknown and 
could not be estimated at the time of the study. 
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The diseases of interest were skin, hair, and nails diseases (dermatology diseases). 
According to the AAD (2014a), dermatology diseases represented the most popular 
motivation amongst people who visited a physician’s office in America. Dermatology 
diseases are multiple such as Acne, head lice, below-the-belt dermatology conditions, 
hair loss, melanoma, psoriasis, eczema, imiquimod, rosacea, scabies, vitiligo, and skin 
cancer (AAD, 2014a; University of Texas Medical Branch [UTMB Health], 2014). 
Sampling, Sampling Procedures, and Sites of the Study 
Sampling and procedures. The study’s sampling strategy was the 
nonprobability. The complete list (sampling frame) of the study’s population was not 
available for the use of the random sampling method. Consequently, the type of sampling 
was a nonprobability sample. The lack of a sampling frame made impossible to select 
randomly or to determine the probability of each member of the population to appear in 
the sample (Collins et al., 2006; Frankfort-Nachmias & Nachmias, 2008). 
The nonrandom purposive sample scheme helped to select from the population 
the members of the sample. In fact, the selection of the sample for the study was based on 
the use of the pre-determined inclusion criteria (eligibility section of the questionnaire). 
The selected respondents were available and willing to participate in the study (Collins et 
al., 2006; Frankfort-Nachmias & Nachmias, 2008). The questionnaire contained 
eligibility or screening section. The eligibility sections aimed to filter the respondents and 
to assure that only those who bore the key characteristics of the population participated in 
the study. The screening section was the support to my personal judgment. The selection 
or recruitment of the sample took place in the face-to-face encounters with the adult 
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dermatology patients at the study sites during their medical appointment and church 
service occasions. 
Study sites. There were two study’s sites: MedStar Primary Care Clinic and Saint 
Nicholas Catholic Church both in Houston, Texas. Houston city had a population of 
2,097,217 people in 2010. The Houston’s diversified race make-up was White (50.5%), 
Black or African American (23, 7%), American Indian and Alaska Native (0.7%), Asian 
(6.0%), Native Hawaiian and Other Pacific Islander (0.1%), Two or More Races (3.3%), 
Hispanic or Latino (43.8), and White alone, not Hispanic or Latino (25.6%). Houston city 
had three counties: Fort Bend, Harris, and Montgomery (United States Census Bureau, 
2014). Houston occupied the fourth position as the largest city in population in the United 
States after New York, Los Angeles, and Chicago (The City of Houston, 2014). 
The first study’s site was MedStar Primary Care Clinic in Houston, Texas. The 
study’s target population received primary care medical services. The selection of this 
site was due to the diversity through multicultural and multiethnic groups that 
characterized MedStar Primary Care Clinic’s community. Then, MedStar offered 
diversified types of community services to a diversified target population. Indeed, 
MedStar Primary Care Clinic is a for-profit organization established since 2008 in 
Houston, Texas (MedStar Primary Care Clinic [MedStar], 2014). The community 
members were African-American, African immigrants, Hispanics, and Whites of all ages 
and level of education (MedStar, 2014). The members of the community had different 
dermatology services utilization experiences. Indeed, MedStar, in addition to check-ups, 
cancer screening, and treatment of chronic diseases (diabetes), offered hypertension, 
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weight loss program, smoking cessation, travel medicine, women health, and 
hypercholesterolemia treatment/medical services to patients (MedStar, 2014). Some of 
those patients were without insurance, had limited insurance, and/or had a full coverage 
health insurance plan (MedStar, 2014). 
The second study’s group was Saint Nicholas Catholic Church in Houston, Texas. 
The target population attended the church services at Saint Nicholas parish. Saint 
Nicholas is a multicultural and multi ethnics’ group community. Then, Saint Nicholas 
had multiple types of community service rendered to the community. Indeed, Saint 
Nicholas Catholics Church was a nonprofit religious organization. Saint Nicholas was the 
oldest church for Blacks in Houston area (Saint Nicholas Catholic Church, 2014). The 
community members were African-American, African immigrants, and Whites of 
different ages and levels of education (Saint Nicholas Catholic Church, 2014). The 
members of the community had a variety of experiences regarding dermatology services 
utilization. Saint Nicholas Catholic Church offered multiples services to the Houston 
community: education, professional skills and financial training, occasional 
accommodation in case of disasters, and parenthood teaching (Saint Nicholas Catholic 
Church, 2014). The population served was unemployed, sick, and other people going 
through any change in their life (Saint Nicholas Catholic Church, 2014). 
Eligibility criteria. The selection of the sample followed some criteria. The 
eligibility criteria for the inclusion of a member of the population to the sample were (a) 
to attend church services at Saint Nicholas Catholic Church or/and to receive primary 
care services at MedStar Primary Care Clinic in Houston, Texas, (b) to have been 
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diagnosed with a dermatology disease in the past 12 months starting from the 
questionnaire completion date, (c) to be at least 18 years old, (d) to have seen, read, or 
heard (exposure) a dermatology advertisement about a dermatology prescription drug, 
or/and disease directed directly to the dermatology patients, and have received a 
treatment for a medical reason because of the exposure to the advertisement within one 
year, (e) to speak, read, and understand English language, (f) to be receiving dermatology 
treatment  at a dermatology facility in Houston, Texas, and (g) to be living in Houston, 
Texas for at least six months continuously. 
Sample size determination. The power analysis method permitted to determine 
the sample size of the study. G*Power 3.1.2 computer software helped to determine the 
sample size of 82 individuals for this research study. The test family selected was t-tests. 
The statistical test used was Correlation: point biserial model. The type of power analysis 
was A priori compute required sample size-given α, power, and effect size. The input 
parameters were two-tailed hypotheses testing, a Cohen’s d medium conventional effect 
size = .30, α = .05 and the power = .80%. The output parameters were a critical value = 
1.99, the degree of freedom = 80 and actual power = .80%. However, by rounding off 82, 
120 people were the final sample size. I equally surveyed this sample size within the two 
settings: 60 respondents at MedStar (with 50% males and 50% female), and 60 
respondents at Saint Nicholas (with 50% males and 50% female). There were no data 
available to breakdown proportionally the sample size. I am going to analyze the 
recruitment strategy used to form the sample. 
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Procedures for Recruitment, Participation, and Data Collection 
Respondents’ recruitment, informed consent provision, and participation. 
The recruitment of the sample took place at the study’s sites. I was the recruiter of the 
sample. I obtained from the authorities of the study’s sites the written permissions to 
conduct the study within the facility (see Appendices R and S).Then, each target patient 
that I met face-to-face in the lobby of the church or patient waiting area of the clinic 
received an A5 format flyer. The A5 flyer introduced the study to the potential 
respondent (see Appendix F). Moreover, A3 format flyers were posted in the church’s 
lobby and the clinic’s patient waiting areas to create the study awareness amongst the 
community (see Appendix D). The patient who accepted to participate in the study 
provided the informed consent and participated in the study as described below. 
The informed consent provision and participation followed multiple steps. This 
study’s informed consent provision started with my completion of the online training 
course about protecting human research participants at 
http://phrp.nihtraining.com/users/login.php on December 7, 2013. The National Institutes 
of Health issued the certificate of completion (See Appendix A) to me as the recognition 
of the qualification and ability to conduct research on human participants (National 
Institutes of Health, 2011). Then, I prepared and submitted the Informed Consent and 
other survey materials to the Walden’s Internal Reviewed Board (IRB) for approval 
(Office of Research Integrity and Compliance, 2011). 
The participant provided the informed consent and participated in the study as 
followed after Walden’s IRB approval and authorization of the study: 
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1. After reading the A5 flyer during the recruitment described above, the 
 patient, who was interested and accepted voluntarily to participate in the study, 
received from me the Informed Consent Form (Appendix C). Then, I specified to 
the patient the place where to meet for the completion after the church service or 
meeting with the physician. The recruit gave the informed consent before the 
completion of the questionnaire after he/she attended to the church service or met 
with the primary care physician. The recruit had adequate time to review study 
information, ask questions if any, before giving an informed consent, and 
participate in the study. 
2. The patient provided an implied informed consent through the completion of  
the questionnaire. The participant did not provide a physical signature on the 
Consent Form because of the participant’s privacy protection. Moreover, to 
respect the participant’s privacy during the completion, the questionnaire 
completion took place at the parish hall behind the closed doors, a different 
building within the parish’s perimeter. Besides, the questionnaire completion with 
individual participant took place at the clinic meeting room (with the doors 
closed) different from the patient waiting area. The recruitment, Informed 
Consent provision, and the completion of the questionnaire happened the same 
day at the study site during each survey day. 
3.  The participant answered to the eligibility questions of the questionnaire 
(Appendix G), and I recorded the answers to reduce the risk of bias. The 
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eligibility questions answer determined if the participant was eligible or not for 
the study before the completion of the main questionnaire. 
4.  The eligible participant answered to the main questionnaire, with me recording 
the answers. 
5.  With a noneligible patient, I terminated the completion, thanked the 
participant, and attempted to recruit a new participant or attended to the next 
scheduled participant. 
6.  During the eligibility section completion for recruitment, the participant who 
could not continue for any reason merely terminated the completion. I continued 
with another recruitment attempt or attended to a next scheduled participant. 
7. The participant who could not continue the main questionnaire completion for 
any reason merely terminated the completion. I, in that case, attended to the next 
scheduled participant. 
8. I reviewed, with the participant, the completed questionnaire for validation 
using the questionnaire completion guide (Appendix H) and terminated the 
specific completion. 
9. Finally, at the end of each survey day, I conducted the last review of the entire 
completed questionnaire to check the accuracy and the consistency of the 
responses. If any mistake or inconsistency noted at that time, I merely eliminated 
that questionnaire. 
The informed consent form was the summarized information about the nature and 
purpose of the study, how to take part to the study, the emphasis on the voluntary 
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participation in the study, the risks and what to gain taking part into the study. Also, the 
informed consent described the confidentiality measures and the ethical considerations of 
the study. 
The specific demographics data were necessary to collect during the survey. 
Indeed, dermatology disease is of all age, race, ethnic groups, gender, and locations in the 
United States (Memorial Sloan-Kettering Cancer Center [MSKCC], 2013; Skin Cancer 
Foundation, 2013e). Consequently, the demographic data collected during the survey as 
part of the study questionnaire (see Appendix G) were the age, race, ethnic groups, 
gender, level of education, yearly income, type of dermatology disease, state, city, and 
type of mean of payment of the medical dermatology services received. 
Data collection. I used, for the data collection, the face-to-face technique to 
survey the target individuals eligible for the study (Creswell 2009; Frankfort-Nachmias & 
Nachmias, 2008). According to the literature, the response rate for the face-to-face survey 
turns around 95% versus 20 to 40% for the mail survey (Frankfort-Nachmias & 
Nachmias, 2008). The projected response rate for this study was 85%. The data collection 
following the procedure described earlier lasted a month and 10 days. I coded all the 
completed and approved surveys and used SPSS 21.0 to computerize the surveys and to 
conduct the data analysis. Then, I did the results interpretation and reporting. The survey 
package was (a) a copy of the informed consent (see Appendix C), (b) a copy of the 
questionnaire, (c) a questionnaire completion guide for respondent (see Appendix H), (d) 
a pencil, and an eraser (Creswell 2009; Frankfort-Nachmias & Nachmias, 2008). 
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Survey exit and follow-up. The respondent exited the survey after the joint 
review and approval of all the answers by both the respondent and I. No follow-up was 
necessary during this study. However, a pilot study was necessary to test, correct, and to 
validate the questionnaire before the use for the final study. 
Pilot Study for Instrument Validation  
Instrument development. The research instrument was a structured 
questionnaire. I developed the study questionnaire by the year 2013 end with the 
assistance of the dissertation committee members at Walden University (Dr. Kadrie, 
Chair and Dr Raj, Methodology Expert), and Dr. Patricia Ann Parker, Associate 
Professor at MDACC of Houston, Texas, department of behavioral science. All parties 
reviewed the first and second drafts of the questionnaire from me. I used validated health 
services research samples questionnaires from Dr. Parker (quality of life survey 2010 in 
adult cancer survivors) and Dr. Raj (chronic diseases questionnaire 2007) for inspiration. 
Then, Dr. Parker, Dr. Raj, and Dr. Kadrie made recommendations for improvement after 
the review of the drafts. I corrected the second draft consequently and resubmitted the 
amended copy to the three for final approval. The current study questionnaire was the 
final version approved by Dr. Parker (see Appendix N & L), Dr. Raj (see Appendix I) 
and Dr. Kadrie (see Appendix J).     
This last version of the study questionnaire was first validated using professional 
or expert opinions approach as followed. Indeed, the experts took part to the 
questionnaire design focusing on the professional accuracy of the study’s variables used 
in the questionnaire. In fact, Dr. Mays, dermatologist at MDACC, validated the 
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questionnaire after multiple reviews and three sessions of clinical observations (24 hours) 
with me at the MDACC’s melanoma and skin center (See Appendix T). He focused on 
the dependent variables (types and purposes of treatment). In the same logic, Dr. 
Valencia Thomas, Associate Professor at the MDACC, edited the Mohs section 
(dependent variables) (see Appendix K). Dr. Thomas recommendations for improvement 
were included in the questionnaire.  
Regarding the DTCAs, Thomas Abrams, Masters of Business Administration 
(MBA) from the Food and Drug Administration’s Office of Prescription Drug Promotion 
in Maryland validated the product-claim and help-seeking advertisements characteristics 
from the FDA’s website used in this questionnaire (see Appendix O). The product-claim 
and help-seeking advertisements characteristics were the independent variables of the 
study. 
Instrument validation plan. The version of the questionnaire validated through 
expert opinion as described above (see Appendix G) went through the pilot study and 
reliability test for the second and final validation. The pilot study established the 
reliability of the study’s instrument based on the Cronbach’s Alpha α test results.  The 
final data collection used the validated questionnaire from the pilot study. Indeed, the 
questionnaire was new and used for the first time in this study. Consequently, it was 
necessary to pilot the instrument before the final data collection (Field, 2009). A reliable 
instrument or questionnaire measures most likely the construct under investigation during 
each use in the same conditions (Al-Dmour et al., 2013; Creswell, 2009). The objective 
of the reliability test was to confirm or not that the study’s findings would be the same 
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every time that the researchers repeat the study keeping every condition unchanged 
(Field, 2009; Frankfort-Nachmias & Nachmias, 2008; Thatcher, 2010). The reliability 
test method was the split-half reliability. This method, using SPSS computer program, 
divided into two the data randomly. Then, a high computered correlation between the two 
halves of the data indicated the reliability of the questionnaire. In that regard, a 
Cronbach’s Alpha α value of .7 through .8 (Field, 2009) or 0 through 1(Al-Dmour et al., 
2013; Green & Salkind, 2011) was valid to establish the internal consistency or reliability 
of the scale and consequently, the questionnaire validity (Dedeli & Fadiloglu, 2011; 
Green & Salkind, 2011).  
The planned and achieved pilot sample size was twelve participants. The pilot 
sample was selected identically (six from each study site) from the study sites following 
the selection method presented earlier. The twelve pilot study’s respondents were not part 
of the final sample. The pilot study was planned to help to identify and correct any 
mistake or malfunctioning from the questionnaire regarding questions, format, and scales 
before the final study.  
The Likert scale of attitude permitted to measure the attitude and views of the 
patients regarding the DTCAs of dermatology drug or disease prompting the utilization of 
the medical dermatology services for medical reason(s). The questionnaire had six scales: 
(a) dermatology product claim advertisement exposure scale (DPCAES), (b) dermatology 
help-seeking advertisement exposure scale (DHSAES), (c) types of medical dermatology 
treatments utilized after exposure to the dermatology DTCA of prescription drug scale 
(TDMTUEPDAS) , (d) types of medical dermatology treatments utilized after exposure 
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to the dermatology disease DTCA scale (TDMTUEDDAS), (e) purposes of the utilization 
of medical dermatology treatments after exposure to dermatology DTCA of prescription 
drug scale (PUDMTEDDAS), and (f) purposes of the utilization of medical dermatology 
treatment after exposure to dermatology DTCA of disease scale (PUDMTEDAS). The 
scales (a) had 10 items, (b) five items, (c) seven items, (d) 14 items, (e) four items, and 
(f) four items.  
Instrumentation and Operationalization of Constructs  
Identifying instrument and literature supporting the development. I have 
identified in this paragraph the instrument, mostly the measurement scales, and presented 
the publications that shed light on the instrument development. The quantification of a 
concept is the primary purpose of the measurement (Creswell, 2009; Frankfort-Nachmias 
& Nachmias, 2008; Likert & Hayes, 1957; Rothmann et al., 2009). Therefore, the study’s 
measuring tool was the Likert interval scale of five points included in the questionnaire 
which was the main research instrument. This scale existed since 1920 due to Renis 
Likert’s work (Likert & Hayes, 1957; Hartleya & Betts, 2010). The scale aimed to 
measure the individual’s attitude toward a phenomenon under investigation. In that 
regard, the researcher created a list of positive verbal statements to which people 
provided their answers to each individual item on a scale (Carifio & Perla, 2007; 
Frankfort-Nachmias& Nachmias, 2008; Jamieson, 2004; Likert & Hayes, 1957). The 
scale usually was a five-point scale with equal interval. The point five was always 
assigned to the positive end and one to the negative end of the scale (Chomeya, 2010; 
Hartleya & Betts, 2010; Jamieson, 2004; Likert & Hayes, 1957). 
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The Likert interval scale of five points (where one mean Not agree at all, two 
means Not agree, three means Agree/Not agree, four means Agree, and five means 
Totally agree) served to measure the variables in the questionnaire. Each value from one 
through five was the weight and the direction of the respondent’s answer the item 
depending on how favorable or not he/she was regarding the item (Frankfort-Nachmias & 
Nachmias, 2008). This allowed the generation of the numbered data for the statistical 
tests and analysis using SPSS 21.0 computer software (Creswell, 2009; Frankfort-
Nachmias & Nachmias, 2008; Likert & Hayes). The questionnaire had six scales as 
described in the pilot section above. Each had a certain number of items or positive 
verbal statements on which the respondent expressed his/her attitude about the problem 
under investigation. 
The questionnaire was a set of 38 questions with 24 closed-ended, six matrix 
question/rating, and height open-ended (Frankfort-Nachmias & Nachmias, 2008). The 
questions provided information about the following aspects of the research: (a) eligibility 
criteria, (b) demographics/background, (c) exposure to the dermatology pharmaceutical 
DTCA of prescription drug, (d) exposure to the dermatology pharmaceutical DTCA of 
disease, (e) utilization of medical dermatology service(s)/treatment(s) after exposure to a 
dermatology pharmaceutical drug announcement, (f) utilization of medical dermatology 
service(s)/treatment(s) after exposure to a dermatology pharmaceutical disease 
announcement, (g) purpose of the utilization medical dermatology service(s)/treatment(s) 
after exposure to a dermatology pharmaceutical drug announcement, and (h) purpose of 
the utilization of medical dermatology service(s)/treatment(s) after exposure to a 
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dermatology pharmaceutical disease announcement. The length of the questionnaire was 
around 30 minutes.  
Likert scale reliability and validity critiques. The section addresses the limits 
of this study instrument’s reliability and validity method. The reliability and validity of 
the questionnaire took place during the pilot study as described earlier. Cronbach’s Alpha 
α method allowed in the previous studies to establish the Likert scale’s reliability and 
construct validity. In fact, Dedeli and Fadiloglu (2011) in their study on obesity used test-
retest method to verify the reliability and the content validity of the Likert scale. As 
stated in the pilot section above, a reliable and valid instrument permits to obtain the 
same findings over time (Frankfort-Nachmias & Nachmias, 2008). However, the Likert 
scale’s validity depends on how the researcher creates the positive statement for 
measurement. Moreover, the Likert scale’s validity depends on the identification and 
control by the researcher of the specific threats to the study validity (Creswell, 2009; 
Frankfort-Nachmias & Nachmias, 2008). Finally, the spilt-half reliability or the way the 
data set is divided into two determines the results of the test in certain cases (Field, 2009) 
independently of the variable measured in the study. 
The variables to measure to address the research question. The variables 
measured on the interval scale for hypotheses testing were the characteristics of the 
pharmaceutical product claim and help-seeking DTCAs as defined in general by the FDA 
(independent variables). The other variables for the measurement were the types and 
purposes of the medical dermatology services utilized as the consequence of the target 
population exposure to a dermatology product claim and help-seeking (dependent 
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variables). The complete list of the independent and dependent variables of the study 
were in the Chapters 1 and 2, operational definitions sections.  
The data to assess these variables in order to answer the research questions were 
the primary data collected from the respondents during the face-to-face questionnaire 
completions. The measurement instrument was a structure questionnaire with five-point 
Likert scale as presented above. The respondents rated on the product claim or help-
seeking scales the DTCAs’ characteristics and the medical dermatology services utilized 
after an exposure to dermatology DTCA.  
The variables measurement required the use of different levels of measurement 
that were necessary for this study. The first level was the nominal (use of numbers to 
assign modalities or answers to each categorical variable and demographics). The race, 
ethnic groups, gender, level of education, type of dermatology disease, state, city, and 
type of mean of payment which were categorical variable used this level of measurement 
(Frankfort-Nachmias & Nachmias, 2008). The second level was the interval (to measure 
the continuous variables respecting the same exact and constant distance between them) 
appropriate for the incomes and ages as quantitative variables (Frankfort-Nachmias & 
Nachmias, 2008).  
The third was the ratio level of measurement (to describe variables with absolute 
and fixed natural zero point, or have identical distance between them). This level helped 
to calculate the mean age of the respondents (Frankfort-Nachmias & Nachmias, 2008).  
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Operationalization of the Variables of the Study 
Terminology. DTCAs: Announcements or information  about dermatology drug, 
disease, treatment options, and devices passed directly to the dermatology patients by 
pharmaceutical companies and distributors through the television, radio, newspapers, 
telephone, brochures, magazines or online without any medical professional mediation 
(Hall, Jones, & Hoek, 2010; Lee-Wingate & Xie, 2010).  
Help-seeking advertisement: Announcement that talks only about the dermatology 
disease or condition without any reference to a drug that can treat the condition (FDA, 
2012d, 2012f; La Barbera, 2012).  
Medical services/physician services: Dermatology healthcare services or supplies 
delivered or whose delivery is coordinated by a physician or medical doctor who has a 
medical license to practice medicine or osteopathy (Healthcare.gov, 2013; GPO, 2013). 
Product claim advertisement: Announcement that states the dermatology drug 
name, the treated condition, and the risks and benefits related to the use of the advertised 
drug (FDA, 2012b, 2012f; La Barbera, 2012). 
Purpose of medical services utilization: Reason why the dermatology care seeker 
utilizes medical care services. The reason can be the disease prevention, the treatment of 
disease, the monitoring, to seek the well-being, the protection or to alleviate a condition 
(Aday & Anderson, 1974; Barton, 2010; Shi & Singh, 2008). 
Dermatology disease/condition: Disease(s) that attacks skin, hair, and nails 
(AAD, 2014b). 
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Type of medical services utilization: A particular medical service or care provider 
that can be a nurse, hospital, surgeon, or a physical therapist used by a dermatology care 
seeker (Aday & Anderson, 1974; Shi & Singh, 2008). 
Utilization of medical services: Reception of dermatology services provided by or 
under the supervision of a State’s licensed dermatologist at a physical place, for an 
identified medical reason, and based on a frequency of utilization (Aday & Anderson, 
1974; Shi & Singh, 2008). 
Operational definitions. The following were the operationalization of the study 
variables.  
Dermatology help-seeking/disease advertisement. Description of the type of 
dermatology disease without any recommendation of a specific dermatology drug for 
treatment: The advertisement presents to the public the disease and its symptoms without 
telling what drug can treat the condition (FDA, 2012f). 
Encouraging people with the symptoms of the described type of dermatology 
disease to talk to their doctor: Recommendation to the public to consult the 
dermatologist if the person notices on the skin, hair, or nails any indication/sign of the 
advertised disease (FDA, 2012f). 
Inclusion of the company's name of the advertised dermatology drug: Designation 
of the drug’s manufacturer (FDA, 2012f). 
Provision of a telephone number/website to call or to visit for more information 
about the advertised dermatology disease (described condition): Communication to the 
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public of the available telephone number or website to use to collect extra information 
regarding the particular advertised dermatology disease if necessary (FDA, 2012f). 
Dermatology product claim or prescription drug advertisement 
(characteristics).  Equal statement of the advantages and possible negative effects of the 
dermatology drug use: Presentation to the patients, in a balanced way, of what are the 
benefits and potential negative consequences of using the advertised drug (FDA, 2012d, 
2012f). 
 
Equal statement of the benefits and risks associated with the dermatology drug 
use: Equitable presentation of the advantages and dangers related to the use of the 
advertised drug (FDA, 2012f). 
Inclusion in the dermatology print product claim advertisement of the statement. 
"You are encouraged to report negative side effects of prescription drug to the FDA Visit 
MedWatch5 or call 1-800-FDA-1088.": Clear statement of how the patient can 
communicate to the FDA office any not desired secondary consequences of the drug 
advertised (FDA, 2012f). 
Statement by the dermatology broadcast product claim of different sources where 
to find the FDA approved prescribing information of the advertised drug (adequate 
provision): Statement of where the patient can get additional product information 
approved by the FDA 
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Statement by the dermatology audio broadcast product claim of the most 
important risks of the dermatology drug (major statement): Presentation of the most 
serious dangers that may encounter the dermatology drug user.   
Statement by the dermatology print product claim of all the drug risks approved 
by FDA as prescribing information (brief summary): Presentation of the dangerous 
aspects of the drug approved by the FDA and contained in the drug information or label. 
Statement of the most significant dermatology drug’s risks: Presentation of the 
very important dangers that the patient may face taking the advertised drug (FDA, 
2012f). 
Statement of the name of the dermatology drug: Statement of the vulgar 
designation of the drug approved by the US government (brand) and the US government 
non-approved drug designation used (generic) to advertise the drug (FDA, 2012f). 
Statement of a minimum of one type of dermatology disease (the condition[s]) 
treated by the advertised dermatology disease drug (approved drug use by the FDA): 
Presentation of the form of dermatology disease treated by the advertised drug (FDA, 
2012f). 
Purposes of medical services utilization after exposure to dermatology help-
seeking/disease advertisement. Early detection of the dermatology disease: Diagnosis 
of the condition at its very first stage (MDACC, 2013a; Kontos & Viswanath, 2011). 
Dermatology disease symptom management: Preventive measures taken, self-
examination of the skin to detect any change that may indicate a dermatology disease 
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type, identification of the surrounding possible causes for more prevention and control, 
and screening test when necessary (Kontos & Viswanath, 2011). 
Tumor/disease clearance: Complete cure of the disease (Samarasinghe et al., 
2011). 
Tumor/disease lesion excision: Use of instruments to remove the abnormal part of 
the cell or tissue and its surrounding normal cell in order to cure the dermatology 
condition (MDGuidelines, 2013; Samarasinghe et al., 2011). 
Purposes of medical dermatology services utilization after exposure to a 
dermatology product claim/drug advertisement. Mohs defect repair using a rhombic 
transposition: Rebuilding of the part of the body damaged by the dermatology disease 
using Mohs surgery and the rhombic transposition method (Samarasinghe et al., 2011). 
Treatment/cure of the dermatology disease looking for well-being: Complete 
destruction or removal of the dermatology disease so that the patient will become healthy 
(MDACC, 2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b). 
Tumor/disease clearance:  Complete elimination of the dermatology tumor 
(Samarasinghe et al., 2011). 
Tumor/disease lesion excision: Removal of the abnormal part of the cell and its 
surrounding normal tissue (MDGuidelines, 2013; Samarasinghe et al., 2011). 
Types of medical dermatology services utilized after exposure to dermatology 
help-seeking/disease advertisement. Consulting dermatologist regarding any symptom 
related to dermatology disease for early detection: Discussion with the dermatologist 
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about the possible symptoms of the dermatology disease that the patient has (Kontos & 
Viswanath, 2011). 
Dermatology disease screening test: Checkup to diagnose a dermatology disease 
before any symptom appears (Kontos & Viswanath, 2011; National Cancer Institute 
[NCI], 2013e). 
Gene therapy/biological therapy: Destruction of the dermatology disease   by 
including genes into the patient’s cells affected by the cancer (NCI, 2013a; The Skin 
Cancer Foundation, 2013d). 
Clinical trial/experimental: Participation to a research study that seeks to know 
how well a dermatology disease treatment approach or technique works on individuals 
(American Cancer Society, 2013b; MDACC, 2013a; NCI, 2013e; The Skin Cancer 
Foundation, 2013b). 
Cryotherapy/Cryosurgery: Use of the liquid nitrogen to freeze and eliminate skin 
tissues affected by the disease (Samarasinghe et al., 2011; The Skin Cancer Foundation, 
2013b; MDACC, 2013a). 
Curettage and cautery/Curettage and electrodessiccation/Electrodessiccation and 
curettage: Use of instruments called curette to scrap off the skin tumor followed by the 
destruction of any remaining tumor with the heat generated by the electrocautery needle 
(AAD, 2013; American Cancer Society, 2013b; Samarasinghe et al., 2011; The Skin 
Cancer Foundation, 2013b). 
Laser surgery: Removal of the external layers of the cell (epidermis) and the 
tissues of the skin affected by the tumor using the laser strong beam light, the erbium 
124 
 
YAG laser or the carbon dioxide (, 2013a; NCI, 2013d; The Skin Cancer Foundation, 
2013b). 
Lymph node surgery: Operation of the lymph nodes for biopsy to look for 
cancerous tumor or for the removal of the lymph nodes in case of the presence of the skin 
cancer tumor (American Cancer Society, 2013b). 
Mohs micrographic surgery: Excision of a malignant tumor with the help of 
staged, intraoperative frozen sections processed in the Mohs technique. Sections excised 
are histologically clear of malignancy (American Cancer Society, 2013b; MDACC, 
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b) 
Radiotherapy/Radiation: Destruction or treatment of the tumor in the tissue of the 
patient utilizing X-ray beams (NCI, 2013d; Samarasinghe et al., 2011; The Skin Cancer 
Foundation, 2013b). 
Skin grafting and reconstructive surgery: Removal of the skin cancer tumor 
followed by the collection a skin free of tumor from the patient body to graft it on the 
wound. The grafting helps the wounded part to recover completely (American Cancer 
Society, 2013b). 
Standard surgical excision/resection: Use of the anesthesia to paralyze for a short 
time the area of the skin with tumor. Then, removal of the tumor surrounded with a 
certain normal skin followed by its examination under microscope to make sure the entire 
tumor has been removed. Stitches are used to repair the surgical area to end the procedure 
(AAD, 2013; American Cancer Society, 2013b; NCI, 2013d; Samarasinghe et al., 2011; 
The Skin Cancer Foundation, 2013b). 
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To search for additional health information outside disease advertisement 
(company’s website): Other sources of information are consulted to complete the 
information received from the advertisement and to be able to make an informed health 
decision (Kontos & Viswanath, 2011). 
Types of medical dermatology services utilized after exposure to a 
dermatology product claim/prescription drug advertisement. Request and obtainment 
of a medical prescription of the dermatology drug advertised: Meeting with the 
dermatologist to request and obtain from him/her the prescription of the advertised 
dermatology drug (Gray & Abel, 2012). 
Chemotherapy: Treatment of the patient using the dermatology advertised 
prescription drug following the patient’s request (American Cancer Society, 2013b; NCI, 
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b) 
Adherence to the dermatology disease treatment regimen: Normal participation to 
the treatment plan prescribed by the dermatologist (Frosch, Grande, Tarn, & Kravitz, 
2010; Wellington, 2010). 
Dermatology prescription drug refill: Obtainment of another quantity of the same 
drug from the pharmacist after running out of the drug (Frosch et al., 2010; Wellington, 
2010). 
To talk to dermatologist/doctor about dermatology advertised medication: 
Meeting with the dermatologist/doctor to discussion about the dermatology medicine 
presented in the advertisement (Gray & Abel, 2012). 
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Physician/dermatologist office visit: Meeting with a dermatologist/doctor in 
his/her office for medical dermatology reasons (Gray & Abel, 2012). 
Skin, hair, and nails health maintenance: Treat the patient to improve his/her 
appearance not to take care of a specific dermatology disease (AAD, 2014b). 
Scores and interpretation. The calculated scale scores (Likert scale) were the 
mean scores. SPSS software helped to calculate the mean scores by adding all the values 
in the distribution or all observations and dividing the result by the total number of the 
observations (Frankfort-Nachmias & Nachmias, 2008; Green & Salkind, 2011). Each 
means score indicated the level of the Likert scale with the higher distribution or 
responses for the variable from the respondents. The identified level on the Likert scale 
(from one through five) was the respondents’ opinion about the variable (Field, 2009; 
Frankfort-Nachmias & Nachmias, 2008; Green & Salkind, 2011).  
Data Analysis Strategy 
Data analysis software: statistical package for social sciences (spss) 21.0. The 
statistical package for the social sciences (SPSS) software version 21.0 was the data 
analysis software selected for this study. Windows 7 helped to run SPSS version 21.0 on 
a computer. SPSS software served to analyze social sciences data. Furthermore, SPSS 
software helped to draw reliable conclusions that helped to solve daily life problems in 
the context of medical or health research, market research, pharmaceuticals and 
manufacturing (Frankfort-Nachmias & Nachmias 2008; Green & Salkind, 2011; 
International Business Machines [I.B.M.], 2011). This research belongs to the health 
research category in social sciences. 
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Data cleaning and screening procedures. The data cleaning consisted of 
multiples tasks before the analysis. The first task was the coding of the data. The coding 
was the attribution of number or numeric codes to each observation or variable category. 
Then, the numbers enabled the use of the computer and SPSS 21.0 program to 
computerize, to edit, to retrieve, and to analyze data (Frankfort-Nachmias & Nachmias, 
2008; Green & Salkind, 2011; IBM, 2011). The codebook constituted the coding 
outcome (Frankfort-Nachmias & Nachmias, 2008; Laureate Education, 2009). The data 
editing during the creation of the codebook was to check and to make sure that each 
question had an appropriate answer according to the completion guide for the 
respondents, and the appropriate assigned numeric codes for each modality. Then, I 
verified that all answers were consistent one another when necessary. I conducted this 
task by reviewing all the completed surveys. The development of a codebook took place 
after the data collection via questionnaire completion (data preparation). The higher 
category of each interval-level of variable had the higher score and vice versa. The 
nominal-level variable code assignment followed no rule, but was consistent with all 
cases in the study (Frankfort-Nachmias & Nachmias, 2008). 
 The second task was the data cleaning by me after coded data were in SPSS 
format. Thus, I used the codebook to check, to identify, and to correct manually incorrect 
and inconsistent codes in the data view windows of the SPSS file. Then, I used the SPSS 
data to run the frequency table for each variable in order to track and to replace the code 
that did not exist in the codebook (wild codes) (Frankfort-Nachmias & Nachmias, 2008). 
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 The third cleaning task consisted of tracking and correcting outliers from the 
SPSS data before running the multiple regression’s assumptions test. The assumption test 
aimed to verify if the assumptions were met or not before any statistical test of 
hypotheses (Field, 2009; Laureate Education, 2009). A variable was an outlier if the score 
was higher or lower than any other score of the same variable. In other word, each value 
that did have a standardized score above the absolute value /3.29/ for the variable was 
considered outlier (its standard deviation is more than 3 from the mean score) (Field, 
2009; Laureate Education, 2009). I created the standardized scores or z-scores for each 
variable using the descriptive table of the SPSS. The frequencies were considered the 
new standardized scores. A standardized score with a value higher than the absolute value 
of /3.29/ was considered outlier (Laureate Education, 2009). The plan to correct any 
outlier found was to make the outlier higher by one unit from the extreme score of the 
variable. The new or modified value coming from the correction of the outlier (s) was to 
replace the outlier (s) of the variable before any statistical test. I did not plan to delete 
outliers, if any found, to avoid reducing the sample size of the study (Laureate Education, 
2009). The data analysis did not detect any outlier for this study.  
The fourth task was the Multiple Regression’s assumption test. The multiple 
regression analysis’ assumptions were the (a) normality, (b) normality of error variances 
distribution,  (c) independence, (d) linearity, (e) homoscedasticity, (f) independent  errors, 
(g) predictor variables are quantitative or categorical non-zero variance, (h) no perfect 
multicollinearity, and (h) predictors are uncorrelated with external variables (Field, 2009; 
Green & Salkind, 2011; Laureate Education, 2009). The testable assumptions were the 
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(a) normality of the distribution, (b) normality of error variances distribution, (c) 
independence of errors, (d) homoscedasticity and (e) no perfect multicollinearity (Field, 
2009). The bottom line of the assumption test was to verify if the assumption was met or 
to provide an alternative in case the assumption was not met before any hypothesis test. 
Moreover, parameters of the regression model would be free of bias and the external 
validity (generalization) would be possible if the assumptions were met. Linear multiple 
regression assumption stated that the predictor variables (independent) can be 
quantitative or categorical (with two categories codes zero and one) and the outcome 
variable (dependent) can be quantitative, continuous and unbounded (Field, 2009; Green 
& Salkind, 2011). In addition, more than one predictor would be considered separately as 
predicting the type or purpose of medical service utilized. 
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Research questions and hypotheses. 
       Main research question and hypothesis. This quantitative research sought to 
answer the following main research question: Is there a statistically significant 
relationship between product claim, help-seeking advertisements, and types and purposes 
of medical service utilization amongst adult dermatology patients in the United States? 
The related hypothesis to this main research question was: 
Hypothesis 1 (H0): Product claim and help-seeking advertisements does not 
significantly prompt the utilization of the types and purposes of medical services amongst 
adult dermatology patients in the United States.  
Hypothesis 1 (H1): Product claim and help-seeking advertisements significantly 
prompt the utilization of the types and purposes of the medical services amongst adult 
dermatology patients in the United States. 
Secondary research questions and hypotheses. The secondary research questions 
proceeding from the central question were: 
Is product claim advertisement a predictor of the types of medical services 
utilized amongst adult dermatology patients in the United States? 
Hypothesis 2.1 (H0): Product claim advertisement does not significantly prompt 
the utilization of the types of medical services amongst adult dermatology patients in the 
United States.  
Hypothesis 2.1 (H1): Product claim advertisement significantly prompts the 
utilization of the types of the medical services amongst adult dermatology patients in the 
United States.  
131 
 
Is product claim advertisement a predictor of the purposes of medical services 
utilization amongst adult dermatology patients in the United States? 
Hypothesis 2.2 (H0): Product claim advertisement does not significantly prompt 
the purposes of medical services utilization amongst adult dermatology patients in the 
United States.  
Hypothesis 2.2 (H1): Product claim advertisement significantly prompts the 
purposes of the medical services utilization amongst adult dermatology patients in the 
United States.  
Is help-seeking advertisement a predictor of the types of medical services utilized 
amongst adult dermatology patients in the United States? 
Hypothesis 2.3 (H0): Help-seeking advertisement does not significantly prompt 
the types of medical services utilized amongst adult dermatology patients in the United 
States.  
Hypothesis 2.3 (H1): Help-seeking advertisement significantly prompts the types 
of the medical services utilized amongst adult dermatology patients in the United States.  
Is help-seeking advertisement a predictor of the purposes of medical services 
utilization amongst adult dermatology patients in the United States? 
Hypothesis 2.4 (H0): Help-seeking advertisement does not significantly prompt 
the purposes of medical services utilization amongst adult dermatology patients in the 
United States.  
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Hypothesis 2.4 (H1): Help-seeking advertisement significantly prompts the 
purposes of the medical services utilization amongst adult dermatology patients in the 
United States.  
Data analysis plan. 
 Descriptive and inferential statistics. The first group of analytical tools 
was the descriptive statistics. In fact, the descriptive statistics of interest were the mean 
scores, standard deviations, and frequencies. The three parameters allowed to organize 
and to summarize data. The standard deviation permitted to describe and to measure the 
dispersion of the variable distributions from the mean. The frequencies helped to 
compute the total number of distribution in favor of each categorical variable that were 
the characteristics of each type of advertisements, the types and purposes of medical 
services utilization, and the demographics. The mean scores helped to determine the 
mean of the interval-level variable exact age (Frankfort-Nachmias & Nachmias, 2008; 
Green & Salkind, 2011). Furthermore, the mean score permitted to identify the level of 
the Likert scale that had the higher distribution for the variable. The identified level on 
the Likert scale (from 1-5) enabled me to read the attitude and views of the respondents 
on the scale for the particular item (Field, 2009; Frankfort-Nachmias & Nachmias, 2008; 
Green & Salkind, 2011).  
 The second group of tools was the inferential statistical that enabled to test the 
hypotheses: the linear multiple regressions. Linear multiple regression aims to describe 
the strength of a linear relationship between one dependent variable and multiple 
independent or control variables (Field, 2009; Frankfort-Nachmias & Nachmias, 2008; 
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Green & Salkind, 2011). As stated earlier, the research question was about the linear 
relationship between product claim and help-seeking advertisements (independent 
variables) and the type and purpose (dependent variables) of the utilization of the medical 
services amongst dermatology patients aged 18 and older. The dependent and 
independent variables were observed on the Likert scale of five points. Consequently, 
they were continuous or quantitative. The selection of the predictors to enter into the 
model was based on the current literature reviewed and the results of the pilot study 
(Field, 2009; Frankfort-Nachmias & Nachmias, 2008). This test was appropriate for the 
hypotheses testing of this study.   
The parameters for the interpretation of the test of the hypotheses, using linear 
multiple regression, were the multiple R or multiple correlation coefficient and the sum of 
square R
2
 or effect size (Field, 2009). The multiple correlation R represented the strength 
index of the degree of the correlation between the dependent and independent variables 
for the sample (Green & Salkind, 2011). A large multiple R indicated the large 
correlation between the product claim and help-seeking advertisements and type sand 
purpose of medical services utilization in the sample. Concretely, a multiple R equal to 1 
meant that the predictors affected perfectly the outcome or dependent variable: the 
overall test or model was positive (Field, 2009). The H0 of the main hypothesis was 
rejected to the benefit of H1. Then, the Adjusted R
2
 was the amount of the variance in the 
dependent variable attributed to the set of predictors. In other words, Adjusted R
2
 was the 
level of the overall variance in the outcome explained by a set of the predictors in the 
model or equation. The Adjusted R
2
 represented the amount of variance in a type or 
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purpose of the medical dermatology services utilized explained by the set help-seeking or 
product claim advertisements variables (Field, 2009). The index of effect size (R
2
) or 
Adjusted R
2
 ranged in value from -1 to +1 (Frankfort-Nachmias & Nachmias, 2008; 
Green & Salkind, 2011). 
 Confidence level and margin of error for the hypotheses test. The 
conventional 95% was the confidence level, and 5% the margin of error or level of 
significant (α = .05) for the hypotheses test. Moreover, the test was a two-tailed 
hypothesis testing. In that regard, the null hypothesis was rejected if the sample outcome 
was among the results that would have occurred by chance not more than 5% time 
(Frankfort-Nachmias & Nachmias, 2008). In other words, the null hypothesis was 
rejected when the p-value was less or equal to than .05. P-value or probability indicated 
how confident I was to say that the observation from the sample was the same in the 
population (inference).  
Threats to Validity 
The paragraph addresses the external validity threats and the solutions for this 
research study.  The external validity of a research refers to how accurate or until which 
degree the researcher can generalize the results from the sample to the entire population, 
or can apply those results in a separate context (Frankfort-Nachmias & Nachmias, 2008). 
The first threat to the external validity of this research study was the representativeness of 
the sample. Indeed, the sample most has the key characteristics of the population for the 
statistical inference to be possible. Consequently, the eligibility criteria stated previously 
for the statistical unit inclusion to the sample, the demographics, my personal judgment 
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in selecting the final respondents, and the Walden University’s IRB approval of the 
questionnaire after reviews permitted to address this study’s threat to external validity. In 
addition, the results of this study will not be inferred to any population or setting that was 
not part of the study.  
The second threat to the external validity was the technical nature of the 
independent and dependent variables as well as the items selected for the observation of 
the variables. Product claim, help-seeking advertisements, types and purposes of medical 
dermatology services utilization, and the observation items described in Chapters 1 and 3 
were the language proper to the specific professions. Therefore, the respondent has to 
understand the clear meanings of the variables and items to be able to provide with 
accurate answers in the questionnaire. In doing so, the items would measure effectively 
the intended content or construct (Creswell, 2009; Frankfort-Nachmias & Nachmias, 
2008). Indeed, the construct validity is the effectiveness of the items to measure the 
concepts stated in the hypotheses (Creswell, 2009). The construct validity threat to this 
study can be the selection by me of the inappropriate items for the observation of the 
independent and dependent variable of the study. The experts’ opinions about the DTCAs 
and the medical dermatology services approved the items and operational definitions 
used for the final data collection. The pilot study enabled the test of the target 
population’s understanding and familiarity with the constructs or concepts. Then, I used 
the pilot study results consequently before the final data collection.  
The internal validity threats and solutions are the focus of this paragraph. The 
internal validity of a research is the fact that independent variable, not a different factor, 
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affect or bring change to the dependent variables effectively (Creswell, 2009; Frankfort-
Nachmias & Nachmias, 2008). The threat to internal validity represents those factors, 
different from the independent variable, which can provoke the change in the dependent 
variable. This if they are not identified and addressed properly before or during the study. 
The threat to the internal validity of this study was the patient’s moral and psychological 
conditions due to his/her dermatology condition. Indeed, dermatology diseases such as 
skin cancer are a deadly disease if not diagnosed and cured early (Skin Cancer 
Foundation, 2013c). The dermatology disease patient participant to this study was 
morally and psychologically uncomfortable due to the possible death that he/she could be 
a victim (Skin Cancer Foundation, 2013c). Therefore, the information provided during a 
completion may not be accurate. In that case, the observed relationship between 
dermatology product claim, help-seeking advertisements and types and purposes of 
medical dermatology services utilization may not reflect the reality of the field. Two 
solutions were used to overcome this threat:  the participation and withdrawal at any time 
of the patient from the study were free and voluntary.  
Ethical Procedures 
Access to Data and Research Authorization from the Study Sites and Walden 
University 
This section provides the answer how I proceeded to obtain primary data from 
MedStar and Saint Nicholas Catholic Church communities, the authorization to survey 
dermatology patients at those two study sites without harm, and to obtain the Walden 
University IRB’s approval to collect data for this study. The two study sites issued to me 
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the written permissions to conduct research on the sites (See Appendices R & S). I 
completed successfully the US National Institutes of Health’s online training on the 
protection of human subject in research on December 7
th
, 2013 (See Appendix A) 
(National Institutes of Health, 2011).  
   In the same logic, I requested and obtained the study approval from the Walden 
University IRB before starting any pilot study and primary data collection. Indeed, I 
prepared and submitted to the Walden IRB, after the approval of the committee chair, the 
following documents: the Walden IRB application form version 2010A and the 
supporting materials. The supporting materials were all the appendixes listed in this 
dissertation.  
Concerns Regarding Recruitment Materials and Process   
The respondents’ recruitment materials that were the flyers A5 and A3 formats 
and the screening section of the questionnaire had certain concerns. The concerns 
regarding the flyers and the questionnaire were the length, the color, the typography, the 
quality of the paper, and the illustrations or images on the flyers (Frankfort-Nachmias & 
Nachmias, 2008). The solutions to these concerns were to write short texts for the flyers 
and to use a high quality paper and printing selected by the infographic and/or printing’s 
professionals, Leeland Designs Company. The questionnaire text was double space, times 
news roman, 12 front size for easy and fast readability. 
In terms of process, the concern was the level of the dermatology patient’s 
receptiveness and corporation during the recruitment at the study sites (to allow me to 
talk to him/her or to read the flyers personally about the study). The patient was there to 
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honor a medical appointment or to attend a church service. Therefore, it was not easy to 
know if the participant would be receptive and corporative in that condition to accept to 
have a conversation with me, to read the flyers, and to participate in the study. The 
written approval of the study by the study sites’ authorities solved the receptiveness and 
corporation concerns. Besides, I made sure that the personal introduction or the first 
contact with the potential respondent established a climate of confidence, interest, and 
trust between both parties. Furthermore, I told the respondent how the study would be 
useful for the dermatology patients. Moreover, I explained to the respondent the aim of 
the study, the respondent selection method, and the guarantee of the confidentiality of the 
collected information (Frankfort-Nachmias & Nachmias, 2008).  
Management of Data Collected 
The data collected had no identifier such as name, medical record number, date of 
birth, social security number, account number, email address, and home address. The 
same code or numerical number identified the answers to the same question. The respect 
of confidentiality and respondent privacy was via the no requirement of his/her signature 
on the informed consent form. The respondent signed the informed consent form by 
completing the survey. I clarified that to the respondent at the beginning of the eligibility 
section. Other measures to provide confidentiality of data and respect for the respondent 
privacy were an anonymous analysis of the data collected and the study’s results 
(Frankfort-Nachmias & Nachmias, 2008).   
Furthermore, I stored for five years the data collected on his laptop hard disk, 
USB drive, and CD-Rooms with the access protected by a passed word at my discretion. I 
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am the only one to have access to the data. The data will be destroyed five years after the 
defense and dissemination of the dissertation. In fact, the data will not be current 
anymore after five years.  I keep the questionnaires, USB drive, and CD-Rooms for the 
same number of year in an iron locker secured with a lock and key in my office at home.  
Summary and Transition 
The quantitative nature of the research question led to the selection of the 
quantitative design for this study. The research method was the cross-sectional survey. 
The research aim was to describe the relationship between product claim, help-seeking 
advertisements, and the types and purposes of medical dermatology service utilization 
amongst the target population at a certain point in time. The survey population was 
American residents male and female aged 18 years and over, dermatology patients living 
in Houston, Texas, receiving primary care services at MedStar and/or attending to church 
service at Saint Nicholas Catholic Church. The selection of this population was due to the 
diversity of the communities. There was no sampling frame for this study. Consequently, 
the nonprobability was the sampling strategy. The constitution of the sample was through 
the nonrandom purposive sample scheme. The MedStar and Saint Nicholas Catholic 
Church in Houston, Texas were the two sites of the study. The sample size was 82 
individuals. G*Power 3.1.2 computer software generated this sample size. The 
recruitment of the sample took place at the study sites during their visit to meet with the 
primary care physician or to attend to a church service. The respondents received the 
informed consent approved by the Walden University’s IRB at the site of the study. Each 
participant provided informed consent face-to-face using the Informed Consent Form 
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before answering to the eligibility questions. The respondent signed the informed consent 
form by completing the survey completely. The pilot study enabled the test of the 
reliability and validity of the study instrument before the use of the instrument for the 
final study. Twelve individuals from the target population were the pilot sample. They 
were excluded from the final sample of the study.  
The research instrument was a structured questionnaire of 38 questions with the 
Likert scale as the rating scale. The research independent variables were dermatology 
product claim and help-seeking advertisements as defined by the FDA. The dependent 
variables were the types and purposes of the medical dermatology services utilization 
amongst the target population.  The data analysis used the Statistical Package for the 
Social Sciences (SPSS) software version 21.0. The two groups of analytical tools were 
respectively the descriptive statistics for the data organization and the linear multiple 
regression for hypotheses testing. The interpretation of the results of the hypotheses test 
will be the main focus of the next Chapter 4.  
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Chapter 4: Results  
Introduction 
The intent of this research study was to assess the relationship between 
dermatology product claim, help-seeking advertisements, and types and purposes of the 
use of medical dermatology service amongst adult patients in the United States. Product 
claim and health-seeking advertisements were the two sets of independent variables 
(FDA, 2012b, 2012d; La Barbera, 2012). The types and purposes of the medical 
dermatology services utilization were the two sets of dependent variables of the study 
(Aday & Anderson, 1974; Barton, 2010; Shi & Singh, 2008).  
The main research question of this study was to determine if there was a 
statistically significant relationship between product claim, help-seeking advertisements, 
and types and purposes of medical service utilization amongst adult dermatology patients 
in the United States of America. This question led to the following main hypothesis: 
Hypothesis 1 (H0): Product claim and help-seeking advertisements do not 
significantly prompt the utilization of the types and purposes of medical services amongst 
adult dermatology patients in the United States.  
Hypothesis 1 (H1): Product claim and help-seeking advertisements significantly 
prompt the utilization of the types and purposes of the medical services amongst adult 
dermatology patients in the United States. 
In Chapter 1, I introduced this study, analyzing the study’s background, problem 
statement, purpose, research question(s) and hypotheses, theoretical framework, the 
nature of the study, and the operational definitions. Then, in Chapter 2, I examined the 
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literature on the study variables and identified the gap as the origin of this research study. 
Besides, Chapter 3 was the methodology supporting the investigation of the research 
problem. Finally, Chapter 4 aims to present the results of the study. The components of 
Chapter 4 are the pilot study, the data collection, the results, and the summary and 
transition to Chapter 5. The pilot study results are the object of the following section.  
Pilot Study 
The research study instrument went through a pilot study as outlined in Chapter 3. 
The aim was the final validation of the study instrument before the completion of the 
main study. Indeed, as stated in Chapter 3, the research study instrument was a structured 
questionnaire with 38 questions. I developed this questionnaire, and by end of the year 
2013, I validated the questionnaire using the experts opinion approach presented in 
Chapter 3. 
The pilot study validated the version of the questionnaire approved by the 
research committee. In that regard, Cronbach’s Alpha α statistics allowed me to establish 
the questionnaire’s reliability after the pilot study data analysis (Al-Dmour et al., 2013; 
Creswell, 2009). The reliability test method was the split-half reliability. This method, 
using SPSS computer program, consisted of randomly splitting the data into two. The 
Cronbach’s Alpha α test showed a computerized correlation between the two halves of 
the data and demonstrated, therefore, the reliability of the questionnaire (Table 2). 
Indeed, as stated in Chapter 3, all the Cronbach’s Alpha α value were between zero 
through one (Al-Dmour et al., 2013; Green & Salkind, 2011), establishing the internal 
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consistency or reliability of the scales and the questionnaire validity (Dedeli & Fadiloglu, 
2011; Green & Salkind, 2011).  
The pilot study took place from January 12 through 27, 2015 within the two 
study’s sites: MedStar Primary care clinic and Saint Nicholas Catholic Church in 
Houston, Texas.  The pilot sample size was 12 participants, shared equitably in number 
and by gender between the study sites (six from each study site with three males and 
females) as outlined in Table 1. 
Table 1 
Summary of Pilot Respondents by Place of Questionnaire Completion and Sex (N = 12) 
        Sex 
   
n Male  Female  
Place of questionnaire completion     
    
MedStar Primary Care Clinic 6 3 3 
    
Saint Nicholas Catholic Church 6 3 3 
      
Total     12 6 6 
 
The pilot study followed the study research method described in Chapter 3. The 
12 pilot study respondents were not part of the main study or final sample. The first 
completed and validated 12 questionnaires enabled the pilot study data analysis and 
validation of the research instrument. The pilot study results were as follows. 
The Pilot Study’s Results 
The pilot study generated consistent results that enabled the final validation of the 
study instrument. Six scales permitted me to calculate the reliability statistics for the 
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validation of the instrument using the split-half reliability method. The six reliability 
statistics of the six scales (detailed in Chapter  3) ranged from 0.01 to 0.68, which are 
between the Cronbach's Alpha and acceptable range of zero through one (Al-Dmour et 
al., 2013; Green & Salkind, 2011). Table 2 shows the reliability statistics of each scale 
ranging from 0.01 to 0.68.  
Table 2 
Instrument’s Cronbach’s & Reliability Statistics per Scale  
Scale 
n 
N of 
Items  
Cronbach's Alpha &  
Cronbach's Alpha &  
acceptable range 
 
   
 DPCAES  12 10 0.01 0-1 
     
 DHSAES 12 5 0.27 0-1 
 
    
TDMTUEPDAS 
12 7 0.62 0-1 
 
    
TDMTUEDDAS 12 14 0.68 0-1 
 
    
PUDMTEDDAS 
12 2 0.14 0-1 
 
    
 PUDMTEDAS  12 4 0.31 0-1 
 
Note. DPCAES = dermatology product claim advertisement exposure Scale; DHSAES = dermatology help-
seeking advertisement exposure Scale; TDMTUEPDAS = types of medical dermatology treatments utilized 
after exposure to dermatology DTCA of prescription drug scale; TDMTUEDDAS =  types of medical 
dermatology treatments utilized after exposure to the dermatology Disease DTCA Scale; PUDMTEDDAS 
= purposes of the utilization of medical dermatology treatments after exposure to dermatology DTCA of 
prescription drug scale; PUDMTEDAS = purposes of the utilization of medical dermatology treatment after 
exposure to dermatology DTCA of disease scale. 
 
The DPCAES, DHSAES, TDMTUEPDAS, TDMTUEDDAS, PUDMTEDDAS, 
and PUDMTEDAS have a Cronbach’s Alpha value between 0 through 1. However, the 
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third and fourth scales that are respectively TDMTUEPDAS and TDMTUEDDAS have the 
highest Cronbach’s Alpha values of respectively 0.62 and 0.68. Consequently, those two 
scales have the high reliabilities while the other four scales have the low reliabilities. In 
conclusion and as stated earlier, all six Cronbach’s Alpha α values fell in the region of 
zero to one indicated by Al-Dmour et al. (2013) and Green and Salkind (2011) as the 
indicator of a good reliability. The pilot study results did not generate any change in the 
main study in general, and particularly in the data collection.  
Data Collection 
Data Collection Time Frame, Recruitment, and Response Rate   
The survey or questionnaire completion lasted one month and 10 days, from 
January 12 through February 22, 2015. The survey covered the two study sites located in 
Houston, Texas, MedStar Primary Care Clinic and Saint Nicholas Catholic Church. The 
questionnaire completion took place after the respondent had met with a physician and 
from Monday through Friday at MedStar Primary Care Clinic during the clinic’s business 
hours from 09:00 AM to 05:30 PM (United States Central Standard Time). The 
questionnaire completion at Saint Nicholas took place after church services that started at 
09:00 AM or 11:00 AM on Sundays. Each survey day ended approximately until 03:00 
PM at Saint Nicholas Catholic Church (United States Central Standard Time). The mean 
of the total length of a questionnaire completion for both study sites was 12.03 minutes. 
The recruitment strategy applied for the data collection remained the one 
described in Chapter 3. Indeed, the data collection tool was a structured questionnaire 
with 38 questions. The recruitment and questionnaire completion were face-to-face at 
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each study site. I conducted the recruitment and recorded all the respondents’ answers in 
the questionnaire to reduce the risk of bias. I selected the sample using the pre-
determined inclusion criteria (eligibility section of the questionnaire), two recruiting 
flyers (A5 or Appendix F and A3 or Appendix D), and the Consent Form (see Appendix 
C) as detailed in Chapter 3. The respondent recruitment occurred at the lobby of each 
study site before the church services on Sunday at Saint Nicholas, and before the 
respondent’s meeting with the primary care physician during a medical visit. The 
questionnaire completion occurred at the parish hall or at the clinic meeting rooms. I 
reviewed with each participant the completed questionnaire and validated the 
questionnaire using the questionnaire completion guide (Appendix H) before terminating 
the particular completion. There was no discrepancy noted during the data collection 
compared to the strategy stated in Chapter 3.  
The study’s projected response rate and the final response rate were different at 
the end of data collection. In fact, the study projected response rate based on the literature 
was 85%. An existing literature claimed the response rate for the face-to-face survey 
turned around 95% versus 20 to 40% for the mail survey (Frankfort-Nachmias & 
Nachmias, 2008). I did 335 contacts or attempts to recruit the main or final study’s 
respondents at the two study sites. The 335 contacts led to the completion of 120 
questionnaires which represented the final sample of this study. The ratio 120 completed 
questionnaires and 335 total numbers of contact/attempt gave the study’s response rate of 
35.82 %. This response rate represented 42.14 % achievement rate of the projected 
response rate (85%). The discrepancy was most likely due to the respondent profile 
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detailed through the pre-determined inclusion criteria of the study (See Appendix G). 
Indeed, the use of the pre-determined inclusion criteria to select a final respondent for the 
completion of the questionnaire limited the possibility of meeting the eligible respondent 
during the first contact or recruitment attempt. The final sample has diversified 
characteristics. 
Sample Characteristics 
 The final sample has multiple characteristics. I used the G*Power 3.1.2 computer 
software, as stated in Chapter 3, to determine the sample size of 82 respondents. 
However, by rounding off 82, 100 people were the target final sample size. The final 
sample size achieved at the end of the survey was 120 respondents. The 120 respondents 
were attending church services at Saint Nicholas Catholic Church or/and receiving 
primary care services at MedStar Primary Care Clinic. In addition, the respondents have 
received medical dermatology services for a medical reason as the consequence of having 
seen, read, or heard a dermatology DTCA of prescription drug or/and disease in the past 
12 months starting from the questionnaire completion date. Three hundred and thirty-five 
contacts or attempts to recruit a respondent permitted to achieve the 120 final samples.  
215 out of 335 contacts were not eligible to complete a questionnaire at the time of the 
survey because of one or more of the following reasons: (a) they were not dermatology 
patients, (b) have poor English language skills, (c) were concerned about the reason of 
their medical visit to the doctor office, (d) did not willing to participate in the study, (e) 
were not MedStar’s patients, and (f) did not want to wait after the church service. 
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 Fifty percent of the 120 respondents were from MedStar clinic (60) and 50% 
from Saint Nicholas (60). Moreover, 50% of the sample per study site were male (30) and 
50% were female (30). Seventy-one percent of the 120 respondents had skin disease, 
24% had hair disease, and 5% had nails disease. The largest proportion of the sample was 
skin disease patients. Table 3 shows the achieved sample breakdown by place of 
questionnaire completion. Table 4 shows the achieved sample breakdown by sex. Table 5 
shows the achieved sample breakdown by type of dermatology diseases.  
Table 3 
Frequency Distribution of Participant Place of Questionnaire Completion (N = 120) 
  
Place of questionnaire 
completion 
Frequency % 
Valid 
% 
Cumulative 
% 
Valid MedStar Primary Care Clinic 60 50 50 50 
      
 
Saint Nicholas Catholic 
Church 
60 50 50 100 
      
  Total 120 100 100   
 
Table 4 
Frequency Distribution of Participant Sex (N = 120) 
  Sex Frequency % 
Valid 
% 
Cumulative 
% 
Valid Male 60 50 50 50 
      
 
Female 60 50 50 100 
      
  Total 120 100 100   
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Table 5 
Frequency Distribution of Participant Types of Dermatology Disease (N = 120) 
  
Type of dermatology 
disease 
Frequency % 
Valid 
% 
Cumulative 
% 
Valid Skin disease 86 71 71 71 
      
 
Hair disease 29 24 24 95 
      
 
Nails disease 5 5 5 100 
      
  Total 120 100 100   
 
The sample of 120 respondents had 50% male and 50% female. The sample is 
mostly adults with 44.2% who were 35 to 51 years old while 8.3% were 65 years old and 
over. The sample’s mean age was 42 years old with a S D of 13.63. The sample had a 
multiracial or ethnic characteristic with the largest portion of 72.5% Black, African 
American, or Negro, 14.2% Hispanic, 11.7% white, and the smallest portion of 1.7% 
Vietnamese. In terms of highest level of education completed, 25.8% had graduate 
degrees while 0.8% completed Less than 9
th
 grade. Sixty percent had an annual 
household income of $40, 000 and over, and 0.8% had between $15,000 to $19,999. 
Finally, 57.5% of the samples were married and 3.3% separated. Table 6 shows the 
descriptive statistics for demographics of the study sample. 
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Table 6 
Descriptive Statistics for Demographics (N = 120) 
Demographics 
Frequency  
(Valid %) 
Mean 
score 
Standard 
deviation 
Sex  
   Male ( = 1) 60 (50%) 
  Female ( = 2) 60 (50%) 
  
 
 
  Age  
   18 to 34 years ( = 1) 31 (25.8%) 
  35 to 51 years (= 2) 53 (44.2%) 
  52 to 64 years (= 3) 26 (21.7%) 
  65 and over (= 4) 10 (8.3 %) 
  Exact age 
 
42 13.63 
 
 
  Race/Ethnicity 
 
  White ( = 1) 14 (11.7%) 
  Black, African American, or Negro ( = 2) 87 (72.5%) 
  Vietnamese ( = 13) 2 (1.7%) 
  Some other race: Hispanic ( = 14) 17 (14.2%) 
  
 
 
  Highest grade of school completed 
 
  Less than 9
th
 grade  ( = 1)                                 1 (.8%) 
  
9
th
 to 12
th
 grade, without diploma  ( = 2) 6 (5%) 
  High school graduate ( = 3) 11 (9.2%) 
  Some college, without degree ( = 4) 25 (20.8%) 
  Associate’s degree ( = 5) 19 (15.8 %) 
  Bachelor’s degree ( = 6) 27 (22.5%) 
  Graduate degree ( = 7) 31 (25.8 %) 
  
    
Marital status  
  Married ( = 1) 69 (57.5%) 
  Divorced ( = 2) 7 (5.8%) 
  Widowed ( = 3)  8(6.7%) 
  Separated ( = 4) 4 (3.3%) 
  Never got married ( = 5) 27 (22.5%) 
  Unmarried in couple ( = 6) 5 (4.2 %) 
  
 
(table continues) 
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Demographics 
Frequency  
(Valid %) 
Mean 
score 
Standard 
deviation 
Annual household income  
  
Less than $10,000 ( = 1) 3 (2.5 %) 
  
$10,000 to $14,999 ( = 2) 4 (3.3%) 
  
$15,000 to $19,999 ( = 3) 1 (.8 %) 
  
$20,000 to $24,999 ( = 4) 7 (5.8%) 
  
$25,000 to $29,999 ( = 5) 12 (10 %) 
  
$30,000 to $34,999 ( = 6) 10 (8%) 
  
$35,000 to $39,999 ( = 7) 11 (9.2%) 
  
$40, 000 and over ( = 8) 72 (60%)     
 
In terms of sources of exposure to dermatology pharmaceutical prescription 
drug(s) announcement, TV channels were the main source (85% of the respondents) 
followed by online/websites (56.7%). Then, very few patients heard about drug 
announcement from dermatologists giving the lowest percentage of 1.7%. These results 
were consistent with dermatology pharmaceutical disease(s) announcement exposure: 
90.8% for TV channels, 62.5% for online/websites, and 2.5% as lowest percentage for 
both dermatologists and social media. 
Sample and Population  
 The target population size was unknown and a sample frame was not available. 
Therefore, the use of a random sample or a proportional sample approach was not 
appropriate. In that regards, I used the nonrandom purposive sample scheme to select 
from the population the members of the sample based on the pre-determined inclusion 
criteria (eligibility section of the questionnaire or Appendix G) as described in Chapter 3. 
The selected respondents were available and willing to participate in the study (Collins et 
al., 2006; Frankfort-Nachmias & Nachmias, 2008). The predetermined inclusion criteria 
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aimed to assure the selection of the individuals who had the key characteristics of the 
target population only. In addition, the G*Power 3.1.2 computer software enabled the 
determination of this study minimum sample size of 82 respondents capable to provide 
with consistent statistical tests or analyses. Furthermore, according to Laureate Education 
(2009b) and Andy (2009), a high sample size increases the chance of obtaining an 
accurate multiple regression equation. A multiple regression requires a minimum sample 
size N of 104 plus M. M represents the number of predictors of the regression (Laureate 
Education, 2009b). This study has two sets of predictors for a total of 15 predictors: 
dermatology product claim advertisement exposure scale (DPCAES) with 10 predictors 
or items, and dermatology help-seeking advertisement exposure scale (DHSAES) with 5 
predictors. The final sample achieved of 120 participants met the Laureate Education’s 
multiple regression sample size requirement of 104 plus M (Laureate Education, 2009b). 
Results 
Outliers 
The normal box plots of the normality of error variances distribution assumption 
(Figures 12 to 20) in the assumptions section below show only suspected outliers (small 
empty circles or unfilled). Consequently, this study was free of outliers for the considered 
nine criteria (Field, 2009).  
Assumptions Evaluation  
Multiple Regression has assumptions that require a test before any hypothesis 
testing takes place. The testable assumptions listed in Chapter 3 were (a) the normality of 
the distribution, (b) normality of error variances distribution, (c) independence of errors, 
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(d) homoscedasticity, and (e) no perfect multicollinearity (Field, 2009). The assumption, 
when met, ensures the external validity of the research findings, regression model, and a 
regression model free of bias. The assumptions test is based on the dependent variables or 
criteria of the study. 
Selection of the criteria or dependent variables. They were four sets of 
dependent variables for a total of 29 criteria for this research study. The predictors were 
quantitative and the criteria or outcome variable were quantitative, continuous, and 
unbounded (Field, 2009). The first set was TDMTUEPDAS which had seven items. The 
second containing 14 items was TDMTUEDDAS. The third was PUDMTEDDAS and 
had four items. The fourth was PUDMTEDAS which had four items. A multiple 
regression test run between each set of independent variables and each particular 
dependent variable showed some nonsignificant test results statistically at 95% 
confidence level and 5% margin of error from the model summary tables. Consequently, 
the dependent variables retained and used for the assumptions and hypotheses tests were 
those with a test result statistically significant (p ≤ .05). The dependent variable retained 
from TDMTUEPDAS set were (a) to request and obtain a medical prescription of the 
dermatology drug advertised, (b) to receive the advertised drug therapy/chemotherapy, 
(c) to talk to the dermatologist/surgeon/doctor about dermatology advertised prescription 
drug, (d) to visit a physician/dermatologist office, and (e) to receive skin, hair, and/or 
nails health maintenance treatment. Then, the only one from TDMTUEDDAS set was to 
go for dermatology disease screening test. PUDMTEDDAS set had to receive 
treatment/cure of the dermatology disease in order to excise the tumor lesion. Finally, 
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PUDMTEDAS set had (a) to receive dermatology treatment/service to detect/diagnose 
early the dermatology disease and (b) to receive treatment/cure of the dermatology 
disease in order to clear the tumor/disease. Nine out of 29 criteria are the object of the 
following assumptions evaluation. 
Normality of the distribution assumption. The result of the normality test run 
for the criteria (a) to request and obtain a medical prescription of the dermatology drug 
advertised, (b) to receive the advertised drug therapy/chemotherapy, (c) to talk to the 
dermatologist/surgeon/doctor about dermatology advertised prescription drug, (d) to visit 
a physician/dermatologist office, (e) to receive skin, hair, and/or nails health maintenance 
treatment, (f) to go for dermatology disease screening test, (g) to receive treatment/cure 
of the dermatology disease in order to excise the tumor lesion, (h) to receive dermatology 
treatment/service to detect/diagnose early the dermatology disease, and (i) to receive 
treatment/cure of the dermatology disease in order to clear the tumor/disease in SPSS 
showed that this assumption was met. 
The histograms below show bell shaped curves that indicate the normality of 
distribution of each of the criterion listed above: Figure 3 for the criterion (a), Figure 4 
for the criterion (b), Figure 5 for the criterion (c), Figure 6 for the criterion (d), Figure 7 
for the criterion (e), Figure 8 for the criterion (f), Figure 9 for the criterion (g), Figure 10 
for the criterion (h), and Figure 11 for the criterion (i) (Field, 2009; Laureate Education, 
2009a). 
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Figure 3. Bell shaped curve of the criterion to request and obtain a medical prescription 
of the dermatology drug advertised  
 
 
Figure 4. Bell shaped curve f of the criterion to receive the advertised drug 
therapy/chemotherapy 
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Figure 5. Bell shaped curve f of the criterion to talk to the dermatologist/surgeon/doctor 
about a dermatology advertised prescription drug 
 
 
  
Figure 6. Bell shaped curve of the criterion to visit a physician/dermatologist office
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Figure 7. Bell shaped curve of the criterion to receive skin, hair, and/or nails health 
maintenance treatment 
 
 
Figure 8. Bell shaped curve of the criterion to receive treatment/cure of the dermatology 
disease in order to excise the tumor lesion  
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Figure 9. Bell shaped curve of the criterion to go for dermatology disease screening test 
 
 
 
Figure 10. Bell shaped curve of the criterion to dermatology treatment/service to 
detect/diagnose early the dermatology disease 
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Figure 11. Bell shaped curve of the criterion to receive treatment/cure of the dermatology 
disease in order to clear the tumor/disease 
Normality of error variances distribution. Multiple regression is convenient for 
large sample. The appearance of each box plot of the standardized residual below 
(Figures 12 to 20) permitted to observe how the error variances was normally distributed 
for each of the nine criteria (Field, 2009).  
 
 
 
Figure 12.Normal box plot of the criterion to request and obtain a medical prescription of 
the dermatology drug advertised  
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Figure 13. Normal box plot of the criterion to receive the advertised drug 
therapy/chemotherapy 
 
 
Figure 14. Normal box plot of the criterion to talk to the dermatologist/surgeon/doctor 
about dermatology advertised prescription drug 
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Figure 15. Normal box plot of the criterion to visit a physician/dermatologist office 
 
 
 
Figure 16. Normal box plot of the criterion to receive skin, hair, and/or nails health 
maintenance treatment 
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Figure 17. Normal box Plot of the criterion to go for dermatology disease screening test 
 
 
Figure 18. Normal box plot of the criterion to receive treatment/cure of the dermatology 
disease in order to excise the tumor/lesion 
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Figure 19. Normal box plot of the criterion to receive dermatology treatment/service to 
detect/diagnose early the dermatology disease 
 
 
Figure 20. Normal box plot of the criterion to receive treatment/cure of the dermatology 
disease in order to clear the tumor/disease  
Independence of errors and homoscedasticity. The evaluation of these two 
assumptions for the nine criteria is through the scatterplots observation. The normal p-p 
164 
 
plots show no variation in the variance of the residual terms regarding the predictors. The 
no variation indicates that the homoscedasticity assumption is met (Field, 2009; Green & 
Salkind, 2011). Moreover, the scatterplots show no correlation of residual terms for the 
observations. Consequently, the independent of error assumption is met (Field, 2009; 
Green & Salkind, 2011). The normal p-p plots for the two assumptions and each criterion 
are in Figure 21 for the criterion (a), Figure 22 for the criterion (b), Figure 23 for the 
criterion (c), Figure 24 for the criterion (d), Figure 25 for the criterion (e), Figure 26 for 
the criterion (f), Figure 27 for the criterion (g), Figure 28 for the criterion (h), and Figure 
29 for the criterion (i) (Field, 2009; Green & Salkind, 2011).  
 
 
Figure 21. Normal p-p plots of regression of the criterion to request and obtain a medical 
prescription of the dermatology drug advertised 
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Figure 22. Normal p-p plots of regression of the criterion to receive the advertised drug 
therapy/chemotherapy 
 
Figure 23. Normal p-p plots of regression of the criterion to talk to the 
dermatologist/surgeon/doctor about dermatology advertised prescription drug 
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Figure 24. Normal p-p plots of regression of the criterion to visit a 
physician/dermatologist office 
 
 
Figure 25. Normal p-p plots of regression of the criterion to receive skin, hair, and/or 
nails health maintenance treatment 
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Figure 26. Normal p-p plots of regression of the criterion to go for dermatology disease 
screening test 
 
 
 
Figure 27. Normal p-p plots of regression of the criterion to receive treatment/cure of the 
dermatology disease to excise the tumor/lesion 
168 
 
 
Figure 28. Normal p-p plots of regression of the criterion to receive dermatology 
treatment/service to detect/diagnose early the dermatology disease 
  
 
Figure 29. Normal p-p plots of regression of the criterion to receive treatment/cure of the 
dermatology disease to clear the tumor/disease  
No perfect multicollinearity. The variance inflection factors (VIF) permitted to 
assess the multicollinearity amongst predictors in relation with each of the nine 
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dependent variables. All the VIF values shown in Table 7 are below 10. A value of 10 or 
greater indicates the perfect multicollinearity amongst predictors (Field, 2009). This 
assumption was met. 
Table 7  
Predictors’ Variance Inflection Factors (VIF) for Each Criterion 
Criterion VIF 
  
told to the consumers in a balanced manner the benefits and potential  
negative consequences of using the advertised dermatology drug.  
2.44 
told in a balanced manner about the advantages and dangers  
related to the advertised dermatology drug use.  
2.56 
published in the newspaper, magazines, review, or 
the journal contained this statement "you are encouraged to 
report negative side effects of prescription drugs to the 
US Food and Drugs Administration (FDA) Visit 
wmedwatch5 or call 1-800-FDA-1088." 
1.14 
passed on television/radio station (s) told to the 
viewer/listener where to get additional prescription drug 
information approved by the FDA 
 
1.22 
audio broadcast stated the most serious risks/dangers that the 
dermatology drug user may encounter. 
   
1.29 
said the drug risk(s)/danger(s) approved by F.D.A  and 
included in the drug information or label. 
2.03 
  
Stated the most important dangers that the dermatology patient 
may face taking the advertised drug. 
1.9 
 stated both the vulgar designation/name of the drug approved 
(brand) and non-approved (generic) by the U.S. government.  
 
1.61 
stated at least one form of dermatology  disease treated by 
the advertised drug and approved by the FDA  
 
1.4 
  
 stated "ask your doctor if [drug name] is right for you.'' 
 
1.12 
described the type of dermatology disease without any recommendation of a specific 
dermatology drug for treatment. 
1.22 
encouraged people with the symptoms of the described type of dermatology disease to 
ask/talk to their doctor  
 
1.19 
 
 
  
                                                                                                               (table continues)  
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Criterion VIF 
 
had the company's name of the advertised skin cancer drug. 
                                                                                                                               
1.37 
gave a telephone number/website to call or to visit for more information about the 
advertised dermatology disease type/described condition.  
 
1.35 
stated "ask your healthcare provider for more information''.   1.06 
 
Hypotheses Testing 
Research Question 1: Is product claim advertisement a predictor of the types of 
medical services utilized amongst adult dermatology patients in the United States? 
Hypothesis 1 (H0): Product claim advertisement does not significantly prompt the 
utilization of the types of medical services amongst adult dermatology patients in the 
United States.  
Hypothesis 1 (H1): Product claim advertisement significantly prompts the 
utilization of the types of the medical services amongst adult dermatology patients in the 
United States.  
Analytical Strategy for the Hypothesis Testing 1. The first hypothesis testing 
was product claim advertisement predicting or not the utilization of the types of medical 
dermatology services amongst the target population. Question 27 was the set of 
predictors, and question 32(5) was the unique criterion used to test the hypotheses and to 
answer the related research question. Indeed, question 27 served as the set of predictors 
for the forced entries multiple regression test with each of the seven criteria or question 
32’s items (set of criteria or measures). Amongst the seven multiple regression tests per 
criterion, only five models had the statistically significant  P values with 95% confidence 
interval (P < .05) from the model summary output tables: (a) question 32(1), P = .000 and 
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R = .496, (b) question 32(2), P = .003 and R = .456, (c) question 32(5), P = 0.000 and R = 
.512, (d) question 32(6), P = .036 and R = .397, (e) question 32(7), P = .042 and R = 
.392. The five models had different multiple correlation coefficients R. Question 32(5) 
had the highest multiple correlation coefficient R = .512 amongst the five significant 
criteria.  Thus, question 32(5) helped to answer this research question.  
Answer to Research Question 1. The following multiple regression results 
(Table 8) show that product claim advertisement significantly predicts the utilization of 
the type of the medical services amongst adult dermatology patients. Indeed, a forced 
entry multiple regression analysis was conducted to evaluate how well product claim 
advertisement predicted the type of medical dermatology service utilized. The set of 
predictors was product claim advertisement with 10 measures or items that were (a) told 
to the consumers in a balanced manner the benefits and potential negative consequences 
of using the advertised dermatology drug, (b) to told in a balanced manner about the 
advantages and dangers related to the advertised dermatology drug use, (c) published in 
the newspaper, magazines, review, or journal contained this statement "You are 
encouraged to report negative side effects of prescription drug to the U.S. Food and Drug 
Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088", (d) passed on 
television/radio station (s) told to the viewer/listener where to get additional prescription 
drug information approved by the FDA, (e) audio broadcast stated the most serious 
risks/dangers that the dermatology drug user may encounter, (f) said the drug 
risk(s)/danger(s) approved by FDA  and included in the drug information or label, (g) 
stated the most important dangers that the dermatology patient may face taking the 
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advertised drug, (h) stated both the vulgar designation/name of the drug approved (brand) 
and non-approved (generic) by the U.S. government,(i) stated at least one form of 
dermatology  disease treated by the advertised drug and approved by the FDA, (j) stated 
"Ask your doctor if [drug name] is right for you.'', while the criterion variable was to talk 
to the dermatologist/surgeon/doctor about dermatology advertised prescription drug 
index. The linear combination of the product claim measures was significantly related to 
talk to the dermatologist/surgeon/doctor about dermatology advertised prescription drug, 
F (10,109) = 3.87, p < .05. The sample multiple correlation coefficient R was .51, 
indicating that approximately 26% of the variance of to talk to the 
dermatologist/surgeon/doctor about dermatology advertised prescription drug in the 
sample can be accounted for by the linear combination of the set of the predictors product 
claim advertisement measures, R
2
 = .262. The loss of predicted power or shrinkage of 
6.7% has been verified with the Adjusted R
2
 = .195. Consequently, a model from the 
population would account for approximately 6.7% less variance by the criterion. Table 8 
shows the multiple regression model summary or results. 
Table 9 shows the indices of the relative strength of each particular predictor in 
relation with the criterion to talk to the dermatologist/surgeon/doctor about a dermatology 
advertised prescription drug. Only one out of 10 bivariate correlations between the set of 
predictors product claim strength measures and talk to the dermatologist/surgeon/doctor 
about a dermatology advertised prescription drug index was negative, and one out of 10 
were statistically significant (P < .05). Four out 10 partial correlations between the 
product claim strength measures and to talk to the dermatologist/surgeon/doctor about a 
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dermatology advertised prescription drug index were significant. Out of the four, only the 
partial correlation between the strength measure of stated "Ask your doctor if [drug 
name] is right for you'' predictor and to talk to the dermatologist/surgeon/doctor about a 
dermatology advertised prescription drug index was positive, p = 0.00. These correlation 
analyses may lead to the conclusion that stated "Ask your doctor if [drug name] is right 
for you'' is the only useful predictor. However, it alone accounted for only 0.20% of the 
variance of to talk to the dermatologist/surgeon/doctor about a dermatology advertised 
prescription drug index, while the other variables contributed an additional 25.8% (26% - 
0.20% = 25.8%). Moreover, predictors were correlated. However, the correlation was not 
a source of concern for the multiple regression model giving that all the VIF statistics 
were lower than 10.  
Table 8  
Multiple Regression Model Summary
b
  
Model R 
R 
square 
Adjusted 
R square 
Std. 
error of 
the 
estimate 
    Change statistics 
Durbin-
Watson 
       
R 
Square 
change 
F 
change 
df1 df2 Sig. F change 
  
1 .512
a
 0.262 0.195 0.844     0.262 3.875 10 109 0.000 1.925 
 
Note. a. Predictors: (Constant), DPCAES: "Stated at least one form of dermatology disease treated by the advertised 
drug and approved by the FDA ", DPCAES: "Told in a balanced manner about the advantages and dangers related to 
the advertised dermatology drug use.  ", DPCAES: "Passed on Television/Radio station (s) told to the viewer/listener 
where to get additional prescription drug information approved by the FDA ", DPCAES: "Published in the newspaper, 
magazines, review, or journal contained this statement " "You are encouraged to report negative side effects of 
prescription drug to the US Food and Drug Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088, 
DPCAES: Stated "Ask your doctor if [drug name] is right for you.'', DPCAES: "Stated the most important dangers that 
the dermatology patient may face taking the advertised drug. ", DPCAES: "Audio broadcast stated the most serious 
risks/dangers that the dermatology drug user may encounter.", DPCAES: "Stated both the vulgar designation/name of 
the drug approved (brand) and non-approved (generic) by the U.S. government.", DPCAES: "Said the drug 
risk(s)/danger(s) approved by FDA  and included in the drug information or label).", DPCAES: "Told to the consumers 
in a balanced manner the benefits and potential negative consequences of using the advertised dermatology drug." 
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b. Dependent Variable: TDMTUEPDAS: Talk to the dermatologist/surgeon/doctor about dermatology advertised 
prescription drug. 
 
Table 9 
Bivariate and Partial Correlations between each Predictor and Talk to the 
Dermatologist/Surgeon/Doctor About a Dermatology Advertised Prescription Drug Index 
 
Predictors 
Correlation 
between 
each 
predictor 
and the 
criterion 
Correlation 
between each 
predictor and 
the criterion 
controlling for 
all other 
predictors 
stated "ask your doctor if [drug name] is right for you.'' 0.04* 0.00* 
 told to the consumers in a balanced manner the benefits and potential 
negative consequences of using the advertised dermatology drug  
 
0.06 0.18 
told in a balanced manner about the advantages and dangers related to 
the advertised dermatology drug use    
  
-0.10 -0.24* 
published in the newspaper, magazines, review, or journal contained 
this statement "You are encouraged to report negative side effects of 
prescription drug to the US Food and Drug Administration (FDA) Visit 
MedWatch5 or call 1-800-FDA-1088 
 
0.20 0.19 
passed on Television/Radio station (s) told to the viewer/listener where 
to get additional prescription drug information approved by the FDA 
0.14 0.15 
audio broadcast stated the most serious risks/dangers that the 
dermatology drug user may encounter 
0.24 
 
 
0.07 
said the drug risk(s)/danger(s) approved by the FDA  and included in 
the drug information or label 
0.20 -0.01* 
stated the most important dangers that the dermatology patient may 
face taking the advertised drug 
 
 
0.40 
 
 
0.28 
stated both the vulgar designation/name of the drug approved (brand) 
and non-approved (generic) by the U.S. government 
 
0.17 -0.01* 
stated at least one form of dermatology  disease treated by the 
advertised drug and approved by the FDA 
0.21 0.06 
Note. * P < .05. Confidence interval 95%. 
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Research Question 2: Is product claim advertisement a predictor of the purposes 
of medical services utilization amongst adult dermatology patients in the United States? 
Hypothesis 2 (H0): Product claim advertisement does not significantly prompt the 
purposes of medical services utilization amongst adult dermatology patients in the United 
States.  
Hypothesis 2 (H1): Product claim advertisement significantly prompts the  
purposes of the medical services utilization amongst adult dermatology patients in the 
United States.  
Analytical Strategy for the Hypothesis Testing 2. The second hypothesis 
testing was product claim advertisement predicting or not the purpose of the medical 
dermatology services utilization amongst the target population. Question 27 was the set 
of predictors, and question 36(4) was the unique criterion used to test the hypotheses and 
to answer the related research question. Indeed, question 27 served as set of predictors for 
the forced entry multiple regression tests in relation with each of the four criteria or 
question 36’s items (set of criteria or measures). Amongst the four multiple regression 
tests per criterion, only one model had the statistically significant P values (P ≤ .05) from 
the four model summary output tables: question 36(4), P = .05 and R = .386. 
Consequently, question 36(4) helped to answer this research question.  
Answer to Research Question 2. The following forced entry multiple regression 
results (Table 10) show that product claim advertisement significantly predicts the 
purpose of the utilization of the medical service amongst adult dermatology patients. In 
that regard, a forced entry multiple regression analysis was conducted to evaluate how 
176 
 
well product claim advertisement predicted the purpose of the medical dermatology 
service utilized. The set of predictors was product claim advertisement with 10 measures 
or items. The measures were (a) told to the consumers in a balanced manner the benefits 
and potential negative consequences of using the advertised dermatology drug, (b) to told 
in a balanced manner about the advantages and dangers related to the advertised 
dermatology drug use, (c) published in the newspaper, magazines, review, or journal 
contained this statement "You are encouraged to report negative side effects of 
prescription drug to the U.S. Food and Drug Administration (FDA) Visit MedWatch5 or 
call 1-800-FDA-1088", (d) passed on television/radio station (s) told to the 
viewer/listener where to get additional prescription drug information approved by the 
FDA, (e) audio broadcast stated the most serious risks/dangers that the dermatology drug 
user may encounter, (f) said the drug risk(s)/danger(s) approved by the FDA  and 
included in the drug information or label, (g) stated the most important dangers that the 
dermatology patient may face taking the advertised drug, (h) stated both the vulgar 
designation/name of the drug approved (brand) and non-approved (generic) by the U.S. 
government,(i) stated at least one form of dermatology  disease treated by the advertised 
drug and approved by the FDA, (j) stated "Ask your doctor if [drug name] is right for 
you.'', while the criterion variable was to receive treatment/cure of the dermatology 
disease in order to excise the tumor/lesion. 
The linear combination of the product claim measures was significantly related to 
receive treatment/cure of the dermatology disease to excise the tumor/lesion index, 
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 F (10,109) = 1.91, P ≤ .05. The sample multiple correlation coefficient R was .40, 
indicating that approximately 15% of the variance of to receive treatment/cure of the 
dermatology disease to excise the tumor lesion index in the sample can be accounted for 
by the linear combination of the set of the predictors product claim advertisement 
measures, R
2
 = .149. The loss of predicted power or shrinkage of 7.8% has been verified 
with the Adjusted R
2
 = .071. Consequently, a model from the population would account 
for approximately 7.8% less variance by the criterion. Table 10 shows the multiple 
regression model summary or results. 
Table 11 shows the indices of the relative strength of each particular predictor in 
relation with the criterion to receive treatment/cure of the dermatology disease in order to 
excise the tumor/lesion. Height out of 10 bivariate correlations between the set of 
predictors product claim strength measures and receive treatment/cure of the dermatology 
disease in order to excise the tumor/lesion index were negative, and seven out of 10 were 
statistically significant (P < .05). Seven out 10 partial correlations between the set of 
predictors product claim strength measures and to receive treatment/cure of the 
dermatology disease in order to excise the tumor/lesion index were statistically 
significant (P < .05). The  partial correlations between the predictors strength measures 
(a) told in a balanced manner about the advantages and dangers related to the advertised 
dermatology drug use, P = 0.12, (b) published in the newspaper, magazines, review, or 
journal contained this statement "You are encouraged to report negative side effects of 
prescription drug to the U.S. Food and Drug Administration (FDA). Visit MedWatch5 or 
call 1-800-FDA-1088, P = 0.20, (c) stated the most important dangers that the 
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dermatology patient may face taking the advertised drug, P = 0.07, and (d) receive 
treatment/cure of the dermatology disease to excise the tumor/lesion index were not 
statistically significant, P > .05. 
These correlation analyses may lead to the conclusion that the three predictors 
strength measures with nonsignificant partial correlations with to receive treatment/cure 
of the dermatology disease to excise the tumor/lesion index were relatively not important. 
However, this judgment required caution because predictors were correlated. However, 
the correlation was not sources of concern for the multiple regression model giving that 
all the VIF statistics were lower than 10.  
     
Table 10  
Multiple Regression Model Summary
b
  
Model R 
R 
square 
Adjusted 
R square 
Std. 
error of 
the 
estimate 
    Change statistics 
Durbin-
Watson 
       
R 
square 
change 
F 
change 
df1 df2 
Sig. F 
change   
1 .386a 
 
.149 
 
 
.071 
 
 
.844 
 
    
 
.149 
 
 
1.910 
 
10 109 0.051 1.348 
Note. a. Predictors: (Constant), DPCAES: "Stated at least one form of dermatology disease treated by the 
advertised drug and approved by the FDA", DPCAES: "Told in a balanced manner about the advantages 
and dangers related to the advertised dermatology drug use.", DPCAES: "Passed on Television/Radio 
station (s) told to the viewer/listener where to get additional prescription drug information approved by the 
FDA", DPCAES: "Published in the newspaper, magazines, review, or journal contained this statement " 
"You are encouraged to report negative side effects of prescription drug to the U.S. Food and Drug 
Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088, DPCAES: Stated "Ask your doctor if 
[drug name] is right for you.'', DPCAES: "Stated the most important dangers that the dermatology patient 
may face taking the advertised drug. ", DPCAES: "Audio broadcast stated the most serious risks/dangers 
that the dermatology drug user may encounter." , DPCAES: "Stated both the vulgar designation/name of 
the drug approved (brand) and non-approved (generic) by the U.S. government.", DPCAES: "Said the drug 
risk(s)/danger(s) approved by FDA  and included in the drug information or label).", DPCAES: "Told to the 
consumers in a balanced manner the benefits and potential negative consequences of using the advertised 
dermatology drug." 
b. Dependent Variable: PUDMTEDDAS: Receive treatment/cure of the dermatology disease in order to 
excise the tumor lesion. 
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Table 11 
Bivariate and Partial Correlations Between Each Predictor and to Receive Treatment/Cure of the 
Dermatology Disease in Order to Excise the Tumor Lesion Index 
Predictors 
Correlation between 
each predictor and the 
criterion 
Correlation 
between each 
predictor and 
the criterion 
controlling for 
all other 
predictors 
stated "Ask your doctor if [drug name] is right for you.'' -0.04* -0.03* 
 told to the consumers in a balanced manner the benefits and potential  
negative consequences of using the advertised dermatology drug  
 
-0.25* -0.25* 
told in a balanced manner about the advantages and dangers related to the 
advertised dermatology drug use    
  
-0.08* 0.12 
published in the newspaper, magazines, review, or journal contained  
this statement "You are encouraged to report negative side effects  
of prescription drug to the US Food and Drug Administration (FDA) Visit 
MedWatch5 or call 1-800-FDA-1088 
 
0.23 0.20 
passed on Television/Radio station (s) told to the viewer/listener  
where to get additional prescription drug information approved by the 
FDA 
-0.12 -0.02* 
audio broadcast stated the most serious risks/dangers that 
 the dermatology drug user may encounter 
-0.12 -0.06* 
said the drug risk(s)/danger(s) approved by the FDA  and  
included in the drug information or label 
-0.07* -0.08* 
stated the most important dangers that the dermatology patient  
may face taking the advertised drug 
0.04* 0.07 
stated both the vulgar designation/name of the drug  
approved (brand) and non-approved (generic) by the U.S. government 
 
-0.01*              0.04* 
stated at least one form of dermatology  disease treated  
by the advertised drug and approved by the FDA 
-0.04*            -0.04* 
Note. * p < .05. Confidence interval 95%. 
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Research Question 3: Is help-seeking advertisement a predictor of the types of 
medical services utilized amongst adult dermatology patients in the United States? 
Hypothesis 3 (H0): Help-seeking advertisement does not significantly prompt the 
types of medical services utilized amongst adult dermatology patients in the United 
States.  
Hypothesis 3 (H1): Help-seeking advertisement significantly prompts the types of 
the medical services utilized amongst adult dermatology patients in the United States.  
Analytical Strategy for the Hypothesis Testing 3. The third hypothesis testing 
was about help-seeking advertisement predicting or not the type of the medical 
dermatology services utilized amongst the target population. Question 30 was the set of 
predictors and question 34(2) was the unique criterion used to test the hypotheses and to 
answer the related research question. Indeed, question 30 served as the set of predictors 
for the forced entry multiple regression tests in relation with each of the fourteen criteria 
or question 34’s items (set of criteria or measures). Amongst the fourteen multiple 
regression tests per criterion, only one model had the statistically significant P values (P 
< .05) from the fourteen model summary output tables: question 34(2), P = .04 and R = 
.303. Consequently, question 34(2) helped to answer this research question.  
Answer to Research Question 3. The following forced entry multiple regression 
results (Table 12) show that help-seeking advertisement significantly predicts the type of 
medical services utilized amongst adult dermatology patients. In that regard, a forced 
entry multiple regression analysis was conducted to evaluate how well help-seeking 
advertisement predicted the type of the medical dermatology service utilized. The set of 
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predictors was help-seeking advertisement with five measures. The items were (a) 
described the type of dermatology disease without any recommendation of a specific 
dermatology drug for treatment, (b) encouraged people with the symptoms of the 
described type of dermatology disease to ask/talk to their doctor, (c) had the company's 
name of the advertised dermatology drug, (d) gave a telephone number/website to call or 
to visit for more information about the advertised dermatology disease type/described 
condition, (e) stated "Ask your healthcare provider for more information'', while the 
criterion variable was to go for dermatology disease screening test index. The linear 
combination of the help-seeking measures was significantly related to go for dermatology 
disease screening test index, F (5,114) = 2.31, p < .05. The sample multiple correlation 
coefficient R was .30, indicating that approximately 9.2% of the variance of to go for 
dermatology disease screening test index in the sample can be accounted for by the linear 
combination of the set of the predictors help-seeking advertisement measures, R
2
 = .092. 
The loss of predicted power or shrinkage of 4% has been verified with the Adjusted R
2
 = 
.05. Consequently, a model from the population would account for approximately 4% 
less variance by the criterion. Table 12 shows the multiple regression model summary or 
results. 
Table 13 shows the indices of the relative strength of each particular predictor in 
relation with the criterion to go for dermatology disease screening test index. Only one 
out of five bivariate correlations between the set of predictors help-seeking strength 
measures and to go for dermatology disease screening test index was negative, and the 
same one out of five was statistically significant (P < .05). None of the five partial 
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correlations between the set of predictors help-seeking strength measures and to go for 
dermatology disease screening test index was statistically significant (P > .05).  
These correlation analyses may lead to the conclusion that the five predictors’ strength 
measures having nonsignificant partial correlations with to go for dermatology disease 
screening test index were relatively not important. However, this judgment required 
caution because predictors were correlated. However, the correlation was not a source of 
concern for the multiple regression model giving that all the VIF statistics were lower 
than 10. 
Table 12  
Multiple Regression Model Summary
b
  
Model R 
R 
square 
Adjusted 
R square 
Std. 
error of 
the 
estimate 
    Change statistics 
Durbin-
Watson 
       
R 
Square 
change 
F 
change 
df1 df2 Sig. F change 
  
1 .303a 
 
.092 
 
 
.052 
 
 
.725 
 
    
 
.092 
 
 
2.312 
 
5 114 0.048 1.985 
Note. a. Predictors: (Constant), DHSAES: Stated "Ask your healthcare provider for more 
information''. , DHSAES: Encouraged people with the symptoms of the described type of 
dermatology disease to ask/talk to their doctor, DHSAES:  Had the company's name of the 
advertised skin cancer drug., DHSAES: Described the type of dermatology disease without any 
recommendation of a specific dermatology drug for treatment., DHSAES: Gave a telephone 
number/website to call or to visit for more information about the advertised dermatology disease 
type/described condition. 
b. Dependent Variable: TDMTUEDDAS: Go for dermatology disease screening test. 
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Table 13 
 
Bivariate and Partial Correlations Between Each Predictor and to Go for Dermatology Disease 
Screening Test Index 
Predictors 
Correlation between each 
predictor and the criterion 
Correlation 
between each 
predictor and the 
criterion 
controlling for all 
other predictors 
 
described the type of dermatology disease without any recommendation of a 
specific dermatology drug for treatment.  
 
    0.15 0.11 
 encouraged people with the symptoms of the described type of 
dermatology disease to ask/talk to their doctor  
 
    -0.02* -0.08 
had the company's name of the advertised dermatology drug. 
      0.09 0.45 
gave a telephone number/website to call or to visit for more information 
about the advertised dermatology disease type/described condition.  
 
       0.12 0.09 
stated "Ask your healthcare provider for more information''.           0.25 0.23 
   Note. * P < .05. Confidence interval 95%. 
Research Question 4: Is help-seeking advertisement a predictor of the purposes of 
medical services utilization amongst adult dermatology patients in the United States? 
Hypothesis 4 (H0): Help-seeking advertisement does not significantly prompt the 
purposes of medical services utilization amongst adult dermatology patients in the United 
States.  
Hypothesis 4 (H1): Help-seeking advertisement significantly determines the 
purposes of the medical services utilization amongst adult dermatology patients in the 
United States.  
Analytical Strategy for the Hypothesis Testing 4. The fourth and last 
hypothesis testing was about help-seeking advertisement predicting or not the purpose of 
the medical dermatology services utilized amongst the target population. Question 30 was 
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the set of predictors and question 38(3) was the unique criterion used to test the 
hypotheses and to answer the related research question. Indeed, question 30 served as the 
set of predictors for the forced entry multiple regression tests in relation with each of the 
four criteria or question 38’s items (set of criteria or measures). Amongst the four 
multiple regression tests per criterion, only two models had the statistically significant P 
values (P < .05) from the model summary output tables: (a) question 38(1), P = .01 and R 
= .347, (b) question 38(3), P = .003 and R = .381. The two models had different multiple 
correlation coefficients R. Question 38(3) had the highest multiple correlation coefficient 
R = .381. Question 38(3) helped to answer this research question for that reason.  
Answer to Research Question 4. The following forced entry multiple regression 
results (Table 14) show that help-seeking advertisement significantly predicts the purpose 
of medical service utilized amongst adult dermatology patients. In that regard, a forced 
entry multiple regression analysis was conducted to evaluate how well help-seeking 
advertisement predicted the purpose of the medical dermatology service utilized. The set 
of predictors was help-seeking advertisement with five measures or items. The items  
were (a) described the type of dermatology disease without any recommendation of a 
specific dermatology drug for treatment, (b) encouraged people with the symptoms of the 
described type of dermatology disease to ask/talk to their doctor, (c) had the company's 
name of the advertised dermatology drug, (d) gave a telephone number/website to call or 
to visit for more information about the advertised dermatology disease type/described 
condition, (e) stated "Ask your healthcare provider for more information'', while the 
criterion variable was to receive treatment/cure of the dermatology disease in order to 
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clear the tumor/disease index. The linear combination of the help-seeking measures was 
significantly related to receive treatment/cure of the dermatology disease in order to clear 
the tumor/disease index, F (5,114) = 3.87, p < .05. The sample multiple correlation 
coefficient R was 4, indicating that approximately 14.5% of the variance of to receive 
treatment/cure of the dermatology disease in order to clear the tumor/disease index in the 
sample can be accounted for by the linear combination of the set of the predictors help-
seeking advertisement measures, R
2
 = .145. The loss of predicted power or shrinkage of 
3.7% has been verified with the Adjusted R
2
 = .108. Consequently, a model from the 
population would account for approximately 3.7% less variance by the criterion. Table 14 
shows the multiple regression model summary or results. 
Table 15 shows the indices of the relative strength of each particular predictor in 
relation with the criterion to receive treatment/cure of the dermatology disease to clear 
the tumor/disease index. None of the five bivariate correlations between the set of 
predictors help-seeking strength measures, and to receive treatment/cure of the 
dermatology disease to clear the tumor/disease index was positive, and all the five were 
not statistically significant (P > .05). The partial correlations between the strength 
measures for (a) described the type of dermatology disease without any recommendation 
of a specific dermatology drug for treatment, (b) gave a telephone number/website to call 
or to visit for more information about the advertised dermatology disease type/described 
condition, and (c) to receive treatment/cure of the dermatology disease in order to clear 
the tumor/disease index were statistically significant (P < .05).  
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These correlation analyses may lead to the conclusion that the strength measures for (a) 
described the type of dermatology disease without any recommendation of a specific 
dermatology drug for treatment, (b) gave a telephone number/website to call or to visit 
for more information about the advertised dermatology disease type/described condition, 
and (d) to receive treatment/cure of the dermatology disease to clear the tumor/disease 
are the only useful predictors. However, this judgment required caution because 
predictors were correlated. However, the correlation was not a source of concern for the 
multiple regression model giving that all the VIF statistics were lower than 10. 
Table 14  
Multiple Regression Model Summary
b
  
Model R 
R 
square 
Adjusted 
R square 
Std. 
error of 
the 
estimate 
    Change statistics 
Durbin-
Watson 
       
R 
Square 
change 
F 
change 
df1 df2 
Sig. F 
change   
1 .381a 
 
.145 
 
 
.108 
 
 
1.57 
 
    
 
.145 
 
 
3.88 
 
5 114 0.003 1.19 
Note. a. Predictors: (Constant), DHSAES: Stated "Ask your healthcare provider for more 
information''. , DHSAES: Encouraged people with the symptoms of the described type of 
dermatology disease to ask/talk to their doctor, DHSAES:  Had the company's name of the 
advertised skin cancer drug., DHSAES: Described the type of dermatology disease without any 
recommendation of a specific dermatology drug for treatment., DHSAES: Gave a telephone 
number/website to call or to visit for more information about the advertised dermatology disease 
type/described condition. 
b. Dependent Variable: PUDMTEDAS: receive treatment/cure of the dermatology disease in 
order to clear the tumor/disease. 
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Table 15 
Bivariate and Partial Correlations Between Each Predictor and to Receive Treatment/Cure of the 
Dermatology Disease in Order to Clear the Tumor/Disease Index 
Predictors 
Correlation between 
each predictor and the 
criterion 
Correlation 
between each 
predictor and the 
criterion 
controlling for all 
other predictors 
 
described the type of dermatology disease without any recommendation 
of a specific dermatology drug for treatment.  
 
0.14 -0.02* 
 encouraged people with the symptoms of the described type of 
dermatology disease to ask/talk to their doctor  
 
0.17 0.12 
had the company's name of the advertised dermatology drug. 
0.32 0.28 
gave a telephone number/website to call or to visit for more information 
about the advertised dermatology disease type/described condition.  
 
0.21   0.03* 
stated "ask your healthcare provider for more information''.   0.12 0.16 
   Note. * P < .05. Confidence interval 95%. 
Additional Findings 
Some Predictors and Criteria not Significantly Related 
Data analysis showed that the linear combination of product claim advertisement 
measures was not significantly related to (did not predict) participate normally to the 
dermatology treatment regimen, R
2
 = .145, F (10,109) = 1.84, p = .06 (not significant) 
and to fill the dermatology disease prescription drug, R
2 
= .091, F (10,109) = 1.08, p = 
.378 (not significant) as types of medical dermatology services utilized after exposure.
 
Additionally, the linear combination of product claim advertisement measures was not 
significantly related to the purpose to receive treatment/cure of the dermatology in order 
to look for well-being  R
2
 = .078, F (10,109) = .923, p = .515 (not significant). The linear 
combination of the help-seeking measures was not significantly related the medical 
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service to consult a dermatologist/doctor regarding any symptom/problem related to skin, 
hair, or nails, R
2
 = .060, F (5,114) = .145, p = .212 (not significant) and to the purpose to 
receive dermatology treatment/service for the dermatology disease symptom 
management, R
2
 = .003, F (5,114) = .064, p = .997 (not significant). 
PT Theory Validation in the Context of This Study 
PT is the theoretical framework of this study analyzed in Chapter 2. PT analyzed 
individual behaviors while making a decision in a risky situation. As analyzed in Chapter 
2, the dermatology patient has to make the decision to utilize medical services or not after 
exposure to a dermatology product claim or help-seeking advertisement and as the 
consequence of that exposure. In that condition, dermatology patient may lose his/her life 
by refusing to use or by using medical services after exposure (risky situation). The risk 
consists of losing or saving his/her life by not using or using the medical dermatology 
services.  
The test and validation of the PT in this study was through the study’s hypotheses 
testing, as stated in Chapter 2.The four hypotheses testing (Tables 8, 10, 12, 14) that 
preceded showed  a statistically significant relationship between the DTCAs (product 
claim and help-seeking advertisements) and the utilization of medical dermatology 
services (types and purposes) amongst the target population. Consequently, those results 
permitted to make the claim PT was verified and applicable in the context of medical 
dermatology services utilization prompted by the DTCAs directed directly to consumers.  
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Study Model Validation  
The literature review enabled me to develop the study model presented in Chapter 
2 (Figure 2). Indeed, the model explained, based on the literature, how adult dermatology 
patients utilized medical services as the consequence of their exposure to the dermatology 
product claim or/and help-seeking advertisements. The model, as stated in Chapter 2, 
needed an empirical test and validation amongst the study target population through the 
questionnaire completion and hypotheses testing.  The hypotheses testing permitted to 
review the study model proposed in Chapter 2 (Figure 2). The review consisted of 
selecting only the dependent variables (Table 16) with a statistically significant 
relationship (P ≤ .05) with independent variables for the illustration and validation of the 
model (Figure 30).  
In that regard, the dermatology patient in contact with the product claim 
advertisement (set of predictors) utilized the following services: (a) to request and obtain 
a medical prescription of the dermatology drug advertised (Q32(1)), (b) to receive the 
advertised drug therapy/chemotherapy (Q32(2)), (c) to talk to the 
dermatologist/surgeon/doctor about dermatology advertised prescription drug (Q32(5)), 
(d) to visit a physician/dermatologist office (Q32(6)), and (e) to receive skin, hair, and/or 
nails health maintenance treatment (Q32(7)). Meanwhile, the patient exposed to help-
seeking advertisement went for dermatology disease screening test or used the screening 
test service (Q34 (2)).  
In terms of purposes of utilization, the target dermatology patients exposed to a 
product claim advertisement utilized medical services in order to excise the tumor/lesion 
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(Q36(4)). Al contrary, the dermatology patients in contact with the help-seeking 
advertisement received medical services either to detect/diagnose early the dermatology 
disease (Q38(1)) or to clear the tumor/disease (Q38(3)).  
Table 16 
Dependent Variables With Significant P Values for the Study Model Validation 
Types and purposes of utilization P ≤  .05 
    
Product claim types of medical services utilized 
 to request and obtain a medical prescription of the dermatology drug 
advertised (Q32(1)) 0.00 
to receive the advertised drug therapy/chemotherapy  (Q32(2)) 0.00 
to talk to the dermatologist/surgeon/doctor about dermatology 
advertised prescription drug (Q32(5)) 0.00 
to visit a physician/dermatologist office (Q32(6)) 0.04 
to receive skin, hair, and/or nails health maintenance treatment 
(Q32(7)) 0.04 
 
 Help-seeking type of medical service utilized 
 to go for dermatology disease screening test (Q34(2)) 0.04 
 
 Product claim purpose of utilization 
 to receive treatment/cure of dermatology disease in order to excise the 
tumor/lesion (Q36(4))      0.05 
 
 Help-seeking purpose of utilization  
 to detect/diagnose early the dermatology disease (Q38(1)) 0.01 
to receive treatment/cure of dermatology disease in order to clear the 
tumor lesion/disease (Q38(3) 0.00 
Note. P ≤ .05. Confidence interval = 95%. 
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Figure 30. Empirical and validated model of the relationship between DTCAs and utilization of medical services by adult 
dermatology patients after Exposure to DTCAs, by H. Zouetchou, 2015, “Direct-to-consumer advertisements and medical 
services utilization amongst adult dermatology patients in the United States”, dissertation submitted as partial requirements for 
the degree of Doctor of Philosophy, Health Sciences, p. 191, unpublished. Copyright 2015 by Walden University. 
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The More Predicting Product Claim and Help-seeking Characteristics 
 The measurement items or independent variables used for product claim and help-
seeking advertisements were the characteristics of the advertisements defined by the US 
FDA. This research was interested also to know which characteristic applied in a DTCA 
could predict more than other characteristics a particular type or purpose of medical 
dermatology services utilized amongst the target population. The forced entry simple 
regressions were conducted amongst product claim advertisement (question 27) and the 
types (question 32) and purposes (question 36) of medical services utilization. Moreover, 
the forces entry simple regressions were conducted amongst help-seeking advertisement 
(question 30) and the types (question 34) and purposes (question 38) of medical services 
utilization.    Then, the simple regressions permitted to identify the particular type or 
purpose of medical dermatology service utilized that was prompted significantly more by 
a considered product claim or help-seeking characteristic or item. The simple index of 
effect size R
2
 enabled an identification of the characteristics with the highest simple index 
of effect size R
2
 for a considered type or purpose of utilization. The characteristic/item 
with the highest simple index of effect size R
2
 (amongst all variables significantly 
predicting the variable) was considered being the one predicting more or explaining more 
the variance in a considered type or purpose than other characteristics. 
 Product claim advertisement characteristics and types of utilization. The 
result of the simple regression test showed an independent variable/characteristic told to 
the consumers in a balanced manner the benefits and potential negative consequences of 
using the advertised dermatology drug having the highest R
2
 value of 0.11, p = 0.00, 
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regarding the dependent variable to request and obtain a medical prescription for the 
dermatology drug advertised. This R
2
 value meant that the characteristic told to the 
consumers in a balanced manner the benefits and potential negative consequences of 
using the advertised dermatology drug accounted for 11% of the variance in to request 
and obtain a medical prescription for the dermatology drug advertised. This independent 
variable significantly predicted more than any other the dependent variable to request and 
obtain a medical prescription for the dermatology drug advertised. Moreover, an 
independent variable passed on television/radio station (s) told to the viewer/listener 
where to get additional prescription drug information approved by the FDA, R
2 
= 0.04,  
p = 0.03, significantly predicted less the dependent variable to request and obtain a 
medical prescription for the dermatology drug advertised. 
The characteristic told to the consumers in a balanced manner the benefits and 
potential negative consequences of using the advertised dermatology drug has the highest 
R
2
 value of 0.08, p = 0.00, regarding the dependent variable to receive the advertised drug 
therapy/chemotherapy. Consequently, the independent variable explained 8% of the 
variance in to receive the advertised drug therapy/chemotherapy. Also, the characteristic 
stated "Ask your doctor if [drug name] is right for you.’’, R2 = 0.04, p =0.03, predicted 
significantly less the type of utilization to receive the advertised drug 
therapy/chemotherapy.  Furthermore, the variable stated both the vulgar 
designation/name of the drug approved (brand) and non-approved (generic) by the U.S. 
government, R
2 
= 0.04, p = 0.05, predicted more than the characteristic stated at least one 
form of dermatology disease treated by the advertised drug and approved by the FDA   
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R
2 
= 0.04, p =0.02 the dependent variable to talk to the dermatologist/surgeon/doctor 
about dermatology advertised prescription drug.  
The characteristic stated the most important dangers that the dermatology patient 
may face taking the advertised drug, R
2 
= 0.08, p =0.00, significantly predicted more than 
the characteristic published in the newspaper, magazines, review, or journal contained 
this statement "You are encouraged to report negative side effects of prescription drug to 
the U.S. Food and Drug Administration (FDA) Visit MedWatch5 or call 1-800-FDA-
1088", R
2 
= 0.03, p =0.05, the type to visit a physician/dermatologist office. Finally, only 
stated at least one form of dermatology disease treated by the advertised drug and 
approved by the FDA characteristic, R
2 
= 0.04, p =0.04, significantly predicted the type to 
receive skin, hair, and/or nails health maintenance treatment. 
 Product claim advertisement characteristics and purposes of utilization. In 
terms of purpose of utilization prediction, only the characteristic stated the most 
important dangers that the dermatology patient may face taking the advertised drug, R
2 
= 
0.04, p =0.03, explained 4% of the variance in the purpose to receive dermatology 
treatment to have rebuilt the part of the body damaged by the dermatology disease. 
Moreover, the characteristic stated the most important dangers that the dermatology 
patient may face taking the advertised drug, R
2 
= 0.05, p =0.02, explained 5% of the 
variance in the purpose to receive treatment/cure of the dermatology to look for well-
being. However, the characteristic published in the newspaper, magazines, review, or 
journal contained this statement "You are encouraged to report negative side effects of 
prescription drug to the U.S. Food and Drug Administration (FDA) Visit MedWatch5 or 
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call 1-800-FDA-1088.",  R
2
 = 0.07, p =0.00, the purpose to receive treatment/cure of the 
dermatology disease in order to clear the tumor. Finally, the dependent variables told to 
the consumers in a balanced manner the benefits and potential negative consequences of 
using the advertised dermatology drug.", R
2
 = 0.06, p =0.01, and published in the 
newspaper, magazines, review, or journal contained this statement "You are encouraged 
to report negative side effects of prescription drug to the U.S. Food and Drug 
Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088.",  R
2
 = 0.06, p =0.01, 
both explained equally 6% of the variance in the purpose of receiving treatment/cure of 
the dermatology disease to excise the tumor lesion. 
Help-seeking advertisement characteristics and types of utilization. The 
simple regression tests indicated that the characteristic described the type of dermatology 
disease without any recommendation of a specific dermatology drug for treatment ", R
2
 = 
0.04, p =0.04, accounted for 4% of the variance in the type of utilization to receive gene 
therapy/biological therapy, while the variable stated "Ask your healthcare provider for 
more information'', R
2
 = 0.06, p =0.01, explained 6% of the variance in to go for 
dermatology disease screening test type of utilization. In the mine time, the simple 
regression showed that the variable described the type of dermatology disease without 
any recommendation of a specific dermatology drug for treatment, R
2
 = 0.04, p =0.03, 
accounted for 4% of the variation of to receive laser surgery.    
Help-seeking advertisement characteristics and purposes of utilization. The 
characteristic encouraged people with the symptoms of the described type of dermatology 
disease to ask/talk to their doctor, R
2
 = 0.05, p =0.02, accounted for 5% of the variance in 
196 
 
 
191 
to receive dermatology treatment/service to detect/diagnose early the dermatology 
disease. Lastly, the variable had the company's name of the advertised dermatology drug, 
R
2
 = 0.10, p = 0.00, predicted more than the characteristic gave a telephone 
number/website to call or to visit for more information about the advertised dermatology 
disease type/described condition, R
2
 = 0.04, p =0.02, the purpose of to receive 
treatment/cure of the dermatology disease to clear the tumor/disease. 
Summary and Transition 
Chapter 4 aims to present the pilot study results, to test the multiple regression 
assumptions, to test the four hypotheses, the PT, the study model, and to answer the four 
research questions. The final sample of this study was 120 respondents. 71% of the 120 
had the skin disease, 24% had hair disease, and 5% had nails disease. 
The results of the pilot study showed the Cronbach's Alpha & reliability statistics 
of the six scales ranging from 0.01 to 0.68 and within the Cronbach's Alpha & acceptable 
range of was zero through one. These results enabled the final validation of the research 
study instrument (questionnaire) before its use for the final study.  
All the four multiple regression assumptions were met. Thus, all the multiple 
regressions models of this study were generalizable, free of bias, and the results obtained 
from the sample were applied to the entire population of the study. 
The findings of the study permitted to reject all the four null hypotheses (H0s) and 
to validate all the alternative hypotheses.  Therefore, the results of the study showed that 
product claim and help-seeking advertisements significantly predicted respectively the 
utilization of the following medical services (a) to talk to the 
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dermatologist/surgeon/doctor about dermatology advertised prescription drug and (b) to 
go for dermatology disease screening test amongst adult dermatology patients attending 
church services at the Saint Nicholas Catholic Church or/and receiving primary care 
services at MedStar Primary Care Clinic. Besides, product claim and help-seeking 
advertisements significantly predicted respectively the following purposes (a) to receive 
treatment/cure of the dermatology disease to excise the tumor/lesion and (b) to receive 
treatment/cure of the dermatology disease to clear the tumor/disease. The study model 
and PT were validated based on the study hypotheses testing. 
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Chapter 5:  Discussion, Conclusions, and Recommendations 
Introduction  
Study Purpose, Nature and Motivation   
 The purpose, nature, and motivation of this study are the content of this section. 
The intent of this quantitative correlation study was to describe the relationship between 
product claim, help-seeking (independent variables), and types and purposes of medical 
dermatology services utilization (dependent variable) amongst patients aged at least 18 
years old. The patients were attending church services at Saint Nicholas Catholic Church 
or/and receiving primary care services at MedStar Primary Care Clinic in Houston, 
Texas. Also, I sought to test PT (Kahneman & Tversky, 1979) based on the description of 
the relationship amongst product claim, help-seeking, and types and purposes of medical 
dermatology services utilization.  
The quantitative nature of this study was due to the research question and the use 
of the cross-sectional survey research method. In that regard, a sample of 120 participants 
selected based on the predetermined criteria completed a questionnaire of 38 questions. 
The forced entry multiple regression analysis of the responses permitted me to address 
the research questions. Moreover, all the multiple regression assumptions were met, 
enabling the results from the sample inferable to the general population of the study 
(Field, 2009).   
I undertook this study to fill a gap found in the DTCAs and health services 
utilization literature. In fact, previous researchers found that drug and disease DTCAs 
prompted the utilization of medical services in general (Limbu & Torres, 2009; Mackert 
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et al., 2010). However, those researchers were silent about the question of the 
relationship between the product claim, help-seeking DTCAs, and the types and purposes 
of utilization of medical services amongst the specific group of adult dermatology 
patients attending church services at Saint Nicholas Catholic Church or/and receiving 
primary care services at MedStar Primary Care Clinic in Houston, Texas.   
Findings Summary 
  The results of the study presented in Chapter 4 showed that product claim 
advertisement significantly prompted the utilization of the following medical 
dermatology services: (a) to request and obtain a medical prescription for the 
dermatology drug advertised, (b) to receive the advertised drug therapy/chemotherapy, 
(c) to talk to the dermatologist/surgeon/doctor about dermatology advertised prescription 
drug, (d) to visit a physician/dermatologist office, and (e) to receive skin, hair, and/or 
nails health maintenance treatment. The patients exposed to the help-seeking 
advertisement used the screening test of the dermatology disease.  
Product claim significantly determined the tumor/lesion excision as the purpose of 
medical services utilization. Finally, help-seeking advertisement significantly predicted 
early disease diagnosis and tumor/disease clearance purposes of medical dermatology 
service utilization. Many other types and purposes of medical services utilized had a 
nonsignificant relationship with product claim and help-seeking advertisements. An 
interpretation of the findings, the limitations of the study, recommendations, and 
implications for positive social change are the contents of Chapter 5. 
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Interpretation of the Findings 
Literature Findings Versus Study Findings 
These research findings confirmed, to a certain extent, the literature findings 
regarding an impact of the dermatology DTCAs directed directly to consumers on the use 
of medical dermatology services.  
Research Question 1: Is product claim advertisement a predictor of the types of 
medical services used amongst adult dermatology patients in Houston, Texas? 
Research Question 1 was about product claim advertisement prompting the types 
of medical services that dermatology patients used after exposure. According to the 
literature analyzed in Chapter 2, 94% of cancer nurse practitioners have received a 
request for the cancer drug advertised from patients (Gray & Abel, 2012). Then, these 
cancer patients talked/asked their doctor about the medication featured in the 
advertisement or visit a dermatologist office. Furthermore, 69.6% of APNs have seen 
patients naming the drug they wanted because of their exposure to the DTCAs (Mackert 
et al., 2010). Approximately 26% of the APNs testified that some patients kept their 
treatment plan due to the impact of the DTCA (Mackert et al., 2010). Fifty-three million 
consumers have talked to their physicians about a particular prescription drug that they 
have seen in a DTCA in the United States of America (Limbu & Torres, 2009). Also, 
approximately 21.2 million consumers were prompted to talk to their doctors about an 
illness in response to a drug advertisement influence (Limbu & Torres, 2009). Thirty-one 
percent of Americans claimed in 1999 having discussed with the doctors regarding a 
prescription of a drug seen in an advertisement. A 2003 survey showed 35% of 
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respondents have sought and gained more information from their physicians regarding 
the prescription medicine advertised (Limbu & Torres, 2009). 
The study findings follow now. Sixty-eight percent of the respondents totally 
agreed having requested and obtained a medical prescription of the dermatology drug 
advertised due to their exposure to a dermatology product claim advertisement (P = .000 
and R = .496). In the same logic, 47% of the respondents have totally agreed having 
received the advertised drug therapy (P = .003 and R = .456). Besides, 67% totally agreed 
having talked to the dermatologist/surgeon/doctor about dermatology advertised 
prescription drug (P = 0.000 and R = .512). Seventy percent totally agreed having visit a 
physician/dermatologist office (P = .036 and R = .397). Finally, 55% of the respondents 
agreed having received skin, hair, and/or nails health maintenance treatment under the 
influence of the DTCAs of a prescription drug (P = .042 and R = .392). The preceding 
study findings supported the above relationship between medical services utilization and 
the product claim advertisement from the peer-reviewed literature.  However, some 
nonsignificant results (P > .05) contradicted the peer-reviewed literature by showing 
nonsignificant relationships between product claim and a particular type of the 
dermatology medical service. For example, 52% of the respondents agreed to participate 
normally in the dermatology treatment regimen due to the DTCAs exposure. However, 
the correlation between the variables was statistically nonsignificant (R = .381, P = .06). 
Also, 49% agreed to fill the dermatology prescription drug after exposure to a product 
claim, but the p value was higher than .05 (R = .301, P = .37).  
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The comparative analysis of the literature and study findings demonstrated that 
product claim advertisement persuaded, informed, and educated patients to use medical 
services in general, and certain medical dermatology services in particular amongst the 
study target population. The nonsignificant relationship still showed the presence of the 
relationships with R values. However, the relationships were statistically not important, 
consequently, did not deserve any consideration before Research Question 2.   
Research Question 2: Is product claim advertisement a predictor of the purposes 
of medical services utilization amongst adult dermatology patients in Houston, Texas? 
Research Question 2 was the relationship between product claim and the purpose 
of medical dermatology services utilization. The research findings both confirmed and 
disconfirmed the peer-reviewed literature results analyzed in Chapter 2. According to 
peer-reviewed literature, a dermatology patient exposed to a dermatology product claim 
received medical treatment (a) to clear the tumor, (b) to excise the tumor lesion 
(Samarasinghe et al., 201), or (c) to detect early the skin cancer or other dermatology 
conditions (Kontos & Viswanath, 2011). Furthermore, patients received treatments to 
recover from the dermatology illness or to cure/treat the disease (French et al., 2011).  
These research findings showed only 4% of the respondents totally agreeing 
having received treatment/cure of the dermatology disease to excise the tumor/lesion 
after an exposure to a product claim advertisement. However, the correlation between the 
two variables was statistically significant (R = .386, P = .05). Fifty-six percent 
respondents agreed to receive dermatology treatment/cure to look for well-being. 
However the p value was not statistically significant (R = .279, P = .51).  
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This analysis prompted the claim that product claim effectively decided patients 
about the considered purpose of the dermatology service utilization within the study 
target population. Moreover, product claim effectively decided patients beyond the study 
limits as supported by the literature findings. The statistically significant results showed 
that the relationship was statistically important and deserved consideration. The 
nonsignificant p value meant that the relationship between the product claim and the 
considered purpose was real amongst the study population. However, the same 
relationship was not statistically important and, therefore, did not deserve any attention 
before Research Question 3. 
Research Question 3: Is help-seeking advertisement a predictor of the types of 
medical services utilized amongst adult dermatology patients in Houston, Texas? 
Research Question 3 was about the impact of help-seeking advertisement on the 
types of medical dermatology services utilized. The evidence from the literature reviewed 
in Chapter 2 stated that the patient exposure to a cancer help-seeking advertisement led 
(a) to consult a dermatologist regarding any symptoms observed, (b) to utilize preventive 
services, (c) screening/testing services for early detection of the disease, (d) or to search 
for additional health information outside of the DTCAs (Kontos &Viswanath, 2011). In 
1999, around 25% of survey respondents visited their doctors to ask more about an illness 
due to a help-seeking advertisement effect (Limbu and Torres, 2009). Patients exposed to 
help-seeking advertisement (a) visited/consulted the doctor about symptoms they had, (b) 
talked with the doctor regarding a condition advertised, or (c) discussed new medical 
conditions advertised with their physicians (Flood, 2010; Kornfield et al., 2013; & Limbu 
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and Torres, 2010).  Moreover, help-seeking advertisement prompted patients to search for 
information from outside of the advertisement (Hall et al., 201b).   
This research finding showed that help-seeking advertisement significantly 
prompted 71% patients who totally agreed having gone for dermatology disease 
screening test after exposure (R = .303, p = .04). However, help-seeking advertisement 
nonsignificant decided 81%  patients who totally agreed having consulted a 
dermatologist/doctor regarding any symptom/problem related to skin, hair, or nails (R = 
.245, p = .21). Seventy-nine percent respondents agree having searched for additional 
health information outside of the disease announcement due to their help-seeking 
exposure. However, the correlation between help-seeking advertisement and the search of 
additional health information outside of the disease announcement was not statistically 
significant (R = .082, p = .97).  
The preceding analysis led to the claim that help-seeking effectively was 
impacting patients about the considered types of the medical dermatology services 
utilized within the study target population. Furthermore, help-seeking effectively decided 
patients beyond this study sphere as supported by the literature findings. The 
nonsignificant p values meant that the relationship between the help-seeking and the 
considered types of medical services was factual amongst the study population, however 
were not statistically important, therefore, did not deserve any consideration before 
Research Question 4. 
Research Question 4: Is help-seeking advertisement a predictor of the purposes of 
medical services utilization amongst adult dermatology patients in Houston, Texas? 
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The Research Question 4 was the impact of help-seeking advertisement on the 
purposes of medical dermatology services utilization. According to the literature, skin 
help-seeking advertisement exposure led to seek the treatment of the condition or to 
manage the diseases symptom (MD Anderson Cancer Center, 2013; Samarasinghe et al., 
2011; The Skin Cancer Foundation, 2013a). Patients sought for early detection, wellness, 
and wellbeing when utilizing medical services after an exposure to help-seeking (French 
et al., 2011; Kontos & Viswanath, 2011; Wellington, 2010). In addition, help-seeking 
advertisement exposure prompted patients to receive medical dermatology services (a) to 
treat the condition, (b) to manage the diseases symptom (M D A C C, 2013; 
Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013a), or (c) to detect early the 
disease (Kontos & Viswanath , 2011). 
  These study findings showed that help-seeking advertisement significantly 
prompted 63% patients who totally agreed having received dermatology 
treatment/service to detect/diagnose early the dermatology disease (R = .347, p = .01). 
Then, help-seeking advertisement significantly prompted 34% patients who totally agreed 
having received dermatology treatment/service to clear the tumor or disease (R = .381, p 
= .003). However, help-seeking advertisement nonsignificant prompted 42 % patients 
who agreed having received dermatology treatment/service to manage the disease 
symptoms (R = .053, p = .99). Sixty-nine percent did not agree at all using dermatology 
services to excise the tumor lesion/disease due to help-seeking influence. The p value was 
not significant (R = .206, p = .41). 
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The preceding analysis prompted the claim that help-seeking effectively was 
impacting patients about the considered purposes of the dermatology service utilization 
within the study target population. Also, help-seeking effectively decided patients beyond 
this study sphere as supported by the literature findings. The nonsignificant p values 
meant that the relationship between the help-seeking and the considered purposes of 
medical services was real amongst the study population, however, were not statistically 
important, and did not deserve any attention. 
Finally, the simple regression tests showed that certain single product claim or 
help-seeking characteristic significantly predicted or explained more than others the 
variance in an outcome variable. Consequently, an advertiser who wants to obtain a 
particular outcome or effect on the study population, most use in the advertisement the 
specific characteristic shown by this study results as being the variable predicting more 
the target outcome. Moreover, according to Phrma (2011) and Limbu and Torres (2009), 
the objective of the DTCAs information was not to persuade the consumer to purchase a 
drug or products/services after exposure.  As presented earlier, the results of this study 
showed that the DTCAs significantly prompted the utilization of dermatology medical 
services after exposure to a DTCA. The patient using medical dermatology service(s) due 
to an exposure to a DTCA paid for or purchased the service(s) (2.5% of the sample 
claimed to pay with Medicaid and 97.5% with other means). Therefore, this study results 
constitutes a limit to Phrma (2011) and Limbu and Torres (2009) argument: the DTCAs 
were not planned to be persuasive. However, the DTCAs ended up being persuasive.  
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Study Findings and Theoretical Framework (PT)    
The study findings presented in Chapter 4 provided evidence of the product claim 
and help-seeking advertisements prompting the types and purposes of medical services 
utilization amongst the study population. In that regards, the multiple correlation R of the 
forced entry multiple regression analysis represented the strength index of the degree of 
the correlation between product claim and help-seeking (dependent variables) and types 
and purposes of medical dermatology services utilization (independent variables) for the 
sample (Green & Salkind, 2011). 
This study was a quantitative correlation study, as stated in Chapter 3. Therefore, 
the aim of the study was also to test PT used as the literature foundation of the study and 
describe in Chapter 2. The quantitative design tests a theory. The test of the theory 
consists of describing the relationship between the dependent and independent variables.  
The variables measurement is through the use of instrument or questionnaire to generate 
numbers and check statistically the relationship between variables (Creswell, 2009). This 
study used a questionnaire with 38 questions to measure the study variables product 
claim, help-seeking, types and purposes of medical dermatology services utilization. 
Then, forced entry multiple regression analysis permitted to check and to confirm a 
correlation between the study variables.  
The correlation between the variables led to the claim that PT was valid or 
applicable in the context of this study. The validation of  PT meant that PT was able to 
help to describe the social phenomenon of the medical dermatology services utilization 
due to the impact of the dermatology DTCAs amongst adult dermatology patients 
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attending church services at the Saint Nicholas Catholic Church or/and receiving primary 
medical services at MedStar Primary Care Clinic in Houston, Texas. As stated in Chapter 
2, PT is a decision-making theory model that permits to describe how an individual 
makes a choice when facing a risky situation or uncertainty (Kahneman & Tversky, 1979; 
Kothiyal et al., 2011; Mello & Cajueiro, 2010; O'Connell, 2011). In the context of this 
study, the risky situation is to recover/stay alive due to medical dermatology services 
utilization after exposure to a DTCA, or to lose the life/decease in the case of 
nonutilization. The dermatology patient has to make the decision in the risky condition of 
dermatology disease to utilize medical services or not after being in contact with 
dermatology product claim or help-seeking advertisement. 
Limitations of the Study 
The quantitative nature of this study was the first limitation. The cross-sectional 
survey method served to conduct this study. The cross-sectional survey method led to the 
use of the sophisticated instruments that were a 38-question questionnaire for data 
collection, and the computer software SPSS 21.0 for data analysis. The questionnaire 
gave less flexibility to the respondents in the expression of their attitudes and views 
regarding the problem of the DTCAs and utilization of medical dermatology services. 
SPSS 21.0 program required from the user a particular training and familiarity to be able 
to operate the program. Also, the cross-sectional survey collected data only one time 
from January 12 through February 22, 2015 (one month and 10 days) (Creswell, 2009; 
Frankfort-Nachmias & Nachmias, 2008).  
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The second limitation and threat to this research internal validity was the 
environment and the time of the questionnaire completion. Ideally, the setting of the 
completion has to be free of any source of noise or distraction. The time has to be 
appropriate for the respondent to avoid any bias in the answers (Creswell, 2009; 
Frankfort-Nachmias & Nachmias, 2008). Saint Nicholas Catholic Church’s hall did not 
offer a total noise free environment. Faithful carried out usually multiple activities 
(sources of noises around the hall) after church services within the parish perimeter. 
Then, MedStar Primary Care Clinic’s meeting rooms where the questionnaire completion 
took place were exposed, from time to time, to some little noises from other patients in 
the lobby area or the television sets. However, the doors were kept closed at the two 
locations during questionnaires completion to limit the risk of distraction due to the 
noises in the environment. The time of the questionnaire completion was after the church 
service or the meeting with the doctor at the respondent convenient.  No questionnaire 
completion was terminated prematurely due to the noises or time reason.  
The third limitation was the use of the new instrument or questionnaire to collect 
data for the first time. Indeed, the expert and pilot study validations, as described in 
Chapters 3 and 4, did not eliminate completely the risk of the first-time use of the 
questionnaire. The questionnaire must be capable of exactly measuring the concepts of 
the DTCAs and utilization of medical services under investigation. Only multiple uses of 
this questionnaire will give more assurance of the instrument capability of measuring the 
concepts of interest, and will eliminate the possible construct validity threat due to the 
first time use.  
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The fourth limitation is the geographic limit of the study. The data collection took 
place only in one city, the Houston city. Then, within the city, the data collection covered 
only one church and one clinic. Therefore, the study’s results could not be generalized to 
the national population of adult dermatology patients who have used medical services for 
a medical reason due to an exposure to a DTCA. In the same logic, this study did not 
have a sample frame to avoid sampling bias that could affect the external validity of the 
findings. Thus, using a nonrandom purposive sample scheme to select the sample was a 
risk for the external validity of the study. However, the predetermined inclusion criteria 
in the questionnaire helped to select a representative sample. Then, all the multiple 
regression assumptions were met before the hypotheses testing took place. The use of 
inclusion criteria and the assumption test enabled, until certain extend, the credibility of 
the external validity of this study.  
The fifth and last limitation was the lack of the mediators or moderators effect test 
regarding product claim and help-seeking advertisements predicting the types and 
purposes of medical dermatology services utilization. According to Frosch et al. (2010), 
patients’ age, sex, education, or medical history moderate or mediate the effect of an 
exposure to a DTCA on the medical services utilization in the process of seeking medical 
care. This study failed to test the effect of patients’ sex, age, highest grade of school 
completed, type of dermatology disease, race/ethnicity, or annual household income on 
the product claim and help-seeking advertisements prompting the types and purposes of 
medical dermatology services utilization. Despite the failure, there are recommendations 
for the future researches.   
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Recommendations for Further Research 
This research study offers avenues for further research.  F.D.A. (2012b) and Lee-
Wingate and Xie (2010) distinguish three types of the DTCAs that are product claim, 
help-seeking, and reminder. This study only focused on product claim, and help-seeking 
advertisements. Further research may be interested in the reminder advertisement 
prompting medical dermatology services or not. Moreover, a new research could 
investigate on the type of the DTCAs prompting more than others the utilization of 
medical dermatology services. The bottom line would be to advise pharmaceutical 
announcers on the type of the DTCAs that informs, educates, or prompts more (than other 
types) the patient to use medical dermatology services. The use of medical dermatology 
services as the consequence of the DTCAs exposure could lead to a healthier society.  
The geographic limit of this study constituted a source of possible new studies. 
This study only was limited to the Houston city. Then, the study sites only were two 
locations within Houston city. Finally, the data collection took place amongst 120 
participants. A further study covering the 50 States with more than 120 respondents could 
generate different interesting results. 
It is known from the literature that patients’ age, sex, education, or medical 
history were mediators, and moderators of the DTCAs impacting medical services 
utilization after exposure (Frosch et al., 2010). This study failed to evaluate the possible 
mediation or moderation effect of patients’ sex, age, highest grade of school completed, 
type of dermatology disease, race/ethnicity, or annual household income on the 
relationship between the DTCAs and the utilization of medical dermatology services 
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amongst the study population. A future study focusing on the mediation or moderation 
analysis may generate additional information/results regarding the relationship between 
product claim, help-seeking, and types and purposes of medical dermatology services 
utilization.  
The study findings revealed the television and online/websites as the main media 
of exposure to the DTCAs amongst the study population. However, the study results did 
not specify the television channels and websites of use amongst the population. Further 
study could focus on the television and websites viewers’ usage habits to identify the 
study population familiar television channels and websites. Pharmaceutical announcers 
interested in this study population would select television channels and website 
accordingly for the future product claim and help-seeking diffusion or broadcast. This 
said, there are several implications for this study that deserve analysis. 
Implications  
Positive Social Change 
I undertook this research study to satisfy related plausible social change 
implications. The key study social change implication is the dermatology health 
promotion via education, awareness building, and increase amongst patients aged 18 and 
over attending church services at Saint Nicholas Catholic Church and/or receiving 
primary care services at MedStar Primary Care Clinic in Houston, Texas. In fact, 
according to Williams and Co. (2013), skin cancer is the driving force of the dermatology 
service demand in the United States. Skin cancer health promotion in particular has 
diverse reasons. For instance, an individual victim of skin cancer will have a high chance 
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to be healed when the disease is diagnosed at the early stage. In addition, an increase 
almost up to 77% occurred in nonmelanoma skin cancer treatment from 1992 through 
2006 (American Cancer Society, 2013a; National Cancer Institute, 2013a; Skin Cancer 
Foundation, 2013b).  
 Product claim advertisements enable awareness creation. Product claim created 
based on this study results will educate and create awareness amongst patients about (a) 
benefits and potential negative effects of the drug advertised use, (b) balanced advantages 
and dangers of the drug, (c) how to report the negative side effect of the drug, (d) 
additional sources of information about the drug, (e) the FDA approved drug risks, (f) the 
most important danger of the drug, (g) the brand and generic drug name, (h) at least one 
disease treated by the drug, and (i) the conversation with doctor about the drug 
advertised. Patients exposed to the advertisements will, consequently, (a) request and 
obtain a prescription of the drug advertised, (b) receive the advertised drug therapy, (c) 
adhere to the treatment regimen, (d) have a conversation with the dermatologist regarding 
the drug advertised, (e) visit the dermatology office, and (f) use the dermatology help 
maintenance treatment. The patients impacted by the education on the most important 
danger of the drug advertised will utilize medical dermatology service to rebuild the part of 
the body damaged by the dermatology disease or to look for well-being. The education on 
the benefits and potential negative effects of the drug advertised use and on how to report 
the negative side effect of the prescription drug will prompt the patient to utilize medical 
dermatology services for the tumor excision.  
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Conversely, help-seeking advertisements from this study results presented in 
Chapter 4 will educate and create awareness amongst patients about (a) dermatology 
diseases, (b) diseases symptoms and conversation with the doctor regarding the 
advertised symptoms, (c) dermatology drug manufacturers, and (d) possible sources of 
information about the disease outside the advertisement. In doing so, the help-seeking 
advertisements will prompt the study population (a) to use screening test services, (b) to 
receive gene therapy/biological therapy, and (c) to receive laser surgery. The diseases 
symptoms and conversation with the doctor education will prompt an early diagnosis of 
the dermatology disease. The education about the possible sources of information about 
the disease outside the help-seeking will lead to the tumor/disease clearance. 
Empirical Implication 
The empirical implication of the study is from the explanatory study model 
empirically, statistically validated, and presented in Chapter 4. The study model 
explained how product claim or help-seeking advertisements prompted the types and 
purposes of medical dermatology services utilization amongst the specific study target 
population. The explanation clarified the process of adult dermatology patient exposure 
to the DTCAs and the consequent utilization of medical services. The explanation 
provided the types and purposes of medical dermatology services that product claim or 
help-seeking advertisements significantly prompted within the study population. Also, 
this study results added new knowledge to the field of the DTCAs research. 
215 
 
 
191 
Recommendations for Practice  
The study has practice and policy implications. Past researchers have claimed an 
influence of drug and disease DTCAs on the consumer’s use of medical services. 
However, none of them has focused the analysis on the specific characteristics of the 
drug and disease advertisements, as defined by the FDA, which influenced consumers 
more to utilize medical dermatology services. I run 198 forced entries simple regressions. 
Thirty-one out of 198 were statistically significant. The statistically significant simple 
regression results in Chapter 4 helped to identify, in the particular era of dermatology 
treatment, the FDA’s characteristics of product claim and help-seeking advertisements 
that significantly predicted more certain types and purposes of medical dermatology 
services utilized. Furthermore, for each significantly predicting characteristic, a specific 
predicted type or purpose of utilization was also identified. Consequently, the more 
predicting characteristics identified could be the communication axes for the DTCAs of 
pharmaceutical companies targeting exclusively the population under investigation. 
Indeed, the DTCAs inform and educate patients about drug, diseases, and treatment 
options. The DTCAs prompt the patients to adhere to the drug treatment plan (Phrma, 
2011). As far as policy is concerned, the FDA as well as Phrma may use the results of 
this study to develop the new DTCAs regulations, policies, principles, and laws, or to 
revise the existing one. 
Conclusion 
 This research study aimed to describe the statistically significant relationship 
between product claim and help-seeking advertisements, and each measurement items of 
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the types and purposes of medical dermatology services utilization. The study target 
population was the dermatology patients aged 18 years and over living in Houston, 
Texas, attending church services at Saint Nicholas Catholic Church, and/or receiving 
primary care services at MedStar Primary Care Clinic. A total of 120 participants was the 
final sample. 
 The evidence from the literature reviewed in Chapter 2 showed that product 
claim and help-seeking advertisements significantly predicted the types and purposes of 
medical services utilization in the United States by the dermatology patients (Limbu & 
Torres, 2009; Mackert et al., 2010). I used a cross-sectional survey method to collect data 
and to achieve this study objective. I tested the study’s hypotheses using a forced entry 
multiple regressions test. The study findings enabled me to make the claim that product 
claim and help-seeking advertisements significantly prompted adult dermatology patients 
attending church services at Saint Nicholas Catholic Church and/or receiving primary 
care services at MedStar clinic in Houston, Texas to receive certain medical dermatology 
services for medical reasons. In other words, product claim and help-seeking 
advertisements informed, educated, and persuaded patients to utilize certain medical 
dermatology services for certain medical reasons as presented in Chapter 4. However, the 
patient still needs the physician’s help to use the advertised drug or/and most 
dermatology services despite the education provided by the product claim and help-
seeking advertisements (Kontos & Viswanath, 2011; La Barbera, 2012). Patients are less 
familiar with some of the medical dermatology services.  
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Concretely, the set of independent variables product claim significantly prompted 
the study population to receive the following medical dermatology services: (a) to request 
and obtain a medical prescription of the dermatology drug advertised, (b) to receive the 
advertised drug therapy/chemotherapy, (c) to talk to the dermatologist/surgeon/doctor 
about dermatology advertised prescription drug, (d) to visit a physician/dermatologist 
office, and (e) to receive skin, hair, and/or nails health maintenance treatment. Product 
claim significantly prompted only the purpose to receive treatment/cure of the 
dermatology disease to excise the tumor/lesion.  
Regarding the help-seeking set of independent variables, the only type of 
dermatology service significantly prompted was to go for dermatology disease screening 
test. Finally, help-seeking set significantly prompted to receive dermatology 
treatment/service to detect/diagnose early the dermatology disease, and to receive 
treatment/cure of the dermatology disease to clear the tumor/disease as purposes of 
medical services utilization. 
Besides, forced simple regressions permitted to identify a particular characteristic 
of product claim or help-seeking, as defined by the FDA, prompting significantly more 
than others a particular type or purpose of medical dermatology services amongst the 
study population. For instance, product claim characteristic told to the consumers in a 
balanced manner the benefits and potential negative consequences of using the advertised 
dermatology drug prompted more than any other characteristic (with the highest R
2
 value 
of 0.11, p = 0.00) patients to request and obtain a medical prescription of the dermatology 
drug advertised. Al contrary, the characteristic passed on television/radio station (s) told 
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to the viewer/listener where to get additional prescription drug information approved by 
the FDA (R
2 
= 0.04, p = 0.03) predicted significantly less the request and obtainment of a 
medical prescription of the dermatology drug advertised. Furthermore, the characteristic 
stated both the vulgar designation/name of the drug approved (brand) and nonapproved 
(generic) by the U.S. government (R
2 
= 0.04, p = 0.05) impacted more than the 
characteristic stated at least one form of dermatology disease treated by the advertised 
drug and approved by the FDA (R
2 
= 0.04, p =0.02) patients to talk to the 
dermatologist/surgeon/doctor about dermatology advertised prescription drug. 
Concerning the purposes of utilization, the product claim characteristic stated the most 
important danger that the dermatology patient may face taking the advertised drug (R
2 
= 
0.04, p =0.03) determined significantly more a patient to receive dermatology treatment 
to rebuild the part of the body damaged by the dermatology disease.  
As far as help-seeking advertisement is concerned, the characteristic described the 
type of dermatology disease without any recommendation of a specific dermatology drug 
for treatment (R
2
 = 0.04, p =0.04) determined significantly more a patient to receive gene 
therapy/biological therapy. Furthermore, the characteristics stated ask your healthcare 
provider for more information (R
2
 = 0.06, p =0.01) predicted more a patient to go for 
dermatology disease screening test. In the mine time, the characteristic encouraged 
people with the symptoms of the described type of dermatology disease to ask/talk to 
their doctor (R
2
 = 0.05, p =0.02) significantly predicted more a patient to receive 
dermatology treatment/service to detect/diagnose early the dermatology disease. Lastly, 
the characteristic had the company's name of the advertised dermatology drug (R
2
 = 0.10, 
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p = 0.00), predicted more than the characteristic gave a telephone number/website to call 
or to visit for more information about the advertised dermatology disease type/described 
condition (R
2
 = 0.04, p =0.02) a patient to use the medical service for the tumor/disease 
clearance. 
This study is interesting for the study population for many reasons. Indeed, the 
study’s findings provided evidence of the prescription drug and diseases DTCAs 
influencing significantly the utilization of medical dermatology services amongst the 
target population. The study findings revealed that 71% of the sample had skin diseases, 
24% hair diseases, and 5% nails diseases. Skin diseases patients formed the largest 
proportion of the sample. Most of skin conditions are curable when detected early as 
discovered in the literature. Also, according to the study results, 85% of the samples were 
in contact with drug advertisement through television channels versus 56.7% for the 
online/websites medium. In addition, 90.8% of the samples were exposed to the 
dermatology pharmaceutical disease(s) announcement through television channels versus 
62.5% for online/websites medium. Consequently, announcers are encouraged to use the 
product claim and help-seeking advertisements characteristics that were statistically 
significant predicting or predicted in this study to create the new DTCAs. The announcers 
will broadcast the new product claim and help-seeking announcements using television 
channels and online/websites to reach the study population. The effect of the new DTCAs 
on the population of this study will contribute to more healthy skin, hairs, and nails.  
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Appendix C: Informed Consent Form 
 
 You are invited to take part in a research study that seeks to learn if patients with skin, hair, 
and nails diseases who have seen, read, or heard (exposure) a pharmaceutical drug company's 
dermatology advertisement would receive a treatment for a medical reason because of the 
exposure to that advertisement. The advertisement should be about dermatology drug(s) or 
disease and directed directly to patients.  
 
The researcher is inviting you to be in the study regarding adults of both sexes living in 
Houston, Texas. More details about the eligibility criteria are given in the Background 
Information section below.  
 
This form is part of a process called “informed consent” to allow you to understand this study 
before deciding whether to take part. This study is being conducted by a researcher named 
Heribert Zouetchou, who is a doctoral student at Walden University.  
 
Background Information:  
The purpose of this research study is to describe the relationship between the dermatology 
pharmaceutical direct-to-consumer advertisement (DTCAs) and the utilization of medical 
dermatology services amongst adult patients with skin, hair, and/or nails diseases in the 
United States of America. In other words, this research’s intent is to describe the relationship 
between dermatology product claim, help-seeking advertisements and types and purposes of 
the utilization of medical services amongst adult dermatology patients.  
Inclusion/eligibility criteria are (a) you attend church services at Saint Nicholas Catholic 
Church or receive primary care services at MedStar Primary Care Clinic in Houston, Texas, 
(b) you (the participant) have been diagnosed with a dermatology disease, (c) are at least 18 
years old, (d) have seen, read, or heard (exposure) a dermatology advertisement about a 
dermatology prescription drug or/and disease directed directly to the dermatology patients 
and have received a treatment for a medical reason because of the exposure to the 
advertisement within one year, (e) speak, read, and understand English language, (f) are 
receiving dermatology treatment at a dermatology facility in Houston, Texas, and (g) are 
living in Houston, Texas for at least six months continuously.  
 
Be advised that the researcher cannot answer any questions about your current condition. If 
you have any question(s) of that nature, please, follow up with your primary care physician. 
 
 Procedures:  
If you agree to be in this study, you will be asked to:  
Complete a questionnaire that asks about some demographic information, your 
exposure to a dermatology pharmaceutical company’s advertisement directed directly 
to patient regarding skin, hair, and/or nails prescription drug or disease, and the 
reception for a medical reason of the medical dermatology service as the consequence 
of having seen, heard, or read such advertisement in the past 12 months. The survey 
contains 2 sections:  
241 
 
 
191 
• an eligibility section of the questionnaire that asks about topics such as your 
demographic information (such as race/ethnicity and age), the skin, hair, 
and/or nails disease(s), how you pay for treatments, and your exposure to a 
skin, hair, and/or nails drug or disease advertisement from dermatology 
pharmaceutical companies. Answering the questions should take about 8 
minutes.  
 
• Another section called main questionnaire asks about topics such as your 
exposure to a skin, hair, and/or nails drug or disease advertisement from 
dermatology pharmaceutical companies, and the treatments you have received 
after seeing, hearing, or reading such advertisements, and the medical reason 
why you receive the service. Completing this section should take about 20 
minutes.  
 
Please, respondent, be advised, in order to get accurate results, responses are needed 
for each question and if there are questions that you do not want to answer, you may 
discontinue the completion of the questionnaire at any time without any penalty, 
discontinuation of services, or negative impact of your relationship with the 
researcher.  
 
Here are some sample questions:  
Q.3. Familiarity with English Language (Please, check only one).  
Speak, read and understand.  
Do not speak, read and understand (Terminate the Completion)  
 
Q.4. Attending to church service(s) at Saint Nicholas Catholic Church or receiving primary 
care services at MedStar Primary Clinic in Houston (Please, check only one).  
Yes.  
No (Terminate the Completion)  
 
Q.7. Have you been diagnosed with dermatology disease(s) in the past 12 months (check 
only one)?  
Yes  
No (Terminate the Completion)  
  Other (Specify): (Terminate the Completion)  
 
Q.8. Are you currently receiving dermatology treatment/services (s) here in Houston after 
you have been diagnosed with dermatology disease(s) in the past 12 months (check only 
one)?  
Yes  
No (Terminate the Completion)  
Other (Specify): (Terminate the Completion)  
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Q.19. Race/Ethnicity (Check only one).  
 
            White                                     Asian Indian 
Black, African American, or Negro                      Native Hawaiian 
 Chinese                                                                  Other Pacific Islander (Specify): 
American Indian/Alaska Native           Korean 
Filipinos              Vietnamese 
Japanese             Some Other Race (Specify): 
Other Asians (Specify):                                 Samoan 
Guamanian          
 
Voluntary Nature of the Study:  
This study is voluntary. Everyone will respect your decision of whether or not you choose to 
be in the study. No one at Saint Nicholas Catholic Church or at MedStar Primary Care Clinic 
in Houston will treat you differently if you decide not to be in the study. If you decide to join 
the study now, you can still change your mind during or after the study. You may stop at any 
time.  
 
Risks and Benefits of Being in the Study:  
Being in this type of study involves some risks of the minor discomforts that can be 
encountered in daily life, such as fatigue, pain related to eyes, ears and head, stress or 
becoming upset. If in the course of the completion you feel any of those, the researchers 
recommend that you stop the completion and inform him. In that case, the researcher will 
immediately inform the study site’s supervisor on duty and or call the Emergency Services at 
911 for immediate medical attention with the participant’s agreement. Being, in this study 
would not pose risk to your safety or wellbeing. In addition, the concerns or risks related to 
the participant’s physical (eye for instance) regarding the flyers and the questionnaire are the 
length, the color, and the typography of the flyers. The solutions to these concerns are that 
the flyers are a written in short texts and to use a high quality paper and printing selected by 
infographic and/or printing’s professional (Leelanddesigns company). The questionnaire text 
is double space, times news roman, 12 front size for easy and fast readability.  
The benefit of participating in this study is to contribute to the creation of new knowledge. 
The new knowledge will serve to promote dermatology diseases treatment and prevention 
amongst patients and populations at risk. Also, the new knowledge will enable the creation of 
awareness about dermatology diseases and treatments options through education amongst 
patients. In addition, this study will permit the promotion amongst the patients and the 
population at risk of a regular skin, hair, and nails check and screening test for an early 
diagnosis of a potential dermatology disease.  
 
Payment:  
They will be no financial payment to the participants. This is to avoid any bias on the 
participant’s willingness to participate to the study and on their answers to the questionnaire.  
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Privacy:  
Any information you provide will be kept confidential. The researcher will not use your 
personal information for any purposes outside of this research project. Also, the researcher 
will not include your name or anything else that could identify you in the study reports. Data 
will be kept secure by the researcher in locked file or password protected database. Indeed, 
the data collected will be stored for 5 years on the researcher’s laptop hard disk, USB drive, 
and CD Rooms. The access to those data will be protected by a password at the researcher’s 
discretion. Data will be kept for a period of at least 5 years, as required by the university.  
 
Contacts and Questions:  
You may ask any questions you have now. Or if you have questions later, you may contact 
the researcher via phones numbers (cell) XXX or email addresses: 
XXX@waldenu.edu/XXX@yahoo.fr If you want to talk privately about your rights as a 
participant, you can call Dr. Leilani Endicott. She is the Walden University representative 
who can discuss this with you. Her phone number is 1-800-925-3368, extension 3121210. 
Walden University’s approval number for this study is 
12-09-14-0177813 and it expires on December 10, 2015. 
You may keep the consent form. 
 
Statement of Consent: 
I have read the above information and I feel I understand the study well enough to make a 
decision about my involvement. By completing the survey in a face-to-face completion 
with the researcher, I understand that I am agreeing to the terms described above and 
signing the present form. 
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Appendix D: A3 Recruiting Flyer 
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Appendix F: A5 Recruiting Flyer 
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Appendix G: Study Questionnaire 
 
Time Completion started:                 Time Completion ends:                 Total Length of 
Completion:  
Date of Completion:         /        / 2015 
 
Place of Completion (check only one): 
 
        MedStar Primary Care Clinic                                   
       Saint Nicholas Catholic Church                                        
 
 
 
Your answers to the following questions will help to determine if you meet the criteria to 
participate in this study or not. Please, answer truthfully, clearly, and consistently during 
the completion of this questionnaire.  
 
INCLUSION CRITERIA 
Q.1. City of residence. 
   
          Houston                  
          Other (Specify)                              (Terminate the Completion) 
 
Q.2. Length of Residence in Houston (Check only one).                 
 
           At least six months.       
           Less than six months (Terminate the Completion) 
 
Q.3. Familiarity with English Language (Please, check only one). 
 
  Speak, read and understand.              
 Do not speak, read and understand (Terminate the Completion) 
 
Q.4. Attending to church service(s) at Saint Nicholas Catholic Church or receiving 
primary care 
        services at MedStar Primary Clinic in Houston (Please, check only one). 
 
           Yes.              
          No (Terminate the Completion) 
 
Q.5. What is your age (check only one)? 
 
 18 to 34 years                 
 35 to 51 years                 
 52 to 64 years                
   65 years and above 
ELIGIBILITY SECTION 
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Q.6. Please, write in number your exact age inside the next box (Optional)  
 
 
Q.7. Have you been diagnosed with dermatology disease(s) in the past 12 months 
(check only one)?    
                   
Yes      
No   (Terminate the Completion) 
Other (Specify):                                                                (Terminate the 
Completion) 
 
Q.8. Are you currently receiving dermatology treatment/services (s) here in Houston 
after you have been diagnosed with dermatology disease(s) in the past 12 months (check 
only one)?                               
Yes      
No   (Terminate the Completion) 
Other (Specify):                                                (Terminate the Completion) 
 
Q.9. Please, Indicate your dermatology disease(s) that you are currently receiving 
        treatment for here in Houston (check not more than two) 
 
 Skin diseases (Eczema, dry skin, Contact Dermatitis, skin cancer, Actinic   
 keratosis, effect of sun exposure, acne, atopic dermatitis...)                                                                                           
 Hair disease(s) (hair loss)                         
 Nails disease(s) (artificial nails) 
 Other (Specify):                     (If not skin, hair, or nails related, 
      Terminate the completion). 
           
Q.10. What dermatology treatments/service are you currently receiving at the  
           medical dermatology facility in Houston (Write down a maximum of 3  
           treatment(s) for each applicable disease)? 
 
  Skin Treatment: 
  Hair treatment: 
Nails treatment: 
    Don’t Know/ Not sure 
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In the past 12 months, have you…  
(Terminate completion if "No" for both Q.12.a. and Q.12.b.) 
Yes No 
Don't 
Know/ 
Not 
sure 
Q.11a. Seen, read or heard a pharmaceutical announcement done by pharmaceutical 
companies (s) about a prescription drug(s) and directed directly to consumers? 
      
Q.11.b. Seen, read or heard a pharmaceutical announcement (s) done by 
pharmaceutical companies about a disease(s) and directed directly to patients? 
      
Q.12.a. Seen, read or heard a pharmaceutical announcement (s) done by 
pharmaceutical companies about dermatology  prescription drug(s) and directed 
directly to dermatology patients?  
      
Q.12.b. Seen, read or heard a pharmaceutical announcement (s) done by 
pharmaceutical companies about   dermatology disease(s) and directed directly to 
dermatology patients?  
      
 
Q.13. What is/are the reason (s)/expected result (s) of the dermatology treatment that you 
are currently receiving at a medical dermatology facility in Houston  (Write down 
           a maximum of 3 reason(s) for each applicable disease)? 
 
Reason for skin treatment: 
Reason for hair treatment: 
Reason for Nails treatment: 
Don’t Know/ Not sure 
 
 
 
 
Dermatology  pharmaceutical prescription drug(s) or/and disease(s) 
announcement (s) directed directly to consumers seen, read or heard 
in the past 12 months. Did the announcement… 
(Terminate completion if "No" for both Q.14.a. and Q.14b.)  
Yes No 
Don't 
Know/ 
Not 
sure 
Q.14.a. State the prescription drug name that treats dermatology 
disease, 
              name the treated disease, and give the risks and benefits 
related  
              to the use of the advertised prescription drug? 
      
Q.14.b. Talk only about the dermatology disease without any 
              reference to a prescription drug that can treat the condition 
(s)?  
      
Q.14.c. Communicate the dermatology prescription drug name 
              and did not talk about the drug use? 
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Dermatology treatment (s) currently 
received at a medical dermatology 
facility in Houston . I have been 
PROMPTED by…. (Terminate if 
"No" for both Q.15.a. and Q.15 .b.) 
Yes No 
Don't 
Know/ Not 
sure 
Q.15.a. The  dermatology 
pharmaceutical prescription drug 
             announcement directed directly 
to  dermatology patients 
             that I have seen, read or heard 
in the past 12 months.  
      
Q.15.b.  The  dermatology 
pharmaceutical  disease announcement 
               directed directly to  
dermatology  patients that I have 
               seen, read or heard in the past 
12 months.  
      
Q.15.c. a dermatologist/surgeon’s 
prescription.  
      
Q.15.d.  Another  dermatology patient 
with the same disease who 
               has received or is currently 
receiving the same treatment (s). 
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Reason (s) of the dermatology 
treatment (s) currently received at a 
medical dermatology facility in 
Houston . I have been PROMPTED 
by….   
Yes No 
Don't 
Know/ 
Not sure 
Q.16.a. The  dermatology 
pharmaceutical prescription drug  
             announcement directed 
directly to  dermatology patients that  
             I have seen, read or heard in 
the past 12 months.  
      
Q.16.b.  The  dermatology 
pharmaceutical disease announcement 
              directed directly to  
dermatology  patients that I have seen,  
              read or heard in the past 12 
months.  
      
Q.16c. A dermatologist/ surgeon’s 
prescription.  
      
Q.16.d.  Another  dermatology patient 
with the same disease who has 
               received or is currently 
receiving the same treatment (s). 
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OTHER 
Q.17. Indicate your sex. 
 
  Male  
                        Female 
 
Q.18. Residence Status (Check only one):       
          US Citizen 
           Permanent Resident Alien 
 
Q.19. Race/Ethnicity (Check only one).  
 
            White                                     Asian Indian 
Black, African American, or Negro                      Native Hawaiian 
 Chinese                                                                  Other Pacific Islander (Specify): 
American Indian/Alaska Native           Korean 
Filipinos              Vietnamese 
Japanese             Some Other Race (Specify): 
Other Asians (Specify):                                 Samoan 
Guamanian          
 
Q.20. Indicate the highest grade of school completed (Check only one).  
 
Less than 9
th
 grade                                    Associate’s degree 
9
th
 to 12
th
 grade, without diploma      Bachelor’s degree 
High School graduate     Graduate degree 
Some college, without degree 
 
Q.21. Current marital status (Please, check only one). 
 
Married      Separated 
Divorced      Never got married 
Widowed      Unmarried in couple 
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Q.22. Current annual household income from all sources (check only one). 
 
Less than $10,000     $25,000 to $29,999 
$10,000 to $14,999     $30,000 to $34,999 
$15,000 to $19,999     $35,000 to $39,999 
20,000 to $24,999     40, 000 and over 
 
Q.23.Write the exact total number of your household members inside the next box:   
 
Q.24.   I pay for my current dermatology treatments at medical dermatology facility in 
Houston (check not more than one), 
 
   With Medicaid insurance only. 
With other mean (s) of payment only (private/employer insurance, Medicare,  
  credit/debit card, cash).  
With Medicaid insurance and other mean (s) of payment (Specify other mean(s)): 
  
 
 
 
 
 
 
 
 
 
 
 
 
Please, Continue to the Main Questionnaire or Q.25. 
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Section 1: Dermatology Product Claim Advertisement Exposure Scale (DPCAES) 
 
The set of questions that follow are about the exposure/contact with a dermatology 
pharmaceutical drug(s) announcement (Q.14a), directed directly to patients in the past 12 
months. 
 
Q.25. Indicate where you have seen, read, or heard dermatology pharmaceutical 
prescription drug(s) announcement directed directly to patients in the past 12      
months (check all that applies)  
 
Oncology magazines/Journals        Social media (YouTube, Facebook, Twitter,  
Radio stations                      Skype, Google, LinkedIn, Yahoo) 
TV channels                                    Newspaper            
Pharmacy Journals                      Online/Website (pharmaceutical,   
                                     Companies, U.S. Government, private) 
         Other (Specify): 
       
Q.26. Please, provide the name/title of the dermatology pharmaceutical prescription 
drug(s) announcement (Q.14a) directed directly to patients that you have seen, 
read, or heard in the past 12 months. (Write down a maximum of 3 
name(s)/title(s) for each applicable disease). 
 
Skin drug announcement:  
Hair drug announcement: 
Nails drug announcement: 
Don’t Know/Not sure 
 
MAIN QUESTIONNAIRE 
 
 
 
 
 
 
 
 
254 
 
 
191 
 
Q.27. Instructions: I would like to ask you about some things that  
dermatology prescription drug pharmaceutical announcements (Q.14a) directed 
directly to patients do. Those things can prompt patients to receive dermatology 
treatments for particular reason(s) or purpose(s). You will provide your answer for 
all statements even if you think some are alike. Below is a scale that ranges from 
Not agree at all to Totally agree. Please, indicate the extent to which you agree 
with each statement regarding the dermatology drug pharmaceutical 
announcement(s) that you have seen, read, or heard in the past 12 months 
(Circle one answer for each statement). 
 
 DPCAES 
 
Not 
Agree 
at All 
Not 
Agree 
Agree/ 
Not agree 
Agree 
Totally 
Agree 
 
In the past 12 months, dermatology 
prescription drug announcement(s)… 
     
 
1.  Told to the consumers in a balanced manner 
the benefits and potential negative consequences 
of using the advertised 
     dermatology drug.  
1 2 3 4 5 
 
2.  Told in a balanced manner about the 
advantages and 
     dangers related to the advertised dermatology 
drug use.  
1 2 3 4 5 
 
3.   Published in the newspaper, magazines, 
review, or 
      journal contained this statement "You are 
encouraged to 
     report negative side effects of prescription 
drug to the 
     U.S. Food and Drug Administration (FDA) 
Visit 
    MedWatch5 or call 1-800-FDA-1088." 
1 2 3 4 5 
 
4. Passed on Television/Radio station (s) told to 
the viewer/listener where to get additional 
    prescription drug 
    information approved by the FDA 
1 2 3 4 5 
 
5.  Audio broadcast stated the most serious 
risks/dangers that the 
     dermatology drug user may encounter.   
1 2 3 4 5 
 
6. Said the drug risk(s)/danger(s) approved by 
FDA  and included in the drug information or 
label). 
1 2 3 4 5 
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DPCAES 
 
Not 
Agree 
at All 
Not 
Agree 
Agree/ 
Not 
agree 
Agree 
Totally 
Agree 
 
7. Stated the most important dangers that the 
dermatology patient 
    may face taking the advertised drug. 
 
1 
 
2 
 
3 
 
4 
 
5 
 
8. Stated both the vulgar designation/name of the 
drug approved (brand) and non-approved 
(generic) by the U.S. government.    
1 2 3 4 5 
 
9.   Stated at least one form of dermatology  
disease treated by the advertised drug and 
approved by the FDA 
 
1 2 3 4 5 
10. Stated "Ask your doctor if [drug name] is 
right for you.'' 
1 2 3 4 5 
 
Section 2: Dermatology Help-seeking Advertisement Exposure Scale (DHSAES) 
 
The set of questions that follow are about your contact with dermatology pharmaceutical 
disease(s) announcement(Q.14b), directed directly to patients in the past 12 months. 
 
Q.28. Indicate where you have seen, read, or heard dermatology pharmaceutical 
          disease(s) announcement (Q.14b) in the past 12 months (check all that applies)  
 
         Oncology magazines/Journals          Social media (YouTube, Facebook, Twitter,  
          Radio stations                Skype, Google, LinkedIn, Yahoo) 
          TV channels                                      Newspaper            
         Pharmacy Journals          Online/Website (drug companies, Government, 
                                                                        private)                   
           Other (Specify):     
    
Q.29. Please, provide the name/title of the dermatology pharmaceutical disease(s) 
          announcement (Q.14b) that you have seen, read, or heard in the past 12 months. 
(Write down maximum 3 name(s)/title(s) for each applicable disease). 
  
Skin disease announcement:  
Hair disease announcement: 
Nails disease announcements: 
Don’t Know/Not sure 
 
Q.30. Instructions: I would like to ask you about some things that dermatology 
disease(s) pharmaceutical announcements (Q.14b)directed directly to patients do. 
Those things can prompt patients to receive dermatology treatments for particular 
result(s) or purpose(s).You will provide your answer for all statements even if you 
think some are alike. 
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 Below is a scale that ranges from Not agree at all to Totally agree. Please, indicate the 
extent to which you agree with each statement regarding the dermatology 
pharmaceutical disease announcement (s) that you have seen, read, or heard in the 
past 12 months (Circle one answer for each statement). 
 
 DHSAES 
Not 
Agree 
at All 
Not 
Agree 
Agree/Not 
agree 
Agree 
Totally 
Agree 
In the past 12 months, dermatology 
pharmaceutical disease announcement (s)… 
 
     
1. Described the type of dermatology disease 
without any recommendation of a specific 
dermatology drug for treatment.  
 
1 2 3 4 5 
2. Encouraged people with the symptoms of 
the described type of dermatology disease 
to ask/talk to their doctor  
 
1 2 3 4 5 
3. Had the company's name of the advertised 
dermatology drug. 
 
1 2 3 4 5 
4. Gave a telephone number/website to call or 
to visit for more information about the 
advertised dermatology disease 
type/described condition.  
 
1 2 3 4 5 
5. Stated "Ask your healthcare provider for more 
information''.   
1 2 3 4 5 
 
Section 3: Types of Medical Dermatology Treatments Utilized after Exposure to 
Dermatology DTCA of Prescription Drug Scale (TDMTUEPDAS)  
 
The questions that follow are about the medical dermatology treatments received after 
exposure to dermatology pharmaceutical prescription drug(s) announcement (Q.14a), 
directed directly to patients in the past 12 months. 
 
Q.31. What is/are the medical dermatology treatment(s) that you are currently 
          receiving at  a medical dermatology facility in Houston  because of the prescription 
drug(s) announcement (Q.14a) directed directly to patients that you have seen, read, or 
          heard in the past 12 months? (Write down a maximum of 3 treatment(s) for each 
applicable treatment). 
 
Skin treatment(s):  
Hair treatment(s): 
Nails treatment(s): 
Don’t Know/Not sure 
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Q.32. Patients several times affirmed that they have received the following 
          medical dermatology treatment(s) as the consequence of having seen, heard, or 
read dermatology pharmaceutical drug(s) announcement (Q.14a) directed directly 
to patients. Below is a scale that ranges from Not agree at all to Totally agree. 
Please,          indicate the extent to which you agree with each statement 
regarding the pharmaceutical prescription drug announcement(s) that you 
have seen, read, or heard in the past 12 months (Circle one answer for each 
statement).   
 
 
 
   TDMTUEPDAS 
Not 
Agree 
at All 
Not 
Agree 
Agree/Not 
agree 
Agree 
Totally 
Agree 
 
In the past 12 months,  dermatology 
prescription drug announcement (s) prompted 
me to… 
 
 
 
 
     
1. Request and obtain a medical 
prescription of the dermatology drug 
advertised. 
 
1 2 3 4 5 
2. Receive the advertised drug 
therapy/Chemotherapy. 
 
1 2 3 4 5 
3. Participate normally to the dermatology 
treatment regimen. 
  
1 2 3 4 5 
4. Fill the dermatology disease 
prescription drug.  
 
1 2 3 4 5 
5. Talk to the 
dermatologist/surgeon/doctor about a 
dermatology advertised prescription 
drug. 
 
1 2 3 4 5 
6. Visit a physician/dermatologist office. 
 
1 2 3 4 5 
7. Receive Skin, hair, and/or nails health 
maintenance treatment. 
 
1 2 3 4 5 
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Section 4: Types of Medical Dermatology Treatments Utilized after Exposure to the 
Dermatology Disease DTCA Scale (TDMTUEDDAS) 
 
The questions that follow are about the medical dermatology treatments received after 
exposure to dermatology pharmaceutical disease(s) announcement (Q.14b), directed 
directly to patients in the past 12 months. 
 
Q.33. What is/are the medical dermatology treatment(s) that you are currently 
receiving at a medical dermatology facility in Houston  because of the 
pharmaceutical disease(s) announcement (Q.14b) directed directly to consumers 
that you have seen, read, or heard in the past 12  months? (Write down a 
maximum of 3 treatment(s) for each applicable disease). 
 
Skin disease treatment(s):  
Hair disease treatment(s): 
Nails disease treatment(s): 
Don’t Know/Not sure 
 
Q.34. Patients several times affirmed that they have received the following 
          medical dermatology treatment(s) as the consequence of having seen, heard, or 
          read dermatology pharmaceutical disease(s) announcement directed directly to 
          patients (Q.14b). Below is a scale that ranges from Not agree at all to Totally agree.  
     Please, indicate the extent to which you agree with each statement regarding the  
         dermatology pharmaceutical disease announcement(s) that you have seen, 
        read, or heard in the past 12 months(Circle one answer for each statement). 
           
 TDMTUEDDAS 
Not 
Agree 
at All 
Not 
Agree 
Agree/Not 
agree 
Agree 
Totally 
Agree 
 
In the past 12 months, dermatology 
pharmaceutical disease announcement (s) 
prompted me to… 
 
     
1. Consult a dermatologist/doctor regarding any 
symptom/problem related to skin, hair, or 
nails. 
 
1 2 3 4 5 
2. Go for dermatology disease screening test. 1 2 3 4 5 
 
3.  Receive gene therapy/biological therapy. 
1 2 3 4 5 
 
4.  Participate to dermatology clinical 
trial/experimental 
      treatment. 
1 2 3 4 5 
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5. Receive cryotherapy/Cryosurgery  
1 2 3 4 5 
 
6. Receive  curettage and cautery/Curettage and  
    electrodessiccation/Electrodessiccation and 
curettage. 
1 2 3 4 5 
 
7. Receive an electrodessication /"scraping and 
burning”.  
1 2 3 4 5 
 
8. Receive laser surgery. 
1 2 3 4 5 
 
9. Go through lymph node surgery. 
1 2 3 4 5 
 
10.  Go through a mohs micrographic surgery  
1 2 3 4 5 
 
11.  Go through a radiotherapy/radiation. 
1 2 3 4 5 
 
12. Go through skin grafting and reconstructive 
surgery. 
1 2 3 4 5 
 
13.  Go through a standard surgical 
excision/resection. 
1 2 3 4 5 
 
14. Search for additional health information 
outside of the 
      disease announcement. 
1 2 3 4 5 
      
 
Section 5: Purposes of the Utilization of Dermatology Medical Treatments after 
Exposure to Dermatology DTCA of Prescription Drug Scale (PUDMTEDDAS) 
 
The questions that follow are about expected result(s)/reason(s) of the medical 
dermatology treatments received after exposure to dermatology pharmaceutical 
prescription drug(s) announcement (Q.14a), directed directly to patients in the past 12 
months. 
 
Q.35. What is/are the expected result(s)/reason(s) why of your medical dermatology 
treatment(s) that you are currently receiving at  a medical dermatology facility in 
Houston  because of the pharmaceutical prescription drug(s) announcement 
(Q.14a) directed directly to patients that you have seen, read, or heard in the past 
12 months? (Write down a maximum of 3 reason(s) for each applicable disease). 
 
Reason(s) skin disease treatment(s):  
Reason(s) hair disease treatment(s): 
Reason(s) nails disease treatment(s): 
Don’t Know/Not sure 
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Q.36. Patients several times affirmed that they have received the medical dermatology 
          treatment(s) for the following expected result(s)/reason(s), as the consequence of 
having seen, heard, or read dermatology pharmaceutical prescription drug 
announcement(s) directed directly to patients. Below is a scale that ranges from Not agree 
at all to Totally agree. 
   Please, indicate the extent to which you agree with each statement regarding the  
   Dermatology pharmaceutical prescription drug announcement(s) that you have 
seen, read, or heard in the past 12 months (Circle one answer for each statement). 
 
 
 PUDMTEDDAS 
Not 
Agree 
at All 
Not 
Agree 
Agree/Not 
agree 
Agree 
Totally 
Agree 
 
In the past 12 months, 
dermatology pharmaceutical 
prescription drug announcement 
(s) prompted me to… 
 
     
1. Receive dermatology 
treatment to have rebuilt 
the part of the body 
damaged by the 
dermatology disease. 
 
1 2 3 4 5 
2. Receive treatment/cure of 
the dermatology in order to 
look for well-being.  
 
1 2 3 4 5 
3. Receive treatment/cure of 
the dermatology disease in 
order to clear the tumor. 
 
1 2 3 4 5 
4. Receive treatment/cure of 
the dermatology disease in 
order to excise the tumor 
lesion. 
 
 
1 2 3 4 5 
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Section 6: Purposes of the Utilization of Medical Dermatology Treatment after 
Exposure to Dermatology DTCA of Disease Scale (PUDMTEDAS) 
 
The questions that follow are about expected result(s)/reason(s) of the medical 
dermatology treatments received after exposure to dermatology pharmaceutical disease(s) 
announcement (Q.14b), directed directly to patients in the past 12 months. 
 
Q.37. What is/are the expected result(s)/reason(s) why of your medical dermatology 
          treatment(s) that you are currently receiving at  a medical dermatology facility in 
Houston because of the dermatology pharmaceutical disease(s) announcement (Q.14a)  
directed directly to patients that you have seen, read, or heard in the past 12 months? 
(Write down maximum 3 reason(s) for each applicable treatment). 
           
Reason(s) skin disease treatment(s):  
Reason(s) Hair disease treatment(s): 
Reason(s) Nails disease treatment(s): 
Don’t Know/Not sure 
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Q.38. Patients several times affirmed that they have received the medical dermatology 
          treatment(s) for the following expected result(s)/reason(s), as the consequence of 
having seen, heard, or read dermatology pharmaceutical disease announcement(s) 
(Q.14b) directed directly to patients. Below is a scale that ranges from Not agree at all to 
Totally agree. 
 Please, indicate the extent to which you agree with each statement regarding the 
 dermatology pharmaceutical disease announcement(s) that you have seen,    read, 
or heard in the past 12 months (Circle one answer for each statement).  
 
 PUDMTEDAS 
Not 
Agree 
at All 
Not 
Agree 
Agree/Not 
agree 
Agree 
Totally 
Agree 
 
In the past 12 months, 
dermatology pharmaceutical 
disease announcement (s) 
prompted me to… 
 
     
1. Receive dermatology 
treatment/service to 
detect/diagnose early the 
dermatology disease.  
 
1 2 3 4 5 
2. Receive dermatology 
treatment/service for the 
dermatology disease 
symptom management. 
 
1 2 3 4 5 
3. Receive Treatment/cure of 
the dermatology disease in 
order to clear the 
tumor/disease. 
 
1 2 3 4 5 
4. Receive Treatment/cure of 
the dermatology disease in 
order to excise the tumor 
lesion/disease. 
 
1 2 3 4 5 
 
You have come to the end of this survey. I thank you very much for your valuable 
contribution and precious time. 
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Appendix H: Questionnaire Completion Guide  
 
This Guide provides the researcher with the necessary help to check the answer each 
question. Also, the guide provides with the help to check consistency amongst answers 
for several related questions. This is to be used by the researcher to approve each 
completed questionnaire. 
 
 
 
Your answers to the following questions will help to determine if you meet the criteria to 
participate in this study or not. Please, answer truthfully, clearly, and consistently.  
 
INCLUSION CRITERIA 
 
Q.1. City of residence. 
   
          Houston                  
          Other (Specify)                              (Terminate the completion) 
 
Q.2. Length of Residence in Houston (Check only one).                 
 
           At least six months.       
           Less than six months (Terminate the Completion) 
 
Q.3. Familiarity with English Language. 
 If you check the first answer, continue with the completion. 
  If you check the second answer, terminate the completion because you cannot 
participate in this study if you cannot speak, read, and understand English 
language which is the language of this survey. 
Q.4. Attending to church service(s) at Saint Nicholas Catholic Church in Houston or 
receiving primary care services at MedStar Primary Clinic in Houston (Please, check 
only one). 
         
 Yes, continue to Q.5.              
 No, Terminate the completion. 
  
ELIGIBILITY SECTION 
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Q.5. What is your age? 
 Please, only one answer be checked. 
Q.6. Please, write in number your exact age inside the next box (Optional)   
 This answer is optional.  
 However, if you choose to provide it, use a two digit number (00) to give your 
exact age at the time of the completion. 
Q.7. Have you been diagnosed with dermatology disease (s) in the past 12 months? 
 Only one answer be checked, and if you check “No”, terminate the completion 
completely because the study is designed to survey dermatology disease patients. 
 If you choose “Other” as answer, specify the name of the disease and terminate 
the completion. 
Q.8. Are you currently receiving dermatology disease treatment at a dermatology 
facility in 
          Houston after you have been diagnosed with dermatology disease in the past 12  
           months?    
 Only one answer be checked. 
 If “No”, terminate the completion completely because the study is designed to 
survey dermatology patients who are receiving treatment at a dermatology 
facility in Houston at the time of the completion as the consequence of their 
exposure to dermatology DTCAs in the past 12 months. Then, they attend church 
services at Saint Nicholas Catholic Church in Houston or receiving primary care 
services at MedStar Primary Care Clinic of Houston, Texas.  
 Also, if you choose “Other” as answer, terminate the completion.       
Q.9. Please, Indicate your dermatology disease that you are currently receiving 
treatment for in 
           Houston. 
 There should not be more than three answers checked for this question.  
 If you choose “Other” as answer, terminate the completion.       
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Q.10. What dermatology treatments are you currently receiving at 
            the dermatology facility in Houston ? 
 Write down a maximum of 3 treatment(s) for each applicable disease if your 
answer is different from “Don’t Know/Not Sure”. 
Q.11:  
 It is about both pharmaceutical prescription drug/disease announcements in 
general seen, read, or heard in the past 12 months. Check only one answer for 
each statement.  
Q.12:  
 It is about dermatology pharmaceutical prescription drug/disease announcement 
in particular seen, read, or heard in the past 12 months. 
 Check only one answer for each statement. Terminate the completion if "No" for 
both Q.12.a. and Q.12.b. because the target population for this study is the 
dermatology patients who have seen, read, or heard in the past 12 months 
dermatology  pharmaceutical prescription drug/disease announcement and have 
received treatment as the consequence of that exposure.  
 If you answer “Yes” for Q12a, Q.11a should also be “Yes” too. 
 If you answer “Yes” for Q12b, Q.11b should also be “Yes” too. 
Q.13. What is/are the reason (s)/expected result (s) of the dermatology treatment that you 
 are currently receiving at a dermatology facility in Houston? 
 Write down a maximum of 3 treatment(s) for each applicable disease. 
Q.14.: It is about exposure or contact with dermatology pharmaceutical prescription 
drug, disease, and reminder announcements in particular seen, read, or heard in the 
past 12 months. 
 Check only one answer for each statement. (Terminate completion if "No" for 
both Q.14.a. and Q.14.b.) 
Q.15.: It is about the factors that prompted the patients to receive current 
            dermatology treatment(s) at a dermatology facility in Houston (Terminate if "No"  
            for both Q.15.a. and Q15.b.). 
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 Check only one answer for each statement.  
Q.16.: It is about the factors that prompted the patients to go for the expected 
results/reasons of dermatology treatment currently received in Houston .  
Check only one answer for each statement. 
OTHER 
Q.17. Indicate your sex. 
Please, only one answer be checked. 
 
Q.18. Residence Status (Check only one):   
      
          US Citizen 
           Permanent Resident Alien 
 
Q.19. Race/Ethnicity. 
 Please, do not check more than one answer for this question. 
 
Q.20. Indicate the highest grade of school completed. 
 There should not be more than one answer checked.  
 The checked answer should be the highest grade of school completed by the 
participant 
 at the time of the completion. 
Q.21. Current marital status? 
 There should not be more than one answer checked.  
 The checked answer should be the participant’s marital status at the time of 
completion. 
Q.22. Current annual household income from all sources.  
 Do not check more than one answer here.  
 The checked answer should be the overall income of participant’s household 
made last year. 
Q.23. Write the exact total number of your household members inside the next box:   
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 Use a two digit number (00) to give your exact total number of your household’s 
members. 
 The exact total number of the participant’s household members at the time of the 
completion should not include visitors, however only those who are living 
permanently/at least six months continuously in the household.  
 The researcher will use this information to check the consistency with question 8. 
Q.24. I pay for my current dermatology treatments … 
 They should not be more than one answer checked for this question.  
 
 
 
Section 1: Dermatology Product Claim Advertisement Exposure Scale (DPCAES) 
Q.25. Indicate where you have seen, read, or heard dermatology pharmaceutical 
           prescription drug(s) announcement directed directly to patients in the past 12 
months 
 Please, check all answers that apply to you. If you have an answer that is not 
listed, provide or specify that answer as “other”.    
Q.26. Please, provide the name/title of the dermatology pharmaceutical 
          prescription drug(s) announcement directed directly to patients that you have 
seen, read, or heard in the past 12 months. 
 Write down a maximum of 3 name(s)/title(s) for each applicable disease, if your 
answer is different from “Don’t Know/Not Sure”. 
Q.27. Instructions: We would like to ask you about some things that 
           dermatology prescription drug pharmaceutical announcements directed 
          directly to patients do. Those things can prompt patients to receive  
           dermatology treatments for particular reason(s) or purpose(s). You will 
           provide your answer for all statements even if you think some are alike. Below is  
a scale 
MAIN QUESTIONNAIRE 
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           that ranges from Not agree at all to Totally agree. Please, indicate the extent to 
which you agree with each statement regarding the dermatology drug 
pharmaceutical announcement(s) that you have seen, read, or heard in the past 12 
months.  
 Circle only one answer for each statement. 
Section 2: Dermatology Help-seeking Advertisement Exposure Scale (DHSAES) 
Q.28. Indicate where you have seen, read, or heard dermatology pharmaceutical 
          disease(s) announcement in the past 12 months.  
 Please, check all answers that apply to you. If you have an answer that is not 
listed, provide or specify that answer as “other”. 
Q.29. Please, provide the name/title of the dermatology pharmaceutical 
           disease(s) announcement that you have seen, read, or heard in the  
past 12 months. 
 Write down a maximum of 3 name(s)/title(s) for each applicable disease. 
Q.30. Instructions: We would like to ask you about some things that dermatology 
           disease(s) pharmaceutical announcements directed directly to patients do. Those 
things can prompt patients to receive dermatology treatments for particular result(s) 
           or purpose(s).You will provide your answer for all statements even if you think 
some are alike. Below is a scale that ranges from Not agree at all to Totally agree. Please, 
indicate the extent to which you agree with each statement regarding the 
dermatology pharmaceutical disease announcement (s) that you have seen, read, or 
heard in the past 12 months.  
 Respondent should answer this question by circling one number that represents 
the selected answer for each statement.  
Section 3: Types of Medical Dermatology Treatments Utilized after Exposure to the 
Dermatology DTCA of Prescription Drug Scale (TDMTUEDDAS)  
Q.31. What is/are the medical dermatology treatment(s) that you are currently 
          receiving in Houston because of the dermatology prescription drug(s) 
          announcement directed directly to patients that you have seen, read, or heard  
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          in the past 12 months?  
 Write down a maximum of 3 treatments for each applicable disease, if your 
answer is different from “Don’t Know/Not Sure”. 
 Your answer should be appropriate for Q.9. (dermatology disease that you are 
currently receiving treatment for in Houston ). 
 Your answer should be listed also at Q.10. (the dermatology treatment that you 
are currently receiving at  a dermatology facility in Houston). 
 Your answer should be appropriate for Q.13. (the expected result/reasons for the 
dermatology treatment that you are currently receiving at  a dermatology facility 
in Houston). 
Q.32. Patients several times affirmed that they have received the following 
          medical dermatology treatment(s) as the consequence of having seen, heard, 
          or read dermatology pharmaceutical drug(s) announcement directed directly 
          to patients. Below is a scale that ranges from Not agree at all to Totally agree. 
Please, indicate the extent to which you agree with each statement regarding the 
          dermatology pharmaceutical prescription drug announcement(s) that you have  
 seen, read, or heard in the past 12 months. 
 Respondent should answer this question by circling one number that represents 
the selected answer for each statement.  
 Your “Agree/Totally agree” answer should be appropriate for Q.9. (dermatology 
disease that you are currently receiving treatment for at  a dermatology facility in 
Houston). 
 Your answer should be listed also at Q.10. (the dermatology treatment that you 
are currently receiving at  a dermatology facility in Houston). 
 Your “Agree/Totally agree” answer should be appropriate for Q.13. (the expected 
results/reasons of the  dermatology treatment that you are currently receiving at  a 
dermatology facility in Houston  in Houston ). 
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 Your answer should be “Yes” for Q.33.2. (the dermatology pharmaceutical 
prescription drug announcement prompted you to receive the current dermatology 
treatment). 
 If you agree with Q.32.2 (Receive the advertised drug therapy) and Q.32.4 (Fill 
the dermatology prescription drug), you should have a type of drug treatment 
listed as one of your answers in Q.31. above (the medical dermatology 
treatment(s) that you are currently receiving in Houston because of the 
dermatology prescription drug(s) announcement directed   directly to patients that 
you have seen, read, or heard in the past 12 months). 
Section 4: Types of Medical Dermatology Treatments Utilized after Exposure to 
Dermatology  DTCA of Disease Scale (TDMTUEDAS) 
Q.33. What is/are the medical dermatology treatment(s) that you are currently 
           receiving at a dermatology facility in Houston because of the dermatology  
          pharmaceutical disease(s) announcement directed directly to consumers that you  
 have seen, read, or heard in the past 12 months?  
 Write down a maximum of 3 treatments for each applicable disease, if your 
answer is different from “Don’t Know/Not Sure”. 
 Your answer should be consistent with Q.9. (dermatology disease that you are 
currently receiving treatment for at  a dermatology facility in Houston). 
 Your answer should be listed also at Q.10. (the dermatology treatment that you 
are currently receiving at  a dermatology facility in Houston). 
 Your answer should be consistent with Q.13. (the expected result/reasons for the 
dermatology treatment that you are currently receiving at  a dermatology facility 
in Houston ). 
Q.34. Patients several times affirmed that they have received the following 
medical dermatology treatment(s) as the consequence of having seen, heard,      or 
read dermatology pharmaceutical disease(s) announcement directed directly to 
patients. Below is a scale that ranges from Not agree at all to Totally agree. Please, 
indicate the extent to which you agree with each statement regarding the 
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dermatology  pharmaceutical disease announcement(s) that you have seen, 
read, or heard in the past 12 months. 
 Respondent should answer this question by circling one number that represents 
the selected answer for each statement.  
 Your “Agree/Totally agree” answer should be appropriate for Q.9. (dermatology  
disease that you are currently receiving treatment for at  a dermatology facility in 
Houston ). 
 Your “Agree/Totally agree” answers should be consistent with for Q.10. (the 
dermatology treatment that you are currently receiving at  a dermatology facility 
in Houston).   
 Your answer should be “Yes” for Q.15.b. (the dermatology pharmaceutical 
disease announcement prompted you to receive the current dermatology 
treatment). 
Section 5: Purposes of the Utilization of Medical Dermatology Treatments after 
Exposure to Dermatology DTCA of Prescription Drug Scale (PUDMTEPDAS) 
Q.35. What is/are the expected result(s)/reason(s) why of your dermatology 
           medical treatment(s) that you are currently receiving at  a dermatology facility in 
           Houston because of the pharmaceutical prescription drug(s) announcement 
 directed directly to patients that you have seen, read, or heard in the past 12 months? 
 Write down a maximum of 3 treatments for each applicable disease, if you answer 
is different from “Don’t Know/Not Sure”. 
 Your answer should be consistent with for Q.9. (dermatology disease that you are 
currently receiving treatment for at  a dermatology facility in Houston). 
 Your answer should be listed also at Q.10. (the dermatology treatment that you 
are currently receiving at a dermatology facility in Houston). 
 Your answer should be listed also at Q.13. (the expected results/reasons of the  
dermatology treatment that you are currently receiving at  a dermatology facility 
in Houston). 
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 Your answer should be “Yes” for Q.15.a. (dermatology pharmaceutical 
prescription drug announcement prompted you to receive the current dermatology 
treatment). 
 Verify that if you Agreed/Totally agreed with Q.32.2 (Receive the advertised drug 
therapy) and Q.32.4 (Fill the dermatology disease prescription drug), you should 
have a type of drug treatment listed as one of your answers in Q.31. above (the 
medical dermatology treatment(s) that you are currently receiving at a 
dermatology facility in Houston because of the dermatology pharmaceutical 
prescription drug(s) announcement directed   directly to patients that you have 
seen, read, or heard in the past 12 months). 
Q.36. Patients several times affirmed that they have received the dermatology 
medical treatment(s) for the following expected result(s)/reason(s), as the 
consequence of having seen, heard, or read dermatology pharmaceutical 
prescription drug announcement(s) directed directly to patients. Below is a scale 
that ranges from Not agree at all to Totally agree. Please, indicate the extent to 
which you agree with each statement regarding the dermatology 
pharmaceutical prescription drug announcement(s) that you have seen, read, 
or heard in the past 12 months.  
 Respondent should answer this question by circling one number that represents 
the selected answer for each statement.  
 Your “Agree/Totally agree” answer should be appropriate for Q.9. (dermatology 
disease that you are currently receiving treatment for at  a  dermatology facility in 
Houston). 
 Your “Agree/Totally agree” answers should be listed also at Q.13. (the expected 
results/reasons of the  dermatology treatment that you are currently receiving at a  
dermatology facility in Houston). 
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Section 6: Purposes of the Utilization of Medical Dermatology Treatment after 
Exposure to dermatology DTCA of Disease Scale (PUDMTEDAS) 
Q.37. What is/are the expected result(s)/reason(s) why of your medical dermatology  
treatment(s) that you are currently receiving at a dermatology facility in Houston 
because of the dermatology pharmaceutical disease(s) announcement directed 
directly to patients that you have seen, read, or heard in the past 12 months?  
 Write down a maximum of 3 treatments for each applicable disease, if your  
answer is different from “Don’t Know/Not Sure”. 
 Your answer should be consistent with Q.9. (dermatology disease that you are 
currently receiving treatment for at  a dermatology facility in Houston). 
 Your answer should be consistent with Q.10. (dermatology treatment that you are 
currently receiving at a dermatology facility in Houston ).  
 Your answer should be listed at Q.13. (the expected result/reasons for the 
dermatology treatment that you are currently receiving at  a dermatology facility 
in Houston ). 
 Your answer should be listed at Q.33. (What is/are the medical dermatology 
treatment(s) that you are currently receiving at a dermatology facility in Houston 
because of the pharmaceutical disease(s) announcement directed directly to 
consumers that you have seen, read, or heard in the past 12 months?). 
Q.38. Patients several times affirmed that they have received the dermatology 
           medical treatment(s) for the following expected result(s)/reason(s), as the 
consequence of having seen, heard, or read dermatology pharmaceutical disease 
announcement(s) directed directly to patients. Below is a scale that ranges from 
Not agree at all to Totally agree. 
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           Please, indicate the extent to which you agree with each statement regarding 
the dermatology pharmaceutical disease announcement(s) that you have seen, read, 
or heard in the past 12 months.  
 Respondent should answer this question by circling one number that represents 
the selected answer for each statement.  
 Your “Agree/Totally agree” answers should be consistent with Q.9. (dermatology 
disease that you are currently receiving treatment for at  a dermatology facility in 
Houston ). 
 Your answer should be consistent with Q.10. (dermatology treatment that you are 
currently receiving at a dermatology facility in Houston ). 
 Your “Agree/Totally agree” answers should be listed also at Q.13. (expected 
results/reasons of the  dermatology treatment that you are currently receiving at a 
dermatology facility in Houston ). 
 Your “Agree/Totally agree” answers should be consistent with Q.33. (What is/are 
the medical dermatology treatment(s) that you are currently receiving at a 
dermatology facility in Houston because of the dermatology pharmaceutical 
disease(s) announcement directed directly to consumers that you have seen, read, 
or heard in the past 12 months?. 
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Appendix I:  Dr. Raj Final Approval of the Study Questionnaire 
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Appendix J:  Dr. Kadrie Final Approval of the Study Questionnaire 
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Appendix K:  Dr. Thomas’ Edit of the Mohs Section of the Study Questionnaire 
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Appendix L: Ann Parker First Draft Questionnaire Recommandations After Review 
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Appendix N: Dr Parker Final Approval of the Study 
 
 
 
280 
 
 
191 
Appendix O: Thomas Abrams Approval of the DTCAs Variables of the Questionnaire  
TELEPHONE CONVERSATION WITH THOMAS ABRAMS 
Date: 08/29/2013 
Time: 13: 36 (USCST) – 13:41:13 (0:05:13) 
His phone number: XXX 
Topic: DTCA Characteristics  
Heribert: My name is Heribert from Walden University. Thank you for returning 
my call. I am working on my dissertation and the topic is DTCAs of prescription drug 
and disease. I would like to request for your expertise to review the sections of my 
dissertation on DTCAs written based on the FDA’s website resources and your 
PowerPoint presentations. If you don’t mind, is it possible to have your email address so 
that I can send you an email clarifying my request? 
T. Abram: I do apologize for the voice mail, this is the first one that I have 
received and I don’t know what went wrong with my answering machine. All the 
resources on our website are accurate and updated. You can use them for your 
dissertation. Unfortunately I don’t have resources and time to review external documents. 
We spend a lot of time reviewing internal documents. However, if you have any question, 
call me I can answer for you.  
Thank you! Bye bye! 
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Appendix Q: American Journal of Public Health’s Zouetchou Permission 
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Appendix R: Dr Rachel Kientcha-Tita Letter of Consent  
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Appendix S: Rv. Fr Desmond Ohankwere Letter of Consent  
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Appendix T: Dr Mays Letter on Questionnaire Development and Approval 
 
 
 
 
